U.S. patent application number 16/810233 was filed with the patent office on 2020-06-25 for tamper-resistant dosage form containing ethylene-vinyl acetate polymer.
This patent application is currently assigned to GRUNENTHAL GMBH. The applicant listed for this patent is GRUNENTHAL GMBH. Invention is credited to Lutz Barnscheid, Anja Geibler, Sebastian Schwier, Klaus WENING.
Application Number | 20200197327 16/810233 |
Document ID | / |
Family ID | 48783054 |
Filed Date | 2020-06-25 |
United States Patent
Application |
20200197327 |
Kind Code |
A1 |
WENING; Klaus ; et
al. |
June 25, 2020 |
Tamper-resistant dosage form containing ethylene-vinyl acetate
polymer
Abstract
The invention relates to a tamper-resistant, oral pharmaceutical
dosage form comprising a pharmacologically active ingredient having
psychotropic action and an ethylene-vinyl acetate (EVA) polymer
which provides resistance against solvent extraction, resistance
against grinding, and resistance against dose-dumping in aqueous
ethanol.
Inventors: |
WENING; Klaus; (Koln,
DE) ; Barnscheid; Lutz; (Monchenglad bach, DE)
; Schwier; Sebastian; (Aachen, DE) ; Geibler;
Anja; (Stolberg, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GRUNENTHAL GMBH |
Aachen |
|
DE |
|
|
Assignee: |
GRUNENTHAL GMBH
Aachen
DE
|
Family ID: |
48783054 |
Appl. No.: |
16/810233 |
Filed: |
March 5, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14327671 |
Jul 10, 2014 |
10624862 |
|
|
16810233 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 25/04 20180101;
B29C 48/05 20190201; A61K 9/1635 20130101; A61K 9/146 20130101;
A61K 9/2031 20130101; B29K 2105/0085 20130101; B29C 48/0011
20190201; B29K 2023/083 20130101; A61K 31/135 20130101; A61K 31/137
20130101; B29C 51/002 20130101 |
International
Class: |
A61K 31/135 20060101
A61K031/135; B29C 51/00 20060101 B29C051/00; A61K 9/16 20060101
A61K009/16; A61K 31/137 20060101 A61K031/137; A61K 9/20 20060101
A61K009/20; A61K 9/14 20060101 A61K009/14 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 12, 2013 |
EP |
13176303.9 |
Claims
1. An oral pharmaceutical dosage form comprising a homogeneous
mixture of: (A) a pharmacologically active ingredient and (B) a
prolonged release matrix comprising 55 to 80 wt.-% relative to a
total weight of the dosage form of an ethylene-vinyl acetate (EVA)
polymer.
2. The pharmaceutical dosage form according to claim 1, wherein the
EVA polymer comprises repetition units derived from ethylene and
vinyl acetate and/or vinyl alcohol.
3. The pharmaceutical dosage form according to claim 1, wherein the
EVA polymer contains at least 50 wt.-% of ethylene repetition
units, relative to the total weight of the EVA polymer.
4. The pharmaceutical dosage form according to claim 3, wherein the
EVA polymer contains from 50 to 95 wt.-% of ethylene repetition
units, relative to the total weight of the EVA polymer.
5. The pharmaceutical dosage form according to claim 1, wherein the
EVA polymer has a melt flow rate at 190.degree. C. and 2.16 kg
within the range of from 1 to 160 g/10 min measured according to
ASTM D1238.
6. The pharmaceutical dosage form according to claim 1, which is
monolithic and has a breaking strength of at least 300 N.
7. The pharmaceutical dosage form according to claim 1, which is
multiparticulate, wherein at least a fraction of individual
particles have a breaking strength of at least 300 N.
8. The pharmaceutical dosage form according to claim 1, which is
monolithic and has an extension in any direction of at least 2.0
mm.
9. The pharmaceutical dosage form according to claim 1, which is
multiparticulate, wherein individual drug-containing particles have
an extension in any direction of at least 2.0 mm.
10. The pharmaceutical dosage form according to claim 1, which is
hot-melt extruded.
Description
[0001] This application is a continuation of U.S. Nonprovisional
application Ser. No. 14/327,671, filed Jul. 10, 2014, now allowed,
which, in turn, claims priority of European Patent Application No.
EP 13176303.9, filed Jul. 12, 2013, the contents of which patent
applications are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The invention relates to a tamper-resistant, oral
pharmaceutical dosage form comprising a pharmacologically active
ingredient having psychotropic action and an ethylene-vinyl acetate
(EVA) polymer, which dosage form provides resistance against
solvent extraction, resistance against grinding, and resistance
against dose-dumping in aqueous ethanol.
BACKGROUND OF THE INVENTION
[0003] A large number of pharmacologically active substances have a
potential for being abused or misused, i.e. they can be used to
produce effects which are not consistent with their intended use.
Thus, e.g. opioids which exhibit an excellent efficacy in
controlling severe to extremely severe pain are frequently abused
to induce euphoric states similar to being intoxicated. In
particular, active substances which have a psychotropic effect are
abused accordingly.
[0004] To enable abuse, the corresponding pharmaceutical dosage
forms, such as pharmaceutical dosage forms or capsules are crushed,
for example ground by the abuser, the active substance is extracted
from the thus obtained powder using a preferably aqueous liquid and
after being optionally filtered through cotton wool or cellulose
wadding, the resultant solution is administered parenterally, in
particular intravenously. This type of dosage results in an even
faster diffusion of the active substance compared to the oral
abuse, with the result desired by the abuser, namely the kick. This
kick or these intoxication-like, euphoric states are also reached
if the powdered pharmaceutical dosage form is administered nasally,
i.e. is sniffed.
[0005] Various concepts for the avoidance of drug abuse have been
developed.
[0006] It has been proposed to incorporate in pharmaceutical dosage
forms aversive agents and/or antagonists in a manner so that they
only produce their aversive and/or antagonizing effects when the
pharmaceutical dosage forms are tampered with. However, the
presence of such aversive agents is principally not desirable and
there is a need to provide sufficient tamper-resistance without
relying on aversive agents and/or antagonists.
[0007] Another concept to prevent abuse relies on the mechanical
properties of the pharmaceutical dosage forms, particularly an
increased breaking strength (resistance to crushing). The major
advantage of such pharmaceutical dosage forms is that comminuting,
particularly pulverization, by conventional means, such as grinding
in a mortar or fracturing by means of a hammer, is impossible or at
least substantially impeded. Thus, the pulverization, necessary for
abuse, of the pharmaceutical dosage forms by the means usually
available to a potential abuser is prevented or at least
complicated. Such pharmaceutical dosage forms are useful for
avoiding drug abuse of the pharmacologically active ingredient
contained therein, as they may not be powdered by conventional
means and thus, cannot be administered in powdered form, e.g.
nasally. The mechanical properties, particularly the high breaking
strength of these pharmaceutical dosage forms renders them
tamper-resistant. In the context of such tamper-resistant
pharmaceutical dosage forms it can be referred to, e.g., WO
2005/016313, WO 2005/016314, WO 2005/063214, WO 2005/102286, WO
2006/002883, WO 2006/002884, WO 2006/002886, WO 2006/082097, WO
2006/082099, and WO2009/092601.
[0008] Besides tampering of pharmaceutical dosage forms in order to
abuse the drugs contained therein, the potential impact of
concomitant intake of ethanol on the in vivo release of drugs from
modified release oral formulations (dose-dumping) has recently
become an increasing concern. Controlled or modified release
formulations typically contain a higher amount of the
pharmacologically active ingredient relative to its immediate
release counterpart. If the controlled release portion of the
formulation is easily defeated, the end result is a potential
increase in exposure to the active drug and possible safety
concerns. In order to improve safety and circumvent intentional
tampering (e.g. dissolving a controlled release pharmaceutical
dosage form in ethanol to extract the drug), a reduction in the
dissolution of the modified release fractions of such formulations,
in ethanol, may be of benefit.
[0009] Accordingly, the need exists to develop new formulations
having reduced potential for dose dumping in alcohol.
[0010] The properties of these pharmaceutical dosage forms of the
prior art, however, are not satisfactory in every respect.
[0011] C. Vervaet et al., Eur. J. Pharm. Biopharm. 77, 2011,
297-305 disclose ethylene vinyl acetate as matrix for oral
sustained release dosage forms which contain metoprolol tartrate as
the pharmacologically active ingredient and are produced via
hot-melt extrusion. C. Vervaet et al., Eur. J. Pharm. Biopharm. 82,
2012, 526-533 discloses sustained release of metoprolol tartrate
from hot-melt extruded matrices based on ethylene vinyl acetate and
polyethylene oxide. B. Sreenivasa Rao et al., Indian J. Pharm. Sci.
65, 2003, 496-502 disclose a method of preparation of sintered
matrix tablets of rifampicin with ethylene-vinyl acetate copolymer
for controlling the release rate. However, these references are
fully silent on the possibility of preparing tamper-resistant
pharmaceutical dosage forms from ethylene-vinyl acetate (EVA)
polymers.
[0012] WO 2009/051819 A1 disclose implants for delivery of
therapeutic agents such as opioids, and the manufacture and uses of
such implants. WO 03/070191 A1 discloses a transdermal-delivery
device which is said to be tamper-resistant and comprises an
opioid, or a pharmaceutically acceptable salt thereof, and an acyl
opiod antagonist, or a pharmaceutically acceptable salt
thereof.
[0013] It is an object of the invention to provide tamper-resistant
and dose-dumping resistant, oral pharmaceutical dosage forms
containing a pharmacologically active ingredient having
psychotropic action which have advantages compared to the
pharmaceutical dosage forms of the prior art.
[0014] This object has been achieved by the patent claims.
[0015] It has been surprisingly found that a pharmaceutical dosage
form comprising ethylene-vinyl acetate (EVA) polymer and a
pharmacologically active ingredient having psychotropic action can
be prepared, wherein the pharmaceutical dosage form exhibits tamper
resistance, especially in terms of resistance against solvent
extraction of the pharmacologically active ingredient, resistance
against grinding of the pharmaceutical dosage form, respectively,
and resistance against dose-dumping of the pharmacologically active
ingredient in aqueous ethanol.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The invention will now be described in greater detail with
reference to the drawings, wherein:
[0017] FIG. 1 is a graph depicting the results of the sieving
analysis referred to in Example 1;
[0018] FIG. 2 is a graph depicting the results of the sieving
analysis referred to in Example 2;
[0019] FIG. 3 is a chart showing the release profiles of the
indicated exemplified embodiments;
[0020] FIG. 4 is a chart showing the release profiles of the
indicated exemplified embodiments;
[0021] FIG. 5 is a chart showing the release profiles of the
indicated exemplified embodiments;
[0022] FIG. 6 is a chart showing the release profiles of the
indicated exemplified embodiments;
[0023] FIG. 7 is a chart showing the release profiles of the
indicated exemplified embodiments; and
[0024] FIG. 8 is a chart showing the release profiles of the
indicated exemplified embodiments.
[0025] A first aspect of the invention relates to a
tamper-resistant, oral pharmaceutical dosage form comprising a
pharmacologically active ingredient having psychotropic action and
an ethylene-vinyl acetate (EVA) polymer, which dosage form provides
resistance against solvent extraction, resistance against grinding,
and resistance against dose-dumping in aqueous ethanol.
[0026] Preferably, the pharmaceutical dosage form according to the
invention is thermoformed, more preferably hot-melt extruded.
Thermoforming preferably means that in the course of the
manufacture of the pharmaceutical dosage form the mixture
comprising the EVA polymer and the pharmacologically active
ingredient is heated to a temperature above ambient temperature,
preferably at least 60.degree. C. or at least 80.degree. C., and
compressed, preferably at pressures of at least 1 bar or at least 2
bar, more preferably at least 10 bar or at least 30 bar. The
compression force may be exerted prior to, during or subsequent to
the application of heat.
[0027] As used herein, the term "pharmaceutical dosage form" refers
to a pharmaceutical entity that is comprised of a pharmacologically
active ingredient and which is actually administered to, or taken
by, a patient. It may be compressed or molded in its manufacture,
and it may be of almost any size, shape, weight, and color.
[0028] The pharmaceutical dosage form is preferably solid or
semisolid.
[0029] Examples of pharmaceutical dosage forms according to the
invention include, but are not limited to, tablets, capsules,
pills, granules, pellets, sachets and effervescent, powders, and
the like. In an embodiment of the present invention, the
composition is formulated in a capsule. In accordance with this
embodiment, the pharmaceutical dosage form comprises a hard or soft
gelatin capsule.
[0030] Most pharmaceutical dosage forms are intended to be
swallowed whole and accordingly, the pharmaceutical dosage forms
according to the invention are designed for oral
administration.
[0031] In a preferred embodiment, the pharmaceutical dosage form
according to the invention is monolithic. In this regard,
monolithic preferably means that the pharmaceutical dosage form is
formed or composed of material without joints or seams or consists
of or constitutes a single unit.
[0032] In another preferred embodiment, the pharmaceutical dosage
form according to the invention is not monolithic. Preferably, the
pharmaceutical dosage form according to the invention is
multiparticulate, i.e. comprises a multitude of particles. An
advantage of multiparticulate pharmaceutical dosage forms is that
the particles may be mixed in different amounts to thereby produce
pharmaceutical dosage forms of different strengths.
[0033] In a preferred embodiment, the pharmaceutical dosage form
according to the invention can be regarded as a MUPS formulation
(multiple unit pellet system). Preferably, the pharmaceutical
dosage form according to the invention contains all ingredients in
a dense compact unit which in comparison to capsules has a
comparatively high density. Under these circumstances, the
pharmaceutical dosage forms according to the invention preferably
comprise subunits having different morphology and properties,
namely drug-containing particles and an outer matrix material,
wherein the particles form a discontinuous phase within the outer
matrix material. The constituents of the outer matrix material are
preferably different from the constituents of the drug-containing
particles. Preferably, the outer matrix material neither contains a
pharmacologically active ingredient having psychotropic action nor
an EVA polymer.
[0034] The particles typically have mechanical properties that
differ from the mechanical properties of the outer matrix material.
Preferably, the particles have a higher mechanical strength than
the outer matrix material. The particles can preferably be
visualized by conventional means such as solid state nuclear
magnetic resonance spectroscopy, raster electron microscopy,
terahertz spectroscopy and the like.
[0035] The pharmaceutical dosage form according to the invention
has preferably a total weight in the range of 0.01 to 1.5 g, more
preferably in the range of 0.05 to 1.2 g, still more preferably in
the range of 0.1 g to 1.0 g, yet more preferably in the range of
0.2 g to 0.9 g, and most preferably in the range of 0.3 g to 0.8 g.
In a preferred embodiment, the total weight of the pharmaceutical
dosage form is within the range of 350.+-.300 mg, more preferably
350.+-.250 mg, still more preferably 350.+-.200 mg, yet more
preferably 350.+-.150 mg, most preferably 350.+-.100 mg, and in
particular 350.+-.50 mg. In another preferred embodiment, the total
weight of the pharmaceutical dosage form is within the range of
500.+-.450 mg, more preferably 500.+-.300 mg, still more preferably
500.+-.200 mg, yet more preferably 500.+-.150 mg, most preferably
500.+-.100 mg, and in particular 500.+-.50 mg.
[0036] In a preferred embodiment, the pharmaceutical dosage form
according to the invention is a round pharmaceutical dosage form.
Pharmaceutical dosage forms of this embodiment preferably have a
diameter in the range of about 1 mm to about 30 mm, in particular
in the range of about 2 mm to about 25 mm, more in particular about
5 mm to about 23 mm, even more in particular about 7 mm to about 13
mm; and a thickness in the range of about 1.0 mm to about 12 mm, in
particular in the range of about 2.0 mm to about 10 mm, even more
in particular from 3.0 mm to about 9.0 mm, even further in
particular from about 4.0 mm to about 8.0 mm.
[0037] In another preferred embodiment, the pharmaceutical dosage
form according to the invention is an oblong pharmaceutical dosage
form. Pharmaceutical dosage forms of this embodiment preferably
have a lengthwise extension (longitudinal extension) of about 1 mm
to about 30 mm, in particular in the range of about 2 mm to about
25 mm, more in particular about 5 mm to about 23 mm, even more in
particular about 7 mm to about 20 mm; a width in the range of about
1 mm to about 30 mm, in particular in the range of about 2 mm to
about 25 mm, more in particular about 5 mm to about 23 mm, even
more in particular about 7 mm to about 13 mm; and a thickness in
the range of about 1.0 mm to about 12 mm, in particular in the
range of about 2.0 mm to about 10 mm, even more in particular from
3.0 mm to about 9.0 mm, even further in particular from about 4.0
mm to about 8.0 mm.
[0038] When the pharmaceutical dosage form according to the
invention is monolithic, it preferably has an extension in any
direction of at least 2.0 mm, more preferably at least 2.5 mm,
still more preferably at least 3.0 mm, yet more preferably at least
3.5 mm, even more preferably at least 4.0 mm, most preferably at
least 4.5 mm and in particular at least 5.0 mm. Preferably, when
the dosage form is monolithic, it has an extension in any direction
of more than 2.0 mm.
[0039] For the purpose of specification, "in any direction"
preferably means in every direction in the three-dimensional
space.
[0040] The pharmaceutical dosage form according to the invention
may optionally comprise a coating, e.g. a cosmetic coating. The
coating is preferably applied after formation of the pharmaceutical
dosage form. The coating may be applied prior to or after the
curing process. The pharmaceutical dosage forms according to the
invention are preferably film coated with conventional film coating
compositions. Suitable coating materials are commercially
available, e.g. under the trademarks Opadry.RTM. and
Eudragit.RTM..
[0041] Examples of suitable materials include cellulose esters and
cellulose ethers, such as methylcellulose (MC),
hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC),
hydroxyethylcellulose (HEC), sodium carboxymethylcellulose
(Na-CMC), poly(meth)-acrylates, such as aminoalkylmethacrylate
copolymers, methacrylic acid methylmethacrylate copolymers,
methacrylic acid methylmethacrylate copolymers; vinyl polymers,
such as polyvinylpyrrolidone, polyvinyl alcohol, polyvinylacetate;
and natural film formers.
[0042] The coating can be resistant to gastric juices and dissolve
as a function of the pH value of the release environment. By means
of this coating, it is possible to ensure that the pharmaceutical
dosage form according to the invention passes through the stomach
undissolved and the active compound is only released in the
intestines. The coating which is resistant to gastric juices
preferably dissolves at a pH value of between 5 and 7.5.
[0043] The coating can also be applied e.g. to improve the
aesthetic impression and/or the taste of the pharmaceutical dosage
forms and the ease with which they can be swallowed. Coating the
pharmaceutical dosage forms according to the invention can also
serve other purposes, e.g. improving stability and shelf-life.
Suitable coating formulations comprise a film forming polymer such
as, for example, polyvinyl alcohol or hydroxypropyl
methylcellulose, e.g. hypromellose, a plasticizer such as, for
example, a glycol, e.g. propylene glycol or polyethylene glycol, an
opacifier, such as, for example, titanium dioxide, and a film
smoothener, such as, for example, talc. Suitable coating solvents
are water as well as organic solvents. Examples of organic solvents
are alcohols, e.g. ethanol or isopropanol, ketones, e.g. acetone,
or halogenated hydrocarbons, e.g. methylene chloride. Coated
pharmaceutical dosage forms according to the invention are
preferably prepared by first making the cores and subsequently
coating said cores using conventional techniques, such as coating
in a coating pan.
[0044] Preferably, the pharmaceutical dosage form according to the
invention comprises a prolonged release matrix.
[0045] The prolonged release matrix in turn preferably comprises
the EVA polymer as prolonged release matrix material and optionally
additional prolonged release matrix material.
[0046] In a preferred embodiment, the prolonged release matrix does
not contain any additional prolonged release matrix material.
[0047] The pharmacologically active ingredient is preferably
embedded in the prolonged release matrix comprising the EVA
polymer. Preferably, the pharmacologically active ingredient is
dispersed in the prolonged release matrix.
[0048] Preferably, the pharmaceutical dosage form provides
prolonged release of the pharmacologically active ingredient.
Particularly preferably, the prolonged release matrix comprising
the EVA polymer provides prolonged release of the pharmacologically
active ingredient embedded therein.
[0049] In a preferred embodiment,
[0050] (i) the pharmacologically active ingredient is embedded in a
prolonged release matrix comprising the EVA polymer; and/or
[0051] (ii) the pharmaceutical dosage form provides prolonged
release of the pharmacologically active ingredient.
[0052] When the pharmaceutical dosage form according to the
invention is monolithic and comprises a prolonged release matrix,
the prolonged release matrix preferably forms the body of the
pharmaceutical dosage form.
[0053] When the pharmaceutical dosage form according to the
invention is multiparticulate, e.g. in form of pellets, the
particles preferably comprise the prolonged release matrix and at
least a portion of the total amount of the pharmacologically active
ingredient that is contained in the pharmaceutical dosage form.
Preferably, the particles comprise the total amount of the
pharmacologically active ingredient that is contained in the
pharmaceutical dosage form.
[0054] When the pharmaceutical dosage form according to the
invention can be regarded as a MUPS formulation which preferably
comprises drug-containing particles and an outer matrix material,
the outer matrix material is not a constituent of the prolonged
release matrix and is to be distinguished from the prolonged
release matrix material and the optionally present additional
prolonged release matrix material of the prolonged release matrix
of the pharmaceutical dosage form according to the invention.
[0055] For the purpose of specification, the term "particle" refers
to a discrete mass of material that is solid, e.g. at 20.degree. C.
or at room temperature or ambient temperature. Preferably a
particle is solid at 20.degree. C. Preferably, the particles are
monoliths. Preferably, the pharmacologically active ingredient and
the EVA polymer are intimately homogeneously distributed in the
particles so that the particles do not contain any segments where
either pharmacologically active ingredient is present in the
absence of EVA polymer or where EVA polymer is present in the
absence of pharmacologically active ingredient.
[0056] When the pharmaceutical dosage form is multiparticulate, it
preferably comprises a multitude i.e. plurality of particles
containing pharmacologically active ingredient (drug-containing
particles) and may optionally further comprise particles not
containing any pharmacologically active ingredient (drug-free
particles).
[0057] In a preferred embodiment, the pharmaceutical dosage form
preferably comprises at most 10, more preferably at most 9, still
more preferably at most 8, yet more preferably at most 7, even more
preferably at most 6, most preferably at most 5, and in particular
at most 4 or 3 or 2 drug-containing particles. In another preferred
embodiment, the pharmaceutical dosage form preferably comprises at
least 2, more preferably at least 4, still more preferably at least
6, yet more preferably at least 8, even more preferably at least
10, most preferably at least 15 and in particular at least 20 or at
least 100 or at least 1000 drug-containing particles.
[0058] When the particles are film coated, the EVA polymer is
preferably homogeneously distributed in the core of the particles,
i.e. the film coating preferably does not contain EVA polymer.
[0059] When the particles contain a prolonged release matrix and
are film coated, the prolonged release matrix is preferably
homogeneously distributed in the core of the particles, i.e. the
film coating preferably neither contains prolonged release matrix
material nor optionally present additional prolonged release matrix
material.
[0060] The particles are preferably of macroscopic size, typically
the average diameter is within the range of from 100 .mu.m to 2000
.mu.m, preferably 200 .mu.m to 1500 .mu.m, more preferably 300
.mu.m to 1500 .mu.m, still more preferably 400 .mu.m to 1500 .mu.m,
most preferably 500 .mu.m to 1500 .mu.m, and in particular 600
.mu.m to 1500 .mu.m. Preferably, the particles in the
pharmaceutical dosage form have an average particle size of at
least 50 .mu.m, more preferably at least 100 .mu.m, still more
preferably at least 150 .mu.m or at least 200 .mu.m, yet more
preferably at least 250 .mu.m or at least 300 .mu.m, most
preferably at least 400 .mu.m or at least 500 .mu.m, and in
particular at least 550 nm or at least 600 .mu.m. Preferably, the
particles in the pharmaceutical dosage form have an average
particle size of at least 700 .mu.m, more preferably at least 800
.mu.m, most preferably at least 900 .mu.m and in particular at
least 1000 .mu.m.
[0061] In a preferred embodiment, the pharmaceutical dosage forms
according to the invention comprise particles as a discontinuous
phase, i.e. the particles form a discontinuous phase in an outer
matrix material which in turn preferably forms a continuous phase.
In this regard, discontinuous means that not each and every
particle is in intimate contact with another particle but that the
particles are at least partially separated from one another by the
outer matrix material in which the particles are embedded. In other
words, the particles preferably do not form a single coherent mass
within the pharmaceutical dosage forms according to the
invention.
[0062] Preferably, when the pharmaceutical dosage form is
multiparticulate, the content of the particles in the
pharmaceutical dosage forms according to the invention is at most
95 wt.-%, more preferably at most 90 wt.-%, still more preferably
at most 85 wt.-%, yet more preferably at most 80 wt.-%, most
preferably at most 75 wt.-% and in particular at most 70 wt.-%,
based on the total weight of the pharmaceutical dosage forms.
[0063] Preferably, when the pharmaceutical dosage form is
multiparticulate, the content of the particles in the
pharmaceutical dosage forms according to the invention is at least
10 wt.-%, at least 15 wt.-%, at least 20 wt.-% or at least 25
wt.-%; more preferably at least 30 wt.-%, at least 35 wt.-%, at
least 40 wt.-% or at least 45 wt.-%; most preferably at least 50
wt.-%, at least 55 wt.-%, at least 60 wt.-% or at least 65 wt.-%;
and in particular at least 70 wt.-%, at least 75 wt.-%, at least 80
wt.-% or at least 85 wt.-%; based on the total weight of the
pharmaceutical dosage form.
[0064] When the pharmaceutical dosage form is multiparticulate, the
shape of the particles is not particularly limited. As the
particles are preferably manufactured by hot-melt extrusion,
preferred particles present in the pharmaceutical dosage forms
according to the invention are generally cylindrical in shape. The
diameter of such particles is therefore the diameter of their
circular cross section. The cylindrical shape is caused by the
extrusion process according to which the diameter of the circular
cross section is a function of the extrusion die and the length of
the cylinders is a function of the cutting length according to
which the extruded strand of material is cut into pieces of
preferably more or less predetermined length.
[0065] Typically, the aspect ratio is regarded as an important
measure of the spherical shape. The aspect ratio is defined as the
ratio of the maximal diameter (d.sub.max) and its orthogonal
Feret-diameter. For aspherical particles, the aspect ratio has
values above 1. The smaller the value the more spherical is the
particle. In a preferred embodiment, the aspect ratio of the
particles is at most 1.40, more preferably at most 1.35, still more
preferably at most 1.30, yet more preferably at most 1.25, even
more preferably at most 1.20, most preferably at most 1.15 and in
particular at most 1.10. In another preferred embodiment, the
aspect ratio of the particles is at least 1.10, more preferably at
least 1.15, still more preferably at least 1.20, yet more
preferably at least 1.25, even more preferably at least 1.30, most
preferably at least 1.35 and in particular at least 1.40.
[0066] Preferred particles have an average length and average
diameter of about 1000 .mu.m or less. When the particles are
manufactured by extrusion technology, the "length" of particles is
the dimension of the particles that is parallel to the direction of
extrusion. The "diameter" of particles is the largest dimension
that is perpendicular to the direction of extrusion.
[0067] Particularly preferred particles have an average diameter of
less than about 2000 more preferably less than about 1000 or 800
.mu.m, still more preferably of less than about 650 .mu.m.
Especially preferred particles have an average diameter of less
than 700 .mu.m, particularly less than 600 .mu.m, still more
particularly less than 500 .mu.m, e.g. less than 400 .mu.m.
Particularly preferred particles have an average diameter in the
range of 200-1500 .mu.m, more preferably 400-800 .mu.m, still more
preferably 450-700 .mu.m, yet more preferably 500-650 .mu.m, e.g.
about 500-600 .mu.m. Further preferred particles have an average
diameter of between about 300 .mu.m and about 400 .mu.m, of between
about 400 .mu.m and 500 .mu.m, or of between about 500 .mu.m and
600 .mu.m, or of between 600 .mu.m and 700 .mu.m or of between 700
.mu.m and 800 .mu.m.
[0068] In a preferred embodiment, particles that are present in the
pharmaceutical dosage forms according to the invention have an
average length in the range of 500 to 5000 .mu.m, more preferably
750 to 4600 .mu.m, still more preferably 1000 to 4200 .mu.m, yet
more preferably 1250 to 3800 .mu.m, even more preferably 1500 to
3400 .mu.m, most preferably 1750 to 3200 .mu.m and in particular
2000 to 3000 .mu.m. According to this embodiment, particles that
are present in the pharmaceutical dosage forms according to the
invention preferably have an average length of less than about 4000
.mu.m, more preferably less than about 3000 .mu.m, still more
preferably less than about 2000 .mu.m, e.g. a length of about 1800
.mu.m, about 1600 .mu.m about 1400 .mu.m, about 1200 .mu.m or about
1000 .mu.m.
[0069] In another preferred embodiment, particles that are present
in the pharmaceutical dosage forms according to the invention have
an average length in the range of 200 to 1000 .mu.m, more
preferably 400 to 800 still more preferably 450 to 700 .mu.m, yet
more preferably 500 to 650 .mu.m, e.g. about 500 to 600 .mu.m.
According to this embodiment, particles that are present in the
pharmaceutical dosage forms according to the invention preferably
have an average length of less than about 1000 .mu.m, more
preferably less than about 800 .mu.m, still more preferably less
than about 650 .mu.m, e.g. a length of about 800 .mu.m, about 700
.mu.m about 600 .mu.m, about 500 .mu.m, about 400 .mu.m or about
300 .mu.m. Especially preferred particles have an average length of
less than 700 .mu.m, particularly less than 650 .mu.m, still more
particularly less than 550 .mu.m, e.g. less than 450 .mu.m.
[0070] The minimum average length of the particles is determined by
the cutting step and may be, e.g. 4.0 mm, 3.0 mm, 2.0 mm, 2.5 mm,
2.0 mm, 1.5 mm, 1.0 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4
mm, 0.3 mm or 0.2 mm.
[0071] In a preferred embodiment, when the pharmaceutical dosage
form is multiparticulate, the individual drug-containing particles
have an extension in any direction of at least 2.0 mm, more
preferably at least 2.2 mm, still more preferably at least 2.5 mm,
yet more preferably at least 2.8 mm, even more preferably at least
3.0 mm, most preferably at least 3.2 mm, and in particular at least
3.5 mm or 4.0 mm. Preferably, when the dosage form is
multiparticulate, the individual drug-containing particles have an
extension in any direction of more than 2.0 mm.
[0072] In a preferred embodiment, the pharmaceutical dosage form
according to the invention is monolithic and has an extension in
any direction of more than 2.0 mm; or is multiparticulate, wherein
the individual drug-containing particles have an extension in any
direction of more than 2.0 mm.
[0073] Particularly preferably, the pharmaceutical dosage form
according to the invention is monolithic and has an extension in
any direction of at least 2.0 mm; or is multiparticulate, wherein
the individual drug-containing particles have an extension in any
direction of at least 2.0 mm.
[0074] In another preferred embodiment, [0075] the pharmaceutical
dosage form according to the invention is monolithic and has an
extension in any direction of at least 2.5 mm; or is
multiparticulate, wherein the individual drug-containing particles
have an extension in any direction of at least 2.2 mm; or [0076]
the pharmaceutical dosage form according to the invention is
monolithic and has an extension in any direction of at least 3.0
mm; or is multiparticulate, wherein the individual drug-containing
particles have an extension in any direction of at least 2.5 mm; or
[0077] the pharmaceutical dosage form according to the invention is
monolithic and has an extension in any direction of at least 3.5
mm; or is multiparticulate, wherein the individual drug-containing
particles have an extension in any direction of at least 2.8 mm; or
[0078] the pharmaceutical dosage form according to the invention is
monolithic and has an extension in any direction of at least 4.0
mm; or is multiparticulate, wherein the individual drug-containing
particles have an extension in any direction of at least 3.0 mm; or
[0079] the pharmaceutical dosage form according to the invention is
monolithic and has an extension in any direction of at least 4.5
mm; or is multiparticulate, wherein the individual drug-containing
particles have an extension in any direction of at least 3.2 mm; or
[0080] the pharmaceutical dosage form according to the invention is
monolithic and has an extension in any direction of at least 5.0
mm; or is multiparticulate, wherein the individual drug-containing
particles have an extension in any direction of at least 3.5 mm or
at least 4.0 mm.
[0081] The size of particles may be determined by any conventional
procedure known in the art, e.g. laser light scattering, sieve
analysis, light microscopy or image analysis.
[0082] Preferably, when the pharmaceutical dosage form is
multiparticulate, the plurality of particles that is contained in
the pharmaceutical dosage form according to the invention has an
arithmetic average weight, in the following referred to as "aaw",
wherein at least 70%, more preferably at least 75%, still more
preferably at least 80%, yet more preferably at least 85%, most
preferably at least 90% and in particular at least 95% of the
individual particles contained in said plurality of particles has
an individual weight within the range of aaw.+-.30%, more
preferably aaw.+-.25%, still more preferably aaw.+-.20%, yet more
preferably aaw.+-.15%, most preferably aaw.+-.10%, and in
particular aaw.+-.5%. For example, if the pharmaceutical dosage
form according to the invention contains a plurality of 100
particles and aaw of said plurality of particles is 1.00 mg, at
least 75 individual particles (i.e. 75%) have an individual weight
within the range of from 0.70 to 1.30 mg (1.00 mg.+-.30%).
[0083] In a preferred embodiment, the particles, more preferably
the drug-containing particles, each have a weight of less than 20
mg, more preferably less than 18 mg, still more preferably less
than 16 mg, yet more preferably less than 14 mg, even more
preferably less than 12 mg or less than 10 mg, most preferably less
than 8 mg, and in particular less than 6 or 4 mg. According to this
embodiment, all individual particles each preferably have a weight
of from 1 to 19 mg, more preferably 1.5 to 15 mg, still more
preferably 2.0 to 12 mg, yet more preferably 2.2 to 10 mg, even
more preferably 2.5 to 8 mg, most preferably 2.8 to 6 mg and in
particular 3 to 5 mg.
[0084] In another preferred embodiment, the particles, more
preferably the drug-containing particles, each have a weight of 20
mg or more. According to this embodiment, all individual particles
preferably each have a weight of at least 30 mg, more preferably at
least 40 mg, still more preferably at least 50 mg, most preferably
at least 60 mg and in particular at least 100 mg. Preferably, all
individual particles each have a weight of from 20 to 1000 mg, more
preferably 30 to 800 mg, still more preferably 40 to 600 mg, yet
more preferably 50 to 400 mg, even more preferably 60 to 200 mg,
most preferably 70 to 150 mg and in particular 80 to 120 mg.
According to this embodiment, the particles of the pharmaceutical
dosage form, more preferably the drug-containing particles of the
pharmaceutical dosage form, preferably each have an extension in
any given direction of at least 2.0 mm or 3.0 mm and have a weight
of at least 20 mg.
[0085] In a preferred embodiment, when the pharmaceutical dosage
form is multiparticulate, the particles are not film coated.
[0086] In another preferred embodiment, when the pharmaceutical
dosage form is multiparticulate, the particles are film coated. The
particles according to the invention can optionally be provided,
partially or completely, with a conventional coating. The particles
are preferably film coated with conventional film coating
compositions. Suitable coating materials are commercially
available, e.g. under the trademarks Opadry.RTM. and
Eudragit.RTM..
[0087] Examples of suitable materials include cellulose esters and
cellulose ethers, such as methylcellulose (MC),
hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC),
hydroxyethylcellulose (HEC), sodium carboxymethylcellulose
(Na-CMC), ethylcellulose (EC), cellulose acetate phthalate (CAP),
hydroxypropylmethylcellulose phthalate (HPMCP);
poly(meth)acrylates, such as aminoalkylmethacrylate copolymers,
ethylacrylate methylmethacrylate copolymers, methacrylic acid
methylmethacrylate copolymers, methacrylic acid methylmethacrylate
copolymers; vinyl polymers, such as polyvinylpyrrolidone,
polyvinyl-acetatephthalate, polyvinyl alcohol, polyvinyl
alcohol-polyethylene glycol graft copolymers, polyvinylacetate; and
natural film formers.
[0088] The coating material may contain excipients such as
stabilizers (e.g. surfactants such as macrogol cetostearylether,
sodium dodecylsulfate, and the like). Suitable excipients of film
coating materials are known to the skilled person.
[0089] In a particularly preferred embodiment, the coating is
water-soluble.
[0090] Though less preferred, the coating can principally be
resistant to gastric juices and dissolve as a function of the pH
value of the release environment. By means of this coating, it is
possible to ensure that the pharmaceutical dosage form according to
the invention passes through the stomach undissolved and the active
compound is only released in the intestines. The coating which is
resistant to gastric juices preferably dissolves at a pH value of
between 5 and 7.5. Corresponding materials and methods for the
delayed release of active compounds and for the application of
coatings which are resistant to gastric juices are known to the
person skilled in the art, for example from "Coated Pharmaceutical
dosage forms--Fundamentals, Manufacturing Techniques,
Biopharmaceutical Aspects, Test Methods and Raw Materials" by Kurt
H. Bauer, K. Lehmann, Hermann P. Osterwald, Rothgang, Gerhart, 1st
edition, 1998, Medpharm Scientific Publishers.
[0091] A particularly preferred coating contains polyvinyl alcohol
and optionally, further excipients such as xanthan gum and/or
talcum.
[0092] When the pharmaceutical dosage form is multiparticulate, the
particles contain at least a pharmacologically active ingredient
having psychotropic action and an EVA polymer, preferably a
prolonged release matrix containing the EVA polymer as prolonged
release matrix material and optionally additional prolonged release
matrix material. Preferably, however, the particles further contain
additional pharmaceutical excipients such as antioxidants and
plasticizers.
[0093] When the pharmaceutical dosage form is multiparticulate, the
particles may be e.g. loosely contained in a capsule, or the
particles may be incorporated into an outer matrix material. From a
macroscopic perspective, the outer matrix material preferably forms
a continuous phase in which the particles are embedded as
discontinuous phase.
[0094] Preferably, the outer matrix material is preferably a
homogenous coherent mass, preferably a homogeneous mixture of solid
constituents, in which the particles are embedded thereby spatially
separating the particles from one another. While it is possible
that the surfaces of particles are in contact or at least in very
close proximity with one another, the plurality of particles
preferably cannot be regarded as a single continuous coherent mass
within the pharmaceutical dosage form.
[0095] In other words, when the pharmaceutical dosage form is
multiparticulate and the particles are contained in an outer matrix
material, the pharmaceutical dosage form according to the invention
preferably comprises the particles as volume element(s) of a first
type in which the pharmacologically active ingredient and the EVA
polymer are contained, and the outer matrix material as volume
element of a second type differing from the material that forms the
particles, preferably containing neither pharmacologically active
ingredient nor EVA polymer.
[0096] When the pharmaceutical dosage form is multiparticulate and
the particles are contained in an outer matrix material, the
relative weight ratio of particles to outer matrix material is not
particularly limited. Preferably, said relative weight ratio is
within the range of 1:1.00.+-.0.75, more preferably 1:1.00.+-.0.50,
still more preferably 1:1.00.+-.0.40, yet more preferably
1:1.00.+-.0.30, most preferably 1:1.00.+-.0.20, and in particular
1:1.00.+-.0.10.
[0097] Preferably, the content of the outer matrix material is at
least 2.5 wt.-%, at least 5 wt.-%, at least 7.5 wt.-% or at least
10 wt.-%; at least 12.5 wt.-%, at least 15 wt.-%, at least 17.5
wt.-% or at least 20 wt.-%; at least 22.5 wt.-%, at least 25 wt.-%,
at least 27.5 wt.-% or at least 30 wt.-%; at least 32.5 wt.-%, at
least 35 wt.-%, at least 37.5 wt.-% or at least 40 wt.-%; more
preferably at least 42.5 wt.-%, at least 45 wt.-%, at least 47.5
wt.-% or at least 50 wt.-%; still more preferably at least 52.5
wt.-%, at least 55 wt.-%, at least 57.5 wt.-% or at least 60 wt.-%;
yet more preferably at least 62.5 wt.-%, at least 65 wt.-%, at
least 67.5 wt.-% or at least 60 wt.-%; most preferably at least
72.5 wt.-%, at least 75 wt.-%, at least 77.5 wt.-% or at least 70
wt.-%; and in particular at least 82.5 wt.-%, at least 85 wt.-%, at
least 87.5 wt.-% or at least 90 wt.-%; based on the total weight of
the pharmaceutical dosage form.
[0098] Preferably, the content of the outer matrix material is at
most 90 wt.-%, at most 87.5 wt.-%, at most 85 wt.-%, or at most
82.5 wt.-%; more preferably at most 80 wt.-%, at most 77.5 wt.-%,
at most 75 wt.-% or at most 72.5 wt.-%; still more preferably at
most 70 wt.-%, at most 67.5 wt.-%, at most 65 wt.-% or at most 62.5
wt.-%; yet more preferably at most 60 wt.-%, at most 57.5 wt.-%, at
most 55 wt.-% or at most 52.5 wt.-%; most preferably at most 50
wt.-%, at most 47.5 wt.-%, at most 45 wt.-% or at most 42.5 wt.-%;
and in particular at most 40 wt.-%, at most 37.5 wt.-%, or at most
35 wt.-%; based on the total weight of the pharmaceutical dosage
form.
[0099] Preferably, the outer matrix material is a mixture,
preferably a homogeneous mixture of at least two different
constituents, more preferably of at least three different
constituents. In a preferred embodiment, all constituents of the
outer matrix material are homogeneously distributed in the
continuous phase that is formed by the outer matrix material.
[0100] Preferably, the outer matrix material is also provided in
particulate form, i.e. in the course of the manufacture of the
pharmaceutical dosage forms according to the invention, the
constituents of the outer matrix material are preferably processed
into particles, subsequently mixed with the particles that contain
the pharmacologically active ingredient and the EVA polymer, and
then compressed into the pharmaceutical dosage forms.
[0101] Preferably, the average size of the particles of the outer
matrix material is within the range of .+-.60%, more preferably
.+-.50%, still more preferably .+-.40%, yet more preferably
.+-.30%, most preferably .+-.20%, and in particular .+-.10% of the
average size of the particles that contain the pharmacologically
active ingredient and the EVA polymer.
[0102] The particles of the outer matrix material can be
manufactured by conventional methods for the preparation of
aggregates and agglomerates from powder mixtures such as
granulating and compacting.
[0103] In a preferred embodiment, the mixture of all constituents
of the outer matrix material is blended and pre-compacted thereby
yielding a pre-compacted outer matrix material.
[0104] The outer matrix material preferably does not contain any
pharmacologically active ingredient.
[0105] Preferably, the outer matrix material comprises a filler or
a binder. As many fillers can be regarded as binders and vice
versa, for the purpose of specification "filler/binder" refers to
any excipient that is suitable as filler, binder or both. Thus, the
outer matrix material preferably comprises a filler/binder.
[0106] Preferred fillers (=filler/binders) are selected from the
group consisting of silicium dioxide (e.g. Aerosil.RTM.),
microcrystalline cellulose (e.g. Avicel.RTM., Elcema.RTM.,
Emocel.RTM., ExCel.RTM., Vitacell.RTM.); cellulose ether (e.g.
Natrosol.RTM., Klucel.RTM., Methocel.RTM., Blanose.RTM.,
Pharmacoat.RTM., Viscontran.RTM.); mannitol; dextrines; dextrose;
calciumhydrogen phosphate (e.g. Emcompress.RTM.); maltodextrine
(e.g. Emdex.RTM.); lactose (e.g. Fast-Flow Lactose.RTM.;
Ludipress.RTM., Pharmaceutical dosage Formtose.RTM., Zeparox.RTM.);
polyvinylpyrrolidone (PVP) (e.g. Kollidone.RTM., Polyplasdone.RTM.,
Polydone.RTM.); saccharose (e.g. Nu-Tab.RTM., Sugar Tab.RTM.);
magnesium salts (e.g. MgCO.sub.3, MgO, MgSiO.sub.3); starches and
pretreated starches (e.g. Prejel.RTM., Primotab.RTM. ET,
Starch.RTM. 1500). Preferred binders are selected from the group
consisting of alginates; chitosanes; and any of the fillers
mentioned above (=fillers/binders).
[0107] Some fillers/binders may also serve other purposes. It is
known, for example, that silicium dioxide exhibits excellent
function as a glidant. Thus, preferably, the outer matrix material
comprises a glidant such as silicium dioxide.
[0108] In a preferred embodiment, the content of the filler/binder
or mixture of fillers/binders in the outer matrix material is
within the range of 50.+-.25 wt.-%, more preferably 50.+-.20 wt.-%,
still more preferably 50.+-.15 wt.-%, yet more preferably 50.+-.10
wt.-%, most preferably 50.+-.7.5 wt.-%, and in particular 50.+-.5
wt.-%, based on the total weight of outer matrix material. In
another preferred embodiment, the content of the filler/binder or
mixture of fillers/binders in the outer matrix material is within
the range of 65.+-.25 wt.-%, more preferably 65.+-.20 wt.-%, still
more preferably 65.+-.15 wt.-%, yet more preferably 65.+-.10 wt.-%,
most preferably 65.+-.7.5 wt.-%, and in particular 65.+-.5 wt.-%,
based on the total weight of outer matrix material. In still
another preferred embodiment, the content of the filler/binder or
mixture of fillers/binders in the outer matrix material is within
the range of 80.+-.19 wt.-%, more preferably 80.+-.17.5 wt.-%,
still more preferably 80.+-.15 wt.-%, yet more preferably 80.+-.10
wt.-%, most preferably 80.+-.7.5 wt.-%, and in particular 80.+-.5
wt.-%, based on the total weight of outer matrix material. In
another preferred embodiment, the content of the filler/binder or
mixture of fillers/binders in the outer matrix material is within
the range of 90.+-.9 wt.-%, more preferably 90.+-.8 wt.-%, still
more preferably 90.+-.7 wt.-%, yet more preferably 90.+-.6 wt.-%,
most preferably 90.+-.5 wt.-%, and in particular 90.+-.4 wt.-%,
based on the total weight of outer matrix material.
[0109] In a preferred embodiment, the content of the filler/binder
or mixture of fillers/binders in the pharmaceutical dosage form is
within the range of 25.+-.24 wt.-%, more preferably 25.+-.20 wt.-%,
still more preferably 25.+-.16 wt.-%, yet more preferably 25.+-.12
wt.-%, most preferably 25.+-.8 wt.-%, and in particular 25.+-.4
wt.-%, based on the total weight of pharmaceutical dosage form. In
another preferred embodiment, the content of the filler/binder or
mixture of fillers/binders in the pharmaceutical dosage form is
within the range of 30.+-.29 wt.-%, more preferably 30.+-.25 wt.-%,
still more preferably 30.+-.20 wt.-%, yet more preferably 30.+-.15
wt.-%, most preferably 30.+-.10 wt.-%, and in particular 30.+-.5
wt.-%, based on the total weight of pharmaceutical dosage form. In
still another preferred embodiment, the content of the
filler/binder or mixture of fillers/binders in the pharmaceutical
dosage form is within the range of 35.+-.34 wt.-%, more preferably
35.+-.28 wt.-%, still more preferably 35.+-.22 wt.-%, yet more
preferably 35.+-.16 wt.-%, most preferably 35.+-.10 wt.-%, and in
particular 35.+-.4 wt.-%, based on the total weight of
pharmaceutical dosage form. In another preferred embodiment, the
content of the filler/binder or mixture of fillers/binders in the
pharmaceutical dosage form is within the range of 40.+-.39 wt.-%,
more preferably 40.+-.32 wt.-%, still more preferably 40.+-.25
wt.-%, yet more preferably 40.+-.18 wt.-%, most preferably 40.+-.11
wt.-%, and in particular 40.+-.4 wt.-%, based on the total weight
of pharmaceutical dosage form.
[0110] Preferably, the filler/binder is contained in the outer
matrix material but not in the drug-containing particles of the
pharmaceutical dosage form according to the invention.
[0111] Preferably, the outer matrix material comprises a diluent or
lubricant, preferably selected from the group consisting of calcium
stearate; magnesium stearate; glycerol monobehenate (e.g.
Compritol.RTM.); Myvatex.RTM.; Precirol.RTM.; Precirol.RTM. AtoS;
sodium stearylfumarate (e.g. Pruv.RTM.); and talcum. Magnesium
stearate is particularly preferred. Preferably, the content of the
lubricant in the outer matrix material is at most 10.0 wt.-%, more
preferably at most 7.5 wt.-%, still more preferably at most 5.0
wt.-%, yet more preferably at most 2.0 wt.-%, even more preferably
at most 1.0 wt.-%, and most preferably at most 0.5 wt.-%, based on
the total weight of the outer matrix material and based on the
total weight of pharmaceutical dosage form.
[0112] In particularly preferred embodiment, the outer matrix
material comprises a combination of filler/binder and
lubricant.
[0113] The outer matrix material of the pharmaceutical dosage forms
according to the invention may additionally contain other
excipients that are conventional in the art, e.g. diluents,
binders, granulating aids, colorants, flavor additives, glidants,
wet-regulating agents and disintegrants. The skilled person will
readily be able to determine appropriate quantities of each of
these excipients.
[0114] In a preferred embodiment, however, the outer matrix
material of the pharmaceutical dosage form according to the
invention consists of one or more disintegrants, one or more
filler/binder's and one or more lubricants, but does not contain
any other constituents.
[0115] In a particularly preferred embodiment, the outer matrix
material of the pharmaceutical dosage form according to the
invention does not contain one or more gel-forming agents and/or a
silicone.
[0116] As used herein the term "gel-forming agent" is used to refer
to a compound that, upon contact with a solvent (e.g. water),
absorbs the solvent and swells, thereby forming a viscous or
semi-viscous substance. Preferred gel-forming agents are not
cross-linked. This substance may moderate pharmacologically active
ingredient release from the embedded particles in both aqueous and
aqueous alcoholic media. Upon full hydration, a thick viscous
solution or dispersion is typically produced that significantly
reduces and/or minimizes the amount of free solvent which can
contain an amount of solubilized pharmacologically active
ingredient, and which can be drawn into a syringe. The gel that is
formed may also reduce the overall amount of pharmacologically
active ingredient extractable with the solvent by entrapping the
pharmacologically active ingredient within a gel structure. Thus
the gel-forming agent may play an important role in conferring
tamper-resistance to the pharmaceutical dosage forms according to
the invention.
[0117] Gel-forming agents that preferably are not contained in the
outer matrix material include pharmaceutically acceptable polymers,
typically hydrophilic polymers, such as hydrogels. Representative
examples of gel-forming agent include polyalkylene oxide such as
polyethylene oxide, polyvinyl alcohol, hydroxypropylmethyl
cellulose, carbomers, poly(uronic) acids and mixtures thereof.
[0118] When the pharmaceutical dosage form comprises a prolonged
release matrix in which the pharmacologically active ingredient is
embedded, preferably, the overall content of the prolonged release
matrix, i.e. of the prolonged release matrix material and the
optionally present additional prolonged release matrix material, is
within the range of from 5 to 95 wt.-%, more preferably 15 to 90
wt.-%, still more preferably 25 to 88 wt.-%, yet more preferably 35
to 86 wt.-%, even more preferably 45 to 84 wt.-%, most preferably
55 to 82 wt.-% and in particular 60 to 80 wt.-%, relative to the
total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0119] In a preferred embodiment, the content of the prolonged
release matrix is at least 20 wt.-%, more preferably at least 30
wt.-%, still more preferably at least 40 wt.-%, yet more preferably
at least 50 wt.-% and in particular at least 60 wt.-%, either based
on the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0120] In a preferred embodiment, the overall content of prolonged
release matrix is within the range of 30.+-.20 wt.-%, more
preferably 30.+-.15 wt.-%, most preferably 30.+-.10 wt.-%, and in
particular 30.+-.5 wt.-%, either based on the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, based on the total weight of the particles
that contain the pharmacologically active ingredient.
[0121] In another preferred embodiment, the overall content of
prolonged release matrix is within the range of 35.+-.20 wt.-%,
more preferably 35.+-.15 wt.-%, most preferably 35.+-.10 wt.-%, and
in particular 35.+-.5 wt.-%, either based on the total weight of
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0122] In still another preferred embodiment, the overall content
of prolonged release matrix is within the range of 40.+-.20 wt.-%,
more preferably 40.+-.15 wt.-%, and most preferably 40.+-.10 wt.-%,
and in particular 40.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0123] In yet another preferred embodiment, the overall content of
prolonged release matrix is within the range of 45.+-.20 wt.-%,
more preferably 45.+-.15 wt.-%, and most preferably 45.+-.10 wt.-%,
and in particular 45.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0124] In even another preferred embodiment, the overall content of
prolonged release matrix is within the range of 50.+-.20 wt.-%,
more preferably 50.+-.15 wt.-%, and most preferably 50.+-.10 wt.-%,
and in particular 50.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0125] In a further preferred embodiment, the overall content of
prolonged release matrix is within the range of 55.+-.20 wt.-%,
more preferably 55.+-.15 wt.-%, and most preferably 55.+-.10 wt.-%,
and in particular 55.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0126] In still a further preferred embodiment, the overall content
of prolonged release matrix is within the range of 60.+-.20 wt.-%,
more preferably 60.+-.15 wt.-%, and most preferably 60.+-.10 wt.-%,
and in particular 60.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0127] In yet a further preferred embodiment, the overall content
of prolonged release matrix is within the range of 65.+-.20 wt.-%,
more preferably 65.+-.15 wt.-%, and most preferably 65.+-.10 wt.-%,
and in particular 65.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0128] In even a further preferred embodiment, the overall content
of prolonged release matrix is within the range of 70.+-.20 wt.-%,
more preferably 70.+-.15 wt.-%, and most preferably 70.+-.10 wt.-%,
and in particular 70.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0129] In another further preferred embodiment, the overall content
of prolonged release matrix is within the range of 75.+-.20 wt.-%,
more preferably 75.+-.15 wt.-%, and most preferably 75.+-.10 wt.-%,
and in particular 75.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0130] In still another preferred embodiment, the overall content
of prolonged release matrix is within the range of 80.+-.20 wt.-%,
more preferably 80.+-.15 wt.-%, and most preferably 80.+-.10 wt.-%,
and in particular 80.+-.5 wt.-%, either based on the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0131] Preferably, the relative weight ratio of the prolonged
release matrix to the pharmacologically active ingredient is within
the range of 20:1 to 1:20, more preferably 15:1 to 1:15, still more
preferably 10:1 to 1:10, yet more preferably 7:1 to 1:7, most
preferably 5:1 to 1:5, and in particular 3:1 to 1:1.
[0132] Irrespective of whether the pharmaceutical dosage form is
multiparticulate or not, the pharmaceutical dosage form according
to the invention comprises a pharmacologically active ingredient
having psychotropic action and an EVA polymer.
[0133] Particularly preferably, the pharmaceutical dosage form
according to the invention comprises a prolonged release matrix
containing the EVA polymer as prolonged release matrix material in
which the pharmacologically active ingredient is embedded.
[0134] Preferably, the EVA polymer is obtainable by polymerizing a
mixture containing ethylene and vinyl acetate. Subsequent to the
polymerization reaction, the acetate groups of the vinyl acetate
contained in the EVA polymer may optionally be subjected to a
partial or complete hydrolyzation yielding hydroxy groups.
[0135] In a preferred embodiment, the EVA polymer comprises
repetition units derived from ethylene and vinyl acetate and/or
vinyl alcohol.
[0136] According to this embodiment, the EVA polymer may comprise
repetition units derived from
[0137] (i) ethylene and vinyl acetate; or
[0138] (ii) ethylene and vinyl alcohol; or
[0139] (ii) ethylene, vinyl acetate and vinyl alcohol.
[0140] Embodiments (i) and (iii) are particularly preferred.
[0141] Preferably, the relative molar content of the ethylene
repetition units within the EVA polymer is greater than the
relative molar content of the vinyl acetate repetition units and/or
the vinyl alcohol repetition units within the EVA polymer.
[0142] Preferably, the EVA polymer contains at least 10 wt.-%, more
preferably at least 20 wt.-%, still more preferably at least 25
wt.-%, yet more preferably at least 30 wt.-%, even more preferably
at least 35 wt.-%, most preferably at least 40 wt.-% and in
particular at least 45 wt.-% of ethylene repetition units, relative
to the total weight of the EVA polymer.
[0143] Particularly preferably, the EVA polymer contains at least
50 wt.-%, more preferably at least 52 wt.-%, still more preferably
at least 54 wt.-%, yet more preferably at least 55 wt.-%, even more
preferably at least 56 wt.-%, most preferably at least 57 wt.-% and
in particular at least 58 wt.-% of ethylene repetition units,
relative to the total weight of the EVA polymer.
[0144] In another preferred embodiment, the EVA polymer contains at
least 60 wt.-%, more preferably at least 62 wt.-%, still more
preferably at least 64 wt.-%, yet more preferably at least 66
wt.-%, even more preferably at least 68 wt.-%, most preferably at
least 69 wt.-% and in particular at least 70 wt.-% of ethylene
repetition units, relative to the total weight of the EVA
polymer.
[0145] In still another preferred embodiment, the EVA polymer
contains at least 72 wt.-%, more preferably at least 75 wt.-%,
still more preferably at least 78 wt.-%, yet more preferably at
least 80 wt.-%, even more preferably at least 82 wt.-%, most
preferably at least 84 wt.-% and in particular at least 86 wt.-% of
ethylene repetition units, relative to the total weight of the EVA
polymer.
[0146] Preferably, the EVA polymer contains from 30 to 99 wt.-% of
ethylene repetition units, relative to the total weight of the EVA
polymer.
[0147] Particularly preferably, the EVA polymer contains from 50 to
95 wt.-% of ethylene repetition units, relative to the total weight
of the EVA polymer.
[0148] In a preferred embodiment, the EVA polymer contains 30.+-.25
wt.-%, more preferably 30.+-.20 wt.-%, still more preferably
30.+-.17 wt.-%, yet more preferably 30.+-.13 wt.-%, even more
preferably 30.+-.10 wt.-%, most preferably 30.+-.7 wt.-% and in
particular 30.+-.5 wt.-% of ethylene repetition units, relative to
the total weight of the EVA polymer.
[0149] In another preferred embodiment, the EVA polymer contains
40.+-.35 wt.-%, more preferably 40.+-.30 wt.-%, still more
preferably 40.+-.25 wt.-%, yet more preferably 40.+-.20 wt.-%, even
more preferably 40.+-.15 wt.-%, most preferably 40.+-.10 wt.-% and
in particular 40.+-.5 wt.-% of ethylene repetition units, relative
to the total weight of the EVA polymer.
[0150] In still another preferred embodiment, the EVA polymer
contains 50.+-.45 wt.-%, more preferably 50.+-.35 wt.-%, still more
preferably 50.+-.25 wt.-%, yet more preferably 50.+-.20 wt.-%, even
more preferably 50.+-.15 wt.-%, most preferably 50.+-.10 wt.-% and
in particular 50.+-.5 wt.-% of ethylene repetition units, relative
to the total weight of the EVA polymer.
[0151] In yet another preferred embodiment, the EVA polymer
contains 60.+-.35 wt.-%, more preferably 60.+-.30 wt.-%, still more
preferably 60.+-.25 wt.-%, yet more preferably 60.+-.20 wt.-%, even
more preferably 60.+-.15 wt.-%, most preferably 60.+-.10 wt.-% and
in particular 60.+-.5 wt.-% of ethylene repetition units, relative
to the total weight of the EVA polymer.
[0152] In a further preferred embodiment, the EVA polymer contains
70.+-.25 wt.-%, more preferably 70.+-.20 wt.-%, still more
preferably 70.+-.17 wt.-%, yet more preferably 70.+-.13 wt.-%, even
more preferably 70.+-.10 wt.-%, most preferably 70.+-.7 wt.-% and
in particular 70.+-.5 wt.-% of ethylene repetition units, relative
to the total weight of the EVA polymer.
[0153] In still a further preferred embodiment, the EVA polymer
contains 80.+-.15 wt.-%, more preferably 80.+-.12 wt.-%, still more
preferably 80.+-.10 wt.-%, yet more preferably 80.+-.8 wt.-%, even
more preferably 80.+-.6 wt.-%, most preferably 80.+-.4 wt.-% and in
particular 80.+-.2 wt.-% of ethylene repetition units, relative to
the total weight of the EVA polymer.
[0154] In yet a further preferred embodiment, the EVA polymer
contains 90.+-.15 wt.-%, more preferably 90.+-.12 wt.-%, still more
preferably 90.+-.10 wt.-%, yet more preferably 90.+-.8 wt.-%, even
more preferably 90.+-.6 wt.-%, most preferably 90.+-.4 wt.-% and in
particular 90.+-.2 wt.-% of ethylene repetition units, relative to
the total weight of the EVA polymer.
[0155] In a particularly preferred embodiment, the EVA polymer
contains 60.+-.5 wt.-% of ethylene repetition units, relative to
the total weight of the EVA polymer.
[0156] Preferably, the molar ratio of the vinyl acetate repetition
units to the vinyl alcohol repetition units is within the range of
from 1000:1 to 1:1000, more preferably from 900:1 to 1:900, still
more preferably from 500:1 to 1:500, yet more preferably from 300:1
to 1:100, even more preferably from 200:1 to 1:10, most preferably
from 100:1 to 10:1, and in particular about 100:1.
[0157] In a preferred embodiment, the EVA polymer has a melt flow
rate at 190.degree. C. and 2.16 kg of at least 1 g/10 min, more
preferably at least 2 g/10 min, still more preferably at least 2.5
g/10 min, yet more preferably at least 5 g/10 min, even more
preferably at least 10 g/10 min, most preferably at least 20 g/10
min and in particular at least 30 g/10 min measured according to
ASTM D1238.
[0158] In a preferred embodiment, the EVA polymer has a melt flow
rate at 190.degree. C. and 2.16 kg of at least 40 g/10 min, more
preferably at least 42 g/10 min, still more preferably at least 44
g/10 min, yet more preferably at least 46 g/10 min, even more
preferably at least 48 g/10 min, most preferably at least 49 g/10
min and in particular at least 50 g/10 min measured according to
ASTM D1238.
[0159] In another preferred embodiment, the EVA polymer has a melt
flow rate at 190.degree. C. and 2.16 kg of at least 55 g/10 min,
more preferably at least 70 g/10 min, still more preferably at
least 85 g/10 min, yet more preferably at least 100 g/10 min, even
more preferably at least 115 g/10 min, most preferably at least 130
g/10 min and in particular at least 140 g/10 min measured according
to ASTM D1238.
[0160] Preferably, the EVA polymer has a melt flow rate at
190.degree. C. and 2.16 kg within the range of from 1 to 160 g/10
min measured according to ASTM D1238.
[0161] In a preferred embodiment, the EVA polymer has a melt flow
rate at 190.degree. C. and 2.16 kg of 2.5.+-.2 g/10 min, more
preferably 2.5.+-.1.5 g/10 min, still more preferably 2.5.+-.1.0
g/10 min, yet more preferably 2.5.+-.0.8 g/10 min, even more
preferably 2.5.+-.0.6 g/10 min, most preferably 2.5.+-.0.4 g/10 min
and in particular 2.5.+-.0.2 g/10 min measured according to ASTM
D1238.
[0162] In another preferred embodiment, the EVA polymer has a melt
flow rate at 190.degree. C. and 2.16 kg of 3.+-.2 g/10 min, more
preferably 3.+-.1.5 g/10 min, still more preferably 3.+-.1.0 g/10
min, yet more preferably 3.+-.0.8 g/10 min, even more preferably
3.+-.0.6 g/10 min, most preferably 3.+-.0.4 g/10 min and in
particular 3.+-.0.2 g/10 min measured according to ASTM D1238.
[0163] In still another preferred embodiment, the EVA polymer has a
melt flow rate at 190.degree. C. and 2.16 kg of 10.+-.16 g/10 min,
more preferably 10.+-.14 g/10 min, still more preferably 10.+-.12
g/10 min, yet more preferably 10.+-.10 g/10 min, even more
preferably 10.+-.8 g/10 min, most preferably 10.+-.6 g/10 min and
in particular 10.+-.4 g/10 min measured according to ASTM
D1238.
[0164] In yet another preferred embodiment, the EVA polymer has a
melt flow rate at 190.degree. C. and 2.16 kg of 20.+-.15 g/10 min,
more preferably 20.+-.13 g/10 min, still more preferably 20.+-.11
g/10 min, yet more preferably 20.+-.9 g/10 min, even more
preferably 20.+-.7 g/10 min, most preferably 20.+-.5 g/10 min and
in particular 20.+-.4 g/10 min measured according to ASTM
D1238.
[0165] In even another preferred embodiment, the EVA polymer has a
melt flow rate at 190.degree. C. and 2.16 kg of 30.+-.25 g/10 min,
more preferably 30.+-.20 g/10 min, still more preferably 30.+-.16
g/10 min, yet more preferably 30.+-.13 g/10 min, even more
preferably 30.+-.10 g/10 min, most preferably 30.+-.7 g/10 min and
in particular 30.+-.5 g/10 min measured according to ASTM
D1238.
[0166] In a further preferred embodiment, the EVA polymer has a
melt flow rate at 190.degree. C. and 2.16 kg of 40.+-.35 g/10 min,
more preferably 40.+-.25 g/10 min, still more preferably 40.+-.15
g/10 min, yet more preferably 40.+-.13 g/10 min, even more
preferably 40.+-.10 g/10 min, most preferably 40.+-.7 g/10 min and
in particular 40.+-.5 g/10 min measured according to ASTM
D1238.
[0167] In still a further preferred embodiment, the EVA polymer has
a melt flow rate at 190.degree. C. and 2.16 kg of 52.+-.20 g/10
min, more preferably 52.+-.16 g/10 min, still more preferably
52.+-.13 g/10 min, yet more preferably 52.+-.10 g/10 min, even more
preferably 52.+-.7 g/10 min, most preferably 52.+-.5 g/10 min and
in particular 52.+-.2 g/10 min measured according to ASTM
D1238.
[0168] In yet a further preferred embodiment, the EVA polymer has a
melt flow rate at 190.degree. C. and 2.16 kg of 60.+-.35 g/10 min,
more preferably 60.+-.25 g/10 min, still more preferably 60.+-.15
g/10 min, yet more preferably 60.+-.13 g/10 min, even more
preferably 60.+-.10 g/10 min, most preferably 60.+-.7 g/10 min and
in particular 60.+-.5 g/10 min measured according to ASTM
D1238.
[0169] In even a further preferred embodiment, the EVA polymer has
a melt flow rate at 190.degree. C. and 2.16 kg of 80.+-.35 g/10
min, more preferably 80.+-.25 g/10 min, still more preferably
80.+-.15 g/10 min, yet more preferably 80.+-.13 g/10 min, even more
preferably 80.+-.10 g/10 min, most preferably 80.+-.7 g/10 min and
in particular 80.+-.5 g/10 min measured according to ASTM
D1238.
[0170] In another preferred embodiment, the EVA polymer has a melt
flow rate at 190.degree. C. and 2.16 kg of 100.+-.35 g/10 min, more
preferably 100.+-.25 g/10 min, still more preferably 100.+-.15 g/10
min, yet more preferably 100.+-.13 g/10 min, even more preferably
100.+-.10 g/10 min, most preferably 100.+-.7 g/10 min and in
particular 100.+-.5 g/10 min measured according to ASTM D1238.
[0171] In still another preferred embodiment, the EVA polymer has a
melt flow rate at 190.degree. C. and 2.16 kg of 125.+-.35 g/10 min,
more preferably 125.+-.25 g/10 min, still more preferably 125.+-.15
g/10 min, yet more preferably 125.+-.13 g/10 min, even more
preferably 125.+-.10 g/10 min, most preferably 125.+-.7 g/10 min
and in particular 125.+-.5 g/10 min measured according to ASTM
D1238.
[0172] In yet another preferred embodiment, the EVA polymer has a
melt flow rate at 190.degree. C. and 2.16 kg of 150.+-.35 g/10 min,
more preferably 150.+-.25 g/10 min, still more preferably 150.+-.15
g/10 min, yet more preferably 150.+-.13 g/10 min, even more
preferably 150.+-.10 g/10 min, most preferably 150.+-.7 g/10 min
and in particular 150.+-.5 g/10 min measured according to ASTM
D1238.
[0173] In a particularly preferred embodiment, the EVA polymer has
a melt flow rate at 190.degree. C. and 2.16 kg of 52.+-.2 g/10 min
measured according to ASTM D1238.
[0174] The EVA polymer may comprise a single EVA polymer having a
particular melt flow rate, or a mixture (blend) of different EVA
polymers, such as two, three, four or five EVA polymers, e.g., EVA
polymers of the same chemical nature but different melt flow rates,
EVA polymers of different chemical nature but same melt flow rates,
or EVA polymers of different chemical nature as well as different
melt flow rates.
[0175] In a preferred embodiment, the EVA polymer comprises a
single EVA polymer having a particular melt flow rate. According to
this embodiment, the EVA preferably comprises a single EVA polymer
having a melt flow rate at 190.degree. C. and 2.16 kg of 52.+-.2
g/10 min measured according to ASTM D1238 and preferably containing
60.+-.5 wt.-% of ethylene repetition units, relative to the total
weight of the EVA polymer.
[0176] The EVA polymer preferably has a melting point in the range
of 40 to 100.degree. C., determined via differential scanning
calorimetry (DSC) in accordance with ASTM D3418.
[0177] In a preferred embodiment, the EVA polymer has a melting
point of 40.+-.10.degree. C., 47.+-.10.degree. C., 52.+-.10.degree.
C., 58.+-.10.degree. C., 65.+-.10.degree. C., 70.+-.10.degree. C.,
80.+-.10.degree. C., 90.+-.10.degree. C. or 96.+-.10.degree. C.,
more preferably 40.+-.5.degree. C., 47.+-.5.degree. C.,
52.+-.5.degree. C., 58.+-.5.degree. C., 65.+-.5.degree. C.,
70.+-.5.degree. C., 80.+-.5.degree. C., 90.+-.5.degree. C. or
96.+-.5.degree. C., determined via differential scanning
calorimetry (DSC) in accordance with ASTM D3418.
[0178] The EVA polymer preferably has a freezing point in the range
of 20 to 80.degree. C., determined via DSC in accordance with ASTM
D3418.
[0179] In a preferred embodiment, the EVA polymer has a freezing
point of 20.+-.10.degree. C., 27.+-.10.degree. C., 30.+-.10.degree.
C., 35.+-.10.degree. C., 40.+-.10.degree. C., 49.+-.10.degree. C.,
60.+-.10.degree. C., 70.+-.10.degree. C. or 74.+-.10.degree. C.,
more preferably 20.+-.5.degree. C., 27.+-.5.degree. C.,
30.+-.5.degree. C., 35.+-.5.degree. C., 40.+-.5.degree. C.,
49.+-.5.degree. C., 60.+-.5.degree. C., 70.+-.5.degree. C. or
74.+-..degree. C., determined via DSC in accordance with ASTM
D3418.
[0180] Particularly preferably, the EVA polymer has a melting point
of 47.+-.5.degree. C. and a freezing point of 27.+-.5.degree. C.,
both determined via DSC in accordance with ASTM D3418
[0181] In a preferred embodiment, the EVA polymer is homogeneously
distributed in the pharmaceutical dosage form according to the
invention.
[0182] When the pharmaceutical dosage form is multiparticulate, the
EVA polymer is preferably homogeneously distributed in the
particles according to the invention that contain the
pharmacologically active ingredient. Preferably, the
pharmacologically active ingredient and the EVA polymer are
intimately homogeneously distributed in the pharmaceutical dosage
form and the particles, respectively, so that the pharmaceutical
dosage form and the particles, respectively, do not contain any
segments where either pharmacologically active ingredient is
present in the absence of EVA polymer or where EVA polymer is
present in the absence of pharmacologically active ingredient.
[0183] When the pharmaceutical dosage form and the particles,
respectively, are film coated, the EVA polymer is preferably
homogeneously distributed in the core of the pharmaceutical dosage
form and the particles, respectively, i.e. the film coating
preferably does not contain EVA polymer. Nonetheless, the film
coating as such may of course contain one or more polymers, which
however, preferably differ from the EVA polymer contained in the
core.
[0184] EVA polymers that are suitable for use in the pharmaceutical
dosage forms according to the invention are commercially available,
e.g. from Celanese, for example Ateva.RTM. 1081, Ateva.RTM. 1070,
Ateva.RTM. 1075A, Ateva.RTM. 1221, Ateva.RTM. 11231, Ateva.RTM.
1241, Ateva.RTM. 1615, Ateva.RTM. 1641, Ateva.RTM. 1608, Ateva.RTM.
1609, Ateva.RTM. 1811, Ateva.RTM. 1813, Ateva.RTM. 1820, Ateva.RTM.
1821A, Ateva.RTM. 1850A, Ateva.RTM. 1880A, Ateva.RTM. 1941,
Ateva.RTM. 2005A, Ateva.RTM. 2030, Ateva.RTM. 2020, Ateva.RTM.
2604A, Ateva.RTM. 2810A, Ateva.RTM. 2861A, Ateva.RTM. 9020,
Ateva.RTM. 2820A, Ateva.RTM. 2821A, Ateva.RTM. 9021A, Ateva.RTM.
2825A, Ateva.RTM. 2830A, Ateva.RTM. 2842A, Ateva.RTM. 2842AC,
Ateva.RTM. 2850A, Ateva.RTM. 9030, Ateva.RTM. 3325A, Ateva.RTM.
3325AC, Ateva.RTM. 4030AC, VitalDose.RTM. EVA; and from DuPont, for
example, Elvax.RTM. 40W, Elvax.RTM. 220W, Elvax.RTM. 265,
Elvax.RTM. 40L-03, Elvax.RTM. 660, Elvax.RTM. 150, Elvax.RTM. 150W,
Elvax.RTM. 210W, Elvax.RTM. 240W, Elvax.RTM. 250, Elvax.RTM. 260,
Elvax.RTM. 350, Elvax.RTM. 360, Elvax.RTM. 410, Elvax.RTM. 420,
Elvax.RTM. 440, Elvax.RTM. 450, Elvax.RTM. 460, Elvax.RTM. 470,
Elvax.RTM. 550, Elvax.RTM. 560, Elvax.RTM. 650Q, Elvax.RTM. 670,
Elvax.RTM. 750, Elvax.RTM. 760, Elvax.RTM. 760Q, Elvax.RTM. 770.
Preferred polymers are Elvax.RTM. 40W, Elvax.RTM. 220W, Elvax.RTM.
265, Elvax.RTM. 40L-03 and Elvax.RTM. 660. For details concerning
the properties of these products, it can be referred to e.g. the
product specification.
[0185] The content of the EVA polymer is preferably within the
range of from 5.0 to 95 wt.-%, more preferably 7 to 94 wt.-%, still
more preferably 9 to 93 wt.-%, yet more preferably 11 to 92 wt.-%,
most preferably 13 to 91 wt.-%, and in particular 15 to 90 wt.-%,
relative to the total weight of the pharmaceutical dosage form.
When the pharmaceutical dosage form is multiparticulate, these
percent values preferably are related to the total weight of the
particles, not to the total weight of the pharmaceutical dosage
form.
[0186] In a particularly preferred embodiment, the content of the
EVA polymer is within the range of from 20 to 80 wt.-%, more
preferably 25 to 78 wt.-%, still more preferably 30 to 76 wt.-%,
yet more preferably 35 to 74 wt.-%, most preferably 40 to 72 wt.-%
and in particular 45 to 70 wt.-%, relative to the total weight of
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, relative to the total weight of the
particles that contain the pharmacologically active ingredient.
[0187] In a preferred embodiment, the content of the EVA polymer is
at least 2 wt.-%, more preferably at least 5 wt.-%, still more
preferably at least 10 wt.-%, yet more preferably at least 15 wt.-%
and in particular at least 20 wt.-%, relative to the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, relative to the total weight of
the particles that contain the pharmacologically active
ingredient.
[0188] In another preferred embodiment, the content of the EVA
polymer is at least 30 wt.-%, more preferably at least 35 wt.-%,
still more preferably at least 40 wt.-%, yet more preferably at
least 45 wt.-%, even more preferably at least 50, most preferably
at least 55 wt.-% and in particular at least 60 wt.-%, relative to
the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, relative to the
total weight of the particles that contain the pharmacologically
active ingredient.
[0189] In a preferred embodiment, the content of the EVA polymer is
20.+-.15 wt.-%, more preferably 20.+-.12 wt.-%, still more
preferably 20.+-.10 wt.-%, yet more preferably 20.+-.8 wt.-%, even
more preferably 20.+-.6 wt.-%, most preferably 20.+-.4 wt.-% and in
particular 20.+-.2 wt.-%, relative to the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, relative to the total weight of the particles
that contain the pharmacologically active ingredient.
[0190] In another preferred embodiment, the content of the EVA
polymer is 30.+-.25 wt.-%, more preferably 30.+-.20 wt.-%, still
more preferably 30.+-.17 wt.-%, yet more preferably 30.+-.13 wt.-%,
even more preferably 30.+-.10 wt.-%, most preferably 30.+-.7 wt.-%
and in particular 30.+-.5 wt.-%, relative to the total weight of
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, relative to the total weight of the
particles that contain the pharmacologically active ingredient.
[0191] In still another preferred embodiment, the content of the
EVA polymer is 40.+-.35 wt.-%, more preferably 40.+-.30 wt.-%,
still more preferably 40.+-.25 wt.-%, yet more preferably 40.+-.20
wt.-%, even more preferably 40.+-.15 wt.-%, most preferably
40.+-.10 wt.-% and in particular 40.+-.5 wt.-%, relative to the
total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, relative to the
total weight of the particles that contain the pharmacologically
active ingredient.
[0192] In yet another preferred embodiment, the content of the EVA
polymer is 50.+-.45 wt.-%, more preferably 50.+-.35 wt.-%, still
more preferably 50.+-.25 wt.-%, yet more preferably 50.+-.20 wt.-%,
even more preferably 50.+-.15 wt.-%, most preferably 50.+-.10 wt.-%
and in particular 50.+-.5 wt.-%, relative to the total weight of
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, relative to the total weight of the
particles that contain the pharmacologically active ingredient.
[0193] In even another preferred embodiment, the content of the EVA
polymer is 55.+-.40 wt.-%, more preferably 55.+-.35 wt.-%, still
more preferably 55.+-.25 wt.-%, yet more preferably 55.+-.20 wt.-%,
even more preferably 55.+-.15 wt.-%, most preferably 55.+-.10 wt.-%
and in particular 55.+-.5 wt.-%, relative to the total weight of
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, relative to the total weight of the
particles that contain the pharmacologically active ingredient.
[0194] In a further preferred embodiment, the content of the EVA
polymer is 60.+-.35 wt.-%, more preferably 60.+-.30 wt.-%, still
more preferably 60.+-.25 wt.-%, yet more preferably 60.+-.20 wt.-%,
even more preferably 60.+-.15 wt.-%, most preferably 60.+-.10 wt.-%
and in particular 60.+-.5 wt.-%, relative to the total weight of
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, relative to the total weight of the
particles that contain the pharmacologically active ingredient.
[0195] In still a further preferred embodiment, the content of the
EVA polymer is 65.+-.30 wt.-%, more preferably 65.+-.25 wt.-%,
still more preferably 65.+-.20 wt.-%, yet more preferably 65.+-.15
wt.-%, even more preferably 65.+-.10 wt.-%, most preferably 65.+-.7
wt.-% and in particular 65.+-.5 wt.-%, relative to the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, relative to the total weight of
the particles that contain the pharmacologically active
ingredient.
[0196] In yet a further preferred embodiment, the content of the
EVA polymer is 70.+-.25 wt.-%, more preferably 70.+-.20 wt.-%,
still more preferably 70.+-.17 wt.-%, yet more preferably 70.+-.13
wt.-%, even more preferably 70.+-.10 wt.-%, most preferably 70.+-.7
wt.-% and in particular 70.+-.5 wt.-%, relative to the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, relative to the total weight of
the particles that contain the pharmacologically active
ingredient.
[0197] In even a further preferred embodiment, the content of the
EVA polymer is 80.+-.15 wt.-%, more preferably 80.+-.12 wt.-%,
still more preferably 80.+-.10 wt.-%, yet more preferably 80.+-.8
wt.-%, even more preferably 80.+-.6 wt.-%, most preferably 80.+-.4
wt.-% and in particular 80.+-.2 wt.-%, relative to the total weight
of the pharmaceutical dosage form or, when the pharmaceutical
dosage form is multiparticulate, relative to the total weight of
the particles that contain the pharmacologically active
ingredient.
[0198] When the pharmaceutical dosage form comprises a prolonged
release matrix containing the EVA polymer as prolonged release
matrix material, the content of the EVA polymer is preferably
within the range of from 5 to 100 wt.-%, more preferably 20 to 98
wt.-%, still more preferably 35 to 96 wt.-%, yet more preferably 45
to 95 wt.-%, even more preferably 55 to 94 wt.-%, most preferably
65 to 93 wt.-%, and in particular 75 to 92 wt.-%, relative to the
total weight of the prolonged release matrix, i.e. total weight of
the prolonged release matrix material and the optionally present
additional prolonged release matrix material.
[0199] Preferably, the relative weight ratio of the EVA polymer to
the pharmacologically active ingredient is within the range of 20:1
to 1:20, more preferably 15:1 to 1:15, still more preferably 10:1
to 1:10, yet more preferably 7:1 to 1:7, most preferably 5:1 to
1:5, and in particular 3:1 to 1:1.
[0200] In a preferred embodiment, when the pharmaceutical dosage
form according to the invention comprises a prolonged release
matrix, the prolonged release matrix in turn comprises an
additional prolonged release matrix material besides the prolonged
release matrix material, i.e. the EVA polymer. Thus, the additional
prolonged release matrix material is to be distinguished from the
prolonged release matrix material of the prolonged release matrix
of the pharmaceutical dosage form according to the invention.
[0201] Preferably, the additional prolonged release matrix material
is a polymer selected from the group comprising polyalkylene
oxides, acrylic polymers, crosslinked acrylic polymers, mixtures of
polyvinyl pyrrolidone and polyvinyl acetate, waxy materials,
polyalkylene glycols and natural polysaccharides, such as
celluloses, cellulose derivatives and xanthan gum.
[0202] The content of the additional prolonged release matrix
material is preferably within the range of from 1 to 90 wt.-%, more
preferably 2 to 80 wt.-%, still more preferably 3 to 70 wt.-%, yet
more preferably 3.5 to 60 wt.-%, even more preferably 4 to 50
wt.-%, most preferably 4.5 to 40 wt.-%, and in particular 5 to 30
wt.-%, relative to the total weight of the prolonged release
matrix.
[0203] In a preferred embodiment, the content of the additional
prolonged release matrix material is at least 2 wt.-%, more
preferably at least 5 wt.-%, still more preferably at least 10
wt.-%, yet more preferably at least 15 wt.-% and in particular at
least 20 wt.-%, either based on the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, based on the total weight of the particles
that contain the pharmacologically active ingredient.
[0204] The overall content of additional prolonged release matrix
material is preferably within the range of from 1 to 60 wt.-%, more
preferably 2 to 45 wt.-%, still more preferably 3 to 35 wt.-%, yet
more preferably 4 to 28 wt.-%, even more preferably 5 to 25 wt.-%,
most preferably 5 to 22 wt.-%, and in particular 5 to 20 wt.-%,
either based on the total weight of the pharmaceutical dosage form
or, when the pharmaceutical dosage form is multiparticulate, based
on the total weight of the particles that contain the
pharmacologically active ingredient.
[0205] In a preferred embodiment, the overall content of additional
prolonged release matrix material is within the range of 5.+-.4
wt.-%, more preferably 5.+-.3 wt.-%, most preferably 5.+-.2 wt.-%,
and in particular 5.+-.1 wt.-%, either based on the total weight of
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, based on the total weight of the
particles that contain the pharmacologically active ingredient.
[0206] In another preferred embodiment, the overall content of
additional prolonged release matrix material is within the range of
7.5.+-.6 wt.-%, more preferably 7.5.+-.4 wt.-%, most preferably
7.5.+-.3 wt.-%, and in particular 7.5.+-.2 wt.-%, either based on
the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0207] In still another preferred embodiment, the overall content
of additional prolonged release matrix material is within the range
of 10.+-.8 wt.-%, more preferably 10.+-.6 wt.-%, most preferably
10.+-.4 wt.-%, and in particular 10.+-.2 wt.-%, either based on the
total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0208] In yet another preferred embodiment, the overall content of
additional prolonged release matrix material is within the range of
15.+-.12 wt.-%, more preferably 15.+-.10 wt.-%, most preferably
15.+-.7 wt.-%, and in particular 15.+-.3 wt.-%, either based on the
total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0209] In even another preferred embodiment, the overall content of
additional prolonged release matrix material is within the range of
20.+-.16 wt.-%, more preferably 20.+-.12 wt.-%, most preferably
20.+-.8 wt.-%, and in particular 20.+-.4 wt.-%, either based on the
total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0210] In a further preferred embodiment, the overall content of
additional prolonged release matrix material is within the range of
25.+-.20 wt.-%, more preferably 25.+-.15 wt.-%, most preferably
25.+-.10 wt.-%, and in particular 25.+-.5 wt.-%, either based on
the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0211] In still a further preferred embodiment, the overall content
of additional prolonged release matrix material is within the range
of 30.+-.20 wt.-%, more preferably 30.+-.15 wt.-%, most preferably
30.+-.10 wt.-%, and in particular 30.+-.5 wt.-%, either based on
the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0212] In yet a further preferred embodiment, the overall content
of additional prolonged release matrix material is within the range
of 35.+-.20 wt.-%, more preferably 35.+-.15 wt.-%, most preferably
35.+-.10 wt.-%, and in particular 35.+-.5 wt.-%, either based on
the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0213] In even a further preferred embodiment, the overall content
of additional prolonged release matrix material is within the range
of 40.+-.20 wt.-%, more preferably 40.+-.15 wt.-%, and most
preferably 40.+-.10 wt.-%, and in particular 40.+-.5 wt.-%, either
based on the total weight of the pharmaceutical dosage form or,
when the pharmaceutical dosage form is multiparticulate, based on
the total weight of the particles that contain the
pharmacologically active ingredient.
[0214] In another preferred embodiment, the overall content of
additional prolonged release matrix material is within the range of
45.+-.20 wt.-%, more preferably 45.+-.15 wt.-%, and most preferably
45.+-.10 wt.-%, and in particular 45.+-.5 wt.-%, either based on
the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0215] In still another preferred embodiment, the overall content
of additional prolonged release matrix material is within the range
of 50.+-.20 wt.-%, more preferably 50.+-.15 wt.-%, and most
preferably 50.+-.10 wt.-%, and in particular 50.+-.5 wt.-%, either
based on the total weight of the pharmaceutical dosage form or,
when the pharmaceutical dosage form is multiparticulate, based on
the total weight of the particles that contain the
pharmacologically active ingredient.
[0216] Preferably, the relative weight ratio of the additional
prolonged release matrix material to the pharmacologically active
ingredient is within the range of 20:1 to 1:20, more preferably
10:1 to 1:15, still more preferably 7:1 to 1:10, yet more
preferably 5:1 to 1:7, most preferably 1:1 to 1:5, and in
particular 1:2 to 1:5.
[0217] Preferably, the relative weight ratio of the additional
prolonged release matrix material to the prolonged release matrix
material of the prolonged release matrix is within the range of
20:1 to 1:20, more preferably 10:1 to 1:18, still more preferably
7:1 to 1:16, yet more preferably 5:1 to 1:14, most preferably 1:1
to 1:12, and in particular 1:5 to 1:10.
[0218] In a preferred embodiment, the pharmaceutical dosage form
according to the invention comprises a prolonged release matrix
which in turn comprises [0219] (i) an EVA polymer as a prolonged
release matrix material, wherein the EVA polymer comprises a single
EVA polymer having a melt flow rate at 190.degree. C. and 2.16 kg
of 52.+-.2 g/10 min measured according to ASTM D1238 and preferably
containing 60.+-.5 wt.-% of ethylene repetition units, relative to
the total weight of the EVA polymer; and [0220] (ii) an additional
prolonged release matrix material which is preferably a polymer
selected from the group consisting of polyalkylene oxides,
crosslinked acrylic polymers and matrices based on polyvinyl
acetate and polyvinyl pyrrolidone; [0221] wherein [0222] (iii) the
relative weight content of the prolonged release matrix material is
preferably greater than the relative weight content of the
additional prolonged release matrix material.
[0223] In a preferred embodiment, the additional prolonged release
matrix material is a polyalkylene oxide, preferably a polyethylene
oxide, particularly preferably having a weight average molecular
weight of at least 500,000 g/mol.
[0224] When the additional prolonged release matrix material of the
prolonged release matrix comprises a polyalkylene oxide, it
preferably does not additionally comprise any other additional
prolonged release matrix material.
[0225] When the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, the particles
is/are film coated, the polyalkylene oxide is preferably
homogeneously distributed within the pharmaceutical dosage form or,
when the pharmaceutical dosage form is multiparticulate, the
particles, i.e. the film coating preferably does not contain
polyalkylene oxide. Nonetheless, the film coating as such may of
course contain one or more polymers, which however, preferably
differ from the polyalkylene oxide contained in the pharmaceutical
dosage form or, when the pharmaceutical dosage form is
multiparticulate, the particles.
[0226] Preferably, the polyalkylene oxide is selected from
polymethylene oxide, polyethylene oxide and polypropylene oxide, or
copolymers or mixtures thereof.
[0227] Preferably, the polyalkylene oxide has a weight average
molecular weight (M.sub.W), preferably also a viscosity average
molecular weight (M.sub..eta.) of more than 200,000 g/mol or at
least 500,000 g/mol, preferably at least 1,000,000 g/mol or at
least 2,500,000 g/mol, more preferably in the range of about
1,000,000 g/mol to about 15,000,000 g/mol, and most preferably in
the range of about 5,000,000 g/mol to about 10,000,000 g/mol.
Suitable methods to determine M.sub.W and M.sub..eta. are known to
a person skilled in the art. M is preferably determined by
rheological measurements, whereas M.sub.W can be determined by gel
permeation chromatography (GPC).
[0228] Preferably, the molecular weight dispersity
M.sub.W/M.sub..eta. of the polyalkylene oxide is within the range
of 2.5.+-.2.0, more preferably 2.5.+-.1.5, still more preferably
2.5.+-.1.0, yet more preferably 2.5.+-.0.8, most preferably
2.5.+-.0.6, and in particular 2.5.+-.0.4.
[0229] The polyalkylene oxide preferably has a viscosity at
25.degree. C. of 30 to 17,600 mPas, more preferably 55 to 17,600
mPas, still more preferably 600 to 17,600 mPas, yet more preferably
4,500 to 17,600 mPas, even more preferably 4,500 to 12,000 mPas,
most preferably 5,000 to 10,500 mPas and in particular 5,500 to
7,500 mPas or 7,500 to 10,000 mPas, measured in a 1 wt.-% aqueous
solution.
[0230] The polyalkylene oxide may comprise a single polyalkylene
oxide having a particular average molecular weight, or a mixture
(blend) of different polymers, such as two, three, four or five
polymers, e.g., polymers of the same chemical nature but different
average molecular weight, polymers of different chemical nature but
same average molecular weight, or polymers of different chemical
nature as well as different molecular weight.
[0231] For the purpose of specification, a polyalkylene glycol has
a molecular weight of up to 20,000 g/mol whereas a polyalkylene
oxide has a molecular weight of more than 20,000 g/mol. Preferably,
the weight average over all molecular weights of all polyalkylene
oxides that are contained in the pharmaceutical dosage form is more
than 200,000 g/mol. Thus, polyalkylene glycols, if any, are
preferably not taken into consideration when determining the weight
average molecular weight of polyalkylene oxide.
[0232] In a particularly preferred embodiment, the additional
prolonged release matrix material is a polyalkylene oxide, more
preferably a polyethylene oxide, having a weight average molecular
weight (M.sub.W), preferably also a viscosity average molecular
weight (M.sub..eta.) in the range of about 5,000,000 g/mol to about
10,000,000 g/mol.
[0233] The overall content of polyalkylene oxide is preferably
within the range of from 1 to 60 wt.-%, more preferably 3 to 45
wt.-%, still more preferably 5 to 35 wt.-%, yet more preferably 7
to 28 wt.-%, even more preferably 8 to 25 wt.-%, most preferably 9
to 22 wt.-%, and in particular 10 to 20 wt.-%, either based on the
total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0234] In a preferred embodiment, the overall content of
polyalkylene oxide is within the range of 15.+-.12 wt.-%, more
preferably 15.+-.10 wt.-%, most preferably 15.+-.7 wt.-%, and in
particular 15.+-.3 wt.-%, either based on the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, based on the total weight of the particles
that contain the pharmacologically active ingredient.
[0235] In a preferred embodiment, the additional prolonged release
matrix material is a mixture of polyvinyl pyrrolidone and polyvinyl
acetate.
[0236] When the additional prolonged release matrix material of the
prolonged release matrix comprises a mixture of polyvinyl
pyrrolidone and polyvinyl acetate, it preferably does not
additionally comprise any other additional prolonged release matrix
material.
[0237] When the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, the particles
is/are film coated, the mixture of polyvinyl pyrrolidone and
polyvinyl acetate is preferably homogeneously distributed within
the pharmaceutical dosage form or, when the pharmaceutical dosage
form is multiparticulate, the particles, i.e. the film coating
preferably does not contain any mixture of polyvinyl pyrrolidone
and polyvinyl acetate. Nonetheless, the film coating as such may of
course contain one or more polymers, which however, preferably
differ from the mixture of polyvinyl pyrrolidone and polyvinyl
acetate contained in the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, the particles.
[0238] Preferably, the mixture of polyvinyl pyrrolidone and
polyvinyl acetate contains 10 to 30 wt.-% polyvinyl pyrrolidone and
70 to 90 wt.-% of polyvinyl acetate, more preferably 18 to 21 wt.-%
polyvinyl pyrrolidone and 75 to 85 wt.-% of polyvinyl acetate and
most preferably 19 wt.-% polyvinyl pyrrolidone and 80 wt.-% of
polyvinyl acetate.
[0239] The weight ratio between polyvinyl acetate and polyvinyl
pyrrolidone preferably is in the range from 20:1 to 1:20, more
preferably 16:1 to 1:10, still more preferably 13:1 to 1:5, yet
more preferably 10:1 to 1:2, even more preferably 7:1 to 1:1, most
preferably 5:1 to 2:1 and in particular 4.5:1 to 3.5:1.
[0240] Preferably, the polyvinyl acetate has a weight average
molecular weight (M.sub.W) of 450,000.+-.100,000 g/mol, more
preferably 450,000.+-.80,000 g/mol, still more preferably
450,000.+-.50,000 g/mol, yet more preferably 450,000.+-.10,000
g/mol, even more preferably 450,000.+-.1,000 g/mol, most preferably
450,000.+-.500 g/mol and in particular 450,000.+-.100 g/mol.
M.sub.W can be determined by gel permeation chromatography
(GPC).
[0241] Preferably, the polyvinyl pyrrolidone has a weight average
molecular weight (M.sub.W) of 50,000.+-.10,000 g/mol, more
preferably 50,000.+-.8,000 g/mol, still more preferably
50,000.+-.5,000 g/mol, yet more preferably 50,000.+-.1,000 g/mol,
even more preferably 50,000.+-.800 g/mol, most preferably
50,000.+-.500 g/mol and in particular 50,000.+-.100 g/mol.
[0242] The weight average molecular weight (M.sub.W) of the mixture
of polyvinyl pyrrolidone and polyvinyl acetate can be expressed as
K-value according to the method described in the USP and Ph. Eur.
monographs "Povidone", measured in a 1% solution in
tetrahydrofurane, wherein the K-value preferably is in the range of
from 40 to 80, more preferably 45 to 78, still more preferably 50
to 75, most preferably 55 to 70 and in particular 60 to 65.
[0243] Preferably, the glass transition temperature (T.sub.g) of
the mixture of polyvinyl pyrrolidone and polyvinyl acetate is in
the range of 35.+-.10.degree. C., more preferably 35.+-.6.degree.
C. and most preferably 35.+-.3.degree. C.
[0244] In a particularly preferred embodiment, the additional
prolonged release matrix material is a mixture of polyvinyl
pyrrolidone and polyvinyl acetate, wherein said mixture has a
K-value in the range of from 60 to 65, measured in a 1% solution in
tetrahydrofurane according to the method described in the USP and
Ph. Eur. monographs "Povidone" and/or wherein the weight ratio
between polyvinyl acetate and polyvinyl pyrrolidone is in the range
of 4.5:1 to 3.5:1.
[0245] The overall content of the mixture of polyvinyl pyrrolidone
and polyvinyl acetate is preferably within the range of from 1.0 to
60 wt.-%, more preferably 2.0 to 50 wt.-%, still more preferably
3.0 to 40 wt.-%, yet more preferably 3.5 to 30 wt.-%, even more
preferably 4.0 to 25 wt.-%, most preferably 4.5 to 20 wt.-%, and in
particular 5 to 15 wt.-%, either based on the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, based on the total weight of the particles
that contain the pharmacologically active ingredient.
[0246] In a preferred embodiment, the overall content of the
mixture of polyvinyl pyrrolidone and polyvinyl acetate is within
the range of 10.+-.8 wt.-%, more preferably 10.+-.6 wt.-%, most
preferably 10.+-.4 wt.-%, and in particular 10.+-.2 wt.-%, either
based on the total weight of the pharmaceutical dosage form or,
when the pharmaceutical dosage form is multiparticulate, based on
the total weight of the particles that contain the
pharmacologically active ingredient.
[0247] Mixtures of polyvinyl pyrrolidone and polyvinyl acetate that
are suitable for use in the pharmaceutical dosage forms according
to the invention are commercially available, e.g. from BASF, such
as Kollidon.RTM. SR. For details concerning the properties of this
product, it can be referred to e.g. the product specification.
[0248] In another preferred embodiment, the additional prolonged
release matrix material is an acrylic polymer.
[0249] When the additional prolonged release matrix material of the
prolonged release matrix comprises an acrylic polymer, it
preferably does not additionally comprise any other additional
prolonged release matrix material.
[0250] When the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, the particles
is/are film coated, the acrylic polymer is preferably homogeneously
distributed within the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, the particles, i.e.
the film coating preferably does not contain acrylic polymer.
Nonetheless, the film coating as such may of course contain one or
more polymers, which however, preferably differ from the acrylic
polymer contained in the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, the particles.
[0251] Preferably, the acrylic polymer has a weight average
molecular weight within the range of from 100,000 g/mol to
2,000,000 g/mol. In a preferred embodiment, the acrylic polymer has
a weight average molecular weight (M.sub.W) or viscosity average
molecular weight (M.sub..eta.) of at least 150,000 or at least
200,000 g/mol, preferably at least 250,000 g/mol or at least
300,000 g/mol, more preferably in the range of about 300,000 g/mol
to about 2,000,000 g/mol, and most preferably in the range of about
300,000 g/mol to about 1,000,000 g/mol. Suitable methods to
determine M.sub.W and M.sub..eta. are known to a person skilled in
the art. M.sub..eta. is preferably determined by rheological
measurements, whereas M.sub.W can be determined by gel permeation
chromatography (GPC).
[0252] The acrylic polymer can be a nonionic acrylic polymer or an
ionic acrylic polymer. For the purpose of specification, "nonionic
polymer" refers to a polymer not containing more than 1 mole.-%
ionic, i.e. anionic or cationic, monomer units, preferably
containing no ionic monomer units at all.
[0253] In a preferred embodiment, the additional prolonged release
matrix material is an ionic acrylic polymer.
[0254] Preferred ionic acrylic polymers are anionic acrylic
polymers. Preferred anionic acrylic polymers include but are not
limited to homopolymers or copolymers of one or two different
C.sub.1-4-alkyl (meth)acrylate monomers and copolymerizable anionic
monomers such as acrylic acid.
[0255] For the purpose of the specification, "(meth)acryl" refers
to acryl as well as methacryl.
[0256] In a preferred embodiment, the additional prolonged release
matrix material is an anionic acrylic polymer, preferably
polyacrylic acid. According to this embodiment, the polyacrylic
acid preferably has a viscosity within the range of 2,000 to 20,000
mPas, more preferably 3,000 to 18,000 mPas, still more preferably
3,500 to 16,000 mPas, yet more preferably 3,600 to 14,000 mPas,
even more preferably 3,700 to 13,000 mPas, most preferably 3,800 to
12,000, and in particular 4,000 to 11,000 mPas, measured with a
Brookfield RVT, 20 rpm, spindle no. 5 at 25.degree. C. and 0.5
wt.-% neutralized to pH 7.3-7.8.
[0257] The acrylic polymer, preferably the anionic acrylic polymer,
more preferably the polyacrylic acid polymer can optionally be
crosslinked. Preferred crosslinking agents include allyl
pentaerythritol, allyl sucrose, ethylene glycol di(methacrylate),
methylenebisacrylamide and divinyl benzene.
[0258] In a particularly preferred embodiment, the anionic acrylic
polymer is a polyacrylic acid polymer which is crosslinked,
preferably with ally pentaerythritol, and has a viscosity of 4,000
to 11,000 mPas, measured with a Brookfield RVT, 20 rpm, spindle no.
5 at 25.degree. C. and 0.5 wt.-% neutralized to pH 7.3-7.8.
[0259] Preferably, the overall content of anionic acrylic polymer,
preferably polyacrylic acid, more preferably crosslinked
polyacrylic acid, is within the range of from 1.0 to 60 wt.-%, more
preferably 2.0 to 50 wt.-%, still more preferably 3.0 to 40 wt.-%,
yet more preferably 3.5 to 30 wt.-%, even more preferably 4.0 to 20
wt.-%, most preferably 4.5 to 15 wt.-%, and in particular 5.0 to 12
wt.-%, either based on the total weight of the pharmaceutical
dosage form or, when the pharmaceutical dosage form is
multiparticulate, based on the total weight of the particles that
contain the pharmacologically active ingredient.
[0260] Polyacrylic acid polymers that are suitable for use in the
pharmaceutical dosage forms according to the invention are
commercially available, e.g. from Lubrizol, such as Carbopol.RTM.
71G, Carbopol.RTM. 971P, Carbopol.RTM. 981 and Carbopol.RTM. 941.
For details concerning the properties of these products, it can be
referred to e.g. the product specification.
[0261] Other preferred anionic acrylic polymers are ternary
copolymers of methyl acrylate, methyl methacrylate and methacrylic
acid. Preferably, the anionic acrylic polymer has a weight average
molecular weight within the range of 280,000.+-.250,000 g/mol, more
preferably 280,000.+-.200,000 g/mol, still more preferably
280,000.+-.180,000 g/mol, yet more preferably 280,000.+-.160,000
g/mol, even more preferably 280,000.+-.140,000 g/mol, most
preferably 280,000.+-.120,000 g/mol, and in particular
280,000.+-.100,000 g/mol.
[0262] Further preferred ionic acrylic polymers are cationic
acrylic polymers. Preferred cationic acrylic polymers include but
are not limited to copolymers of one or two different
C.sub.1-4-alkyl (meth)acrylate monomers and copolymerizable
cationic monomers such as trimethylammonioethyl methacrylate
chloride. Preferred representatives are ternary copolymers of ethyl
acrylate, methyl methacrylate and a low content of methacrylic acid
ester with quaternary ammonium groups, preferably
trimethylammonioethyl methacrylate chloride. Preferably, the
cationic acrylic polymer has a weight average molecular weight
within the range of 32,000.+-.30,000 g/mol, more preferably
32,000.+-.27,000 g/mol, still more preferably 32,000.+-.23,000
g/mol, yet more preferably 32,000.+-.20,000 g/mol, even more
preferably 32,000.+-.17,000 g/mol, most preferably 32,000.+-.13,000
g/mol, and in particular 32,000.+-.10,000 g/mol.
[0263] In another preferred embodiment, the additional prolonged
release matrix material is a nonionic acrylic polymer.
[0264] Nonionic acrylic polymers that are suitable for use in the
pharmaceutical dosage forms according to the invention are
commercially available, e.g. from Evonik. For example,
Eudragit.RTM. NE30D, Eudragit.RTM. NE40D and Eudragit.RTM. NM30D,
which are provided as aqueous dispersions of poly(ethyl
acrylate-co-methyl methacrylate) 2:1, may be used in the
pharmaceutical dosage form according to the invention. For details
concerning the properties of these products, it can be referred to
e.g. the product specification.
[0265] In another preferred embodiment, the additional prolonged
release matrix material is a waxy material.
[0266] Preferably, the waxy material is selected from the group
consisting of [0267] glycerides, especially monoglycerides,
diglycerides, triglycerides, [0268] esters of fatty acids with
fatty alcohols, and [0269] paraffins.
[0270] When the additional prolonged release matrix material of the
prolonged release matrix comprises a waxy material, it preferably
does not additionally comprise any other additional prolonged
release matrix material.
[0271] As used herein a "waxy material" refers to a material which
melts into liquid form having low viscosity upon heating and sets
again to a solid state upon cooling. Preferably, the waxy material
has a melting point of at least 30.degree. C., more preferably at
least 35.degree. C., still more preferably at least 40.degree. C.,
yet more preferably at least 45.degree. C., even more preferably at
least 50.degree. C., most preferably at least 55.degree. C., and in
particular at least 60.degree. C.
[0272] When the waxy material is or comprises a monoglyceride,
diglyceride, triglyceride or a mixture thereof, it is preferably a
mono-, di- or triester of glycerol and carboxylic acids, whereas
the carboxylic acid is preferably selected from the group
consisting of fatty acids, hydroxy fatty acids and aromatic
acids.
[0273] Preferred glycerides of fatty acids include monoglycerides,
diglycerides, triglycerides, and mixtures thereof; preferably of
C.sub.6 to C.sub.22 fatty acids. Especially preferred are partial
glycerides of the C.sub.16 to C.sub.22 fatty acids such as glycerol
behenat, glycerol palmitostearate, glycerol monostearate, glycerol
trimyristate and glycerol distearate.
[0274] The term "fatty acid" is well acknowledged in the art and
includes for example unsaturated representatives such as
myristoleic acid, palmitoleic acid, sapienic acid, oleic acid,
elaidic acid, vaccenic acid, linoleic acid, linoelaidic acid,
.alpha.-linolenic acid, arachidonic acid, eicosapentaenoic acid,
erucic acid, and docosahexaenoic acid; as well as saturated
representatives such as caprylic acid, capric acid, lauric acid,
myristic acid, palmitic acid, stearic acid, arachidic acid, behenic
acid, lignoceric acid, and cerotic acid.
[0275] The term "hydroxy fatty acid" is also well acknowledged in
the art and includes for example 2-hydroxyhexanoic acid,
2-hydroxyoctanoic acid, 2-hydroxydecanoic acid,
2-hydroxy-dodecanoic acid, .beta.-hydroxylauric acid,
2-hydroxytetradecanoic acid, .beta.-hydroxymyristic acid,
15-hydroxypentadecanoic acid, 16-hydroxyhexadecanoic acid,
.beta.-hydroxypalmitic acid, 12-hydroxyoctadecanoic acid,
.alpha.-hydroxystearic acid, and .alpha.-hydroxyarachidic acid.
[0276] The fatty acids and the hydroxy fatty acids are preferably
saturated.
[0277] When the waxy material is or comprises a diglyceride or a
triglyceride, the fatty acids, hydroxy fatty acids and aromatic
acids, respectively, may be identical or different.
[0278] According to this embodiment of the invention, the waxy
material is preferably a hard fat (adeps solidus) in accordance
with Ph. Eur.
[0279] Preferably, the waxy material is a monoglyceride,
diglyceride, triglyceride or a mixture thereof, selected from the
group consisting of hydrogenated soybean oil, hydrogenated palm
oil, hydrogenated castor oil, hydrogenated cottonseed oil, and
mixtures thereof.
[0280] When the waxy material is or comprises an ester of a fatty
acid with a fatty alcohol, the fatty acid is preferably a saturated
fatty acid. Preferred examples of fatty acids are already mentioned
above in connection with the glycerides. The fatty alcohol is
preferably derived from a fatty acid and preferably also
saturated.
[0281] Preferred representatives of esters of fatty acids with
fatty alcohols include but are not limited to natural waxes such as
beeswax, carnaubawax, cetyl palmitate, oleyl oleate, spermaceti
(cetaceum), candelilla wax, ouricury wax, sugarcane wax, and retamo
wax.
[0282] When the waxy material is or comprises a paraffin, the
paraffin is preferably a hard paraffin (paraffinum solidum,
ceresin, zeresin) in accordance with Ph. Eur.
[0283] The waxy material may comprise a single waxy material, or a
mixture (blend) of different waxy materials, such as two, three,
four or five waxy materials, each of which preferably being
selected from the group consisting of glycerides, especially
monoglycerides, diglycerides, triglycerides; esters of fatty acids
with fatty alcohols; and paraffins.
[0284] Waxy materials that are suitable for use in the
pharmaceutical dosage forms according to the invention are
commercially available, e.g. Cera alba, Cera flava, Kolliwax.TM.
HCO, Dynasan 118, Compritol.RTM. 888 ATO, Precirol.RTM. ATO 5,
Gelucire.RTM. 44/14. For details concerning the properties of these
products, it can be referred to e.g. the product specification.
[0285] Preferred polyalkylene glycols include but are not limited
to polymethylene oxide, polyethylene oxide, polypropylene oxide,
and the copolymers and mixtures thereof. For the purpose of the
specification, a polyalkylene glycol has a molecular weight of up
to 20,000 g/mol whereas a polyalkylene oxide has a molecular weight
of more than 20,000 g/mol.
[0286] In a preferred embodiment, the polyalkylene glycol has a
weight average molecular weight (M.sub.W) or viscosity average
molecular weight (M.sub..eta.) in the range of about 1,000 g/mol to
about 18000 g/mol, and most preferably in the range of about 5,000
g/mol to about 8,000 g/mol. Suitable methods to determine M.sub.W
and M.sub..eta. are known to a person skilled in the art.
M.sub..eta. is preferably determined by rheological measurements,
whereas M.sub.W can be determined by gel permeation chromatography
(GPC).
[0287] Preferred celluloses and cellulose derivatives include but
are not limited to microcrystalline cellulose, cellulose esters and
cellulose ethers.
[0288] Preferred cellulose ethers include nonionic cellulose ethers
such as methylcellulose, ethylcellulose, propylcellulose,
hydroxymethylcellulose, hydroxyethylcellulose,
hydroxypropylcellulose, and hydroxypropylmethylcellulose; as well
as ionic cellulose ethers, i.e. cationic cellulose ethers or
anionic cellulose ethers such as carboxymethyl cellulose.
[0289] In view of their good solubility in aqueous ethanol,
however, ethylcellulose and propylcellulose are preferably only
contained in comparatively low amounts (preferably at most 1.0
wt.-%) or not contained at all in the pharmaceutical dosage form
according to the invention.
[0290] Preferred xanthan gums include but are not limited to
Grindsted.RTM. Xanthan 80 Pharma available from Danisco and CEROGA
Xanthan Gum Type 602 available from Roeper.
[0291] Suitable xanthan gums which are commercially available
include XANTURAL.RTM. 75, XANTURAL.RTM. 180 and XANTURAL.RTM. 11K
from CP Kelco; VANZAN.RTM. NF, VANZAN.RTM. NF-F, VANZAN.RTM. NF-C
from Vanderbilt Minerals; Haixan.RTM. PM80, Haixan.RTM. PM200,
Haixan.RTM. PM40 from Zibo Hailan Chemical Co.; Xanthan Gum
Pharmaceutical Grade PHARM200 from ICD Biochemistry Co. and Xanthan
Gum from Jungbunzlauer.
[0292] Alternatively or additionally, the additional prolonged
release matrix material may comprise one or more polymers,
preferably selected from the group consisting of polyethylene,
polypropylene, polyvinyl chloride, polycarbonate, polystyrene,
polyvinylpyrrolidone, poly(alk)acrylate, poly(hydroxy fatty acids),
such as for example poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
(Biopol.RTM.), poly(hydroxyvaleric acid), polycaprolactone,
polyvinyl alcohol, polyesteramide, polyethylene succinate,
polylactone, polyglycolide, polyurethane, polyamide, polylactide,
polyacetal (for example polysaccharides optionally with modified
side chains), polylactide/glycolide, polylactone, polyglycolide,
polyorthoester, polyanhydride, block polymers of polyethylene
glycol and polybutylene terephthalate (Polyactive.RTM.),
polyanhydride (Polifeprosan), copolymers thereof, block-copolymers
thereof (e.g., Poloxamer.RTM.), and mixtures of at least two of the
stated polymers, or other polymers with the above
characteristics.
[0293] The pharmaceutical dosage form or, when it is
multiparticulate, the particles according to the invention which
contain the pharmacologically active ingredient may contain
additional pharmaceutical excipients conventionally contained in
pharmaceutical dosage forms in conventional amounts, such as
antioxidants, preservatives, lubricants, plasticizer, fillers,
binders, and the like.
[0294] The skilled person will readily be able to determine
appropriate further excipients as well as the quantities of each of
these excipients. Specific examples of pharmaceutically acceptable
carriers and excipients are described in the Handbook of
Pharmaceutical Excipients, American Pharmaceutical Association
(1986).
[0295] In a preferred embodiment, the pharmaceutical dosage form
or, when it is multiparticulate, the particles according to the
invention which contain the pharmacologically active ingredient do
not contain a disintegrant. According to this embodiment, the
pharmaceutical dosage form or, when it is multiparticulate, the
particles according to the invention which contain the
pharmacologically active ingredient preferably do not contain
sodium starch glycolate.
[0296] Preferably, the pharmaceutical dosage form or, when it is
multiparticulate, the particles according to the invention which
contain the pharmacologically active ingredient further comprise an
antioxidant. Suitable antioxidants include ascorbic acid, butylated
hydroxyanisole (BHA), butylated hydroxytoluene (BHT), salts of
ascorbic acid, monothioglycerol, phosphorous acid, vitamin C,
vitamin E and the derivatives thereof, coniferyl benzoate,
nordihydroguaj aretic acid, gallus acid esters, sodium bisulfite,
particularly preferably butylhydroxytoluene or butylhydroxyanisole
and .alpha.-tocopherol. The antioxidant is preferably present in
quantities of 0.01 wt.-% to 10 wt.-%, more preferably of 0.03 wt.-%
to 5 wt.-%, most preferably of 0.05 wt.-% to 2.5 wt.-%, based on
the total weight of the pharmaceutical dosage form and the
particles, respectively.
[0297] In a preferred embodiment, the pharmaceutical dosage form
or, when it is multiparticulate, the particles according to the
invention which contain the pharmacologically active ingredient
further comprise an acid, preferably citric acid. The amount of
acid is preferably in the range of 0.01 wt.-% to about 20 wt.-%,
more preferably in the range of 0.02 wt.-% to about 10 wt.-%, and
still more preferably in the range of 0.05 wt.-% to about 5 wt.-%,
and most preferably in the range of 0.1 wt.-% to about 1.0 wt.-%,
based on the total weight of the pharmaceutical dosage form and the
particles, respectively.
[0298] In a preferred embodiment, the pharmaceutical dosage form
or, when it is multiparticulate, the particles according to the
invention which contain the pharmacologically active ingredient
contain at least one lubricant. In another preferred embodiment,
the pharmaceutical dosage form or, when it is multiparticulate, the
particles according to the invention which contain the
pharmacologically active ingredient contain no lubricant.
[0299] Especially preferred lubricants are selected from [0300]
magnesium stearate and stearic acid; [0301] polyoxyethylene
glycerol fatty acid esters, such as mixtures of mono-, di- and
triesters of glycerol and di- and monoesters of macrogols having
molecular weights within the range of from 200 to 4000 g/mol, e.g.,
macrogolglycerolcaprylocaprate, macrogolglycerollaurate,
macrogolglycerolococoate, macrogolglycerollinoleate,
macrogol-20-glycerolmonostearate,
macrogol-6-glycerolcaprylocaprate, macrogolglycerololeate;
macrogolglycerolstearate, macrogolglycerolhydroxystearate, and
macrogolglycerolrizinoleate; [0302] polyglycolyzed glycerides, such
as the one known and commercially available under the trade name
"Labrasol"; [0303] fatty alcohols that may be linear or branched,
such as cetylalcohol, stearylalcohol, cetylstearyl alcohol,
2-octyldodecane-1-ol and 2-hexyldecane-1-ol; and [0304]
polyethylene glycols having a molecular weight between 10.000 and
60.000 g/mol.
[0305] Preferably, the amount of the lubricant ranges from 0.01
wt.-% to about 10 wt.-%, more preferably in the range of 0.05 wt.-%
to about 7.5 wt.-%, most preferably in the range of 0.1 wt.-% to
about 5 wt.-%, and in particular in the range of 0.1 wt.-% to about
1 wt.-%, based on the total weight of the pharmaceutical dosage
form and the particles, respectively.
[0306] Preferably, the pharmaceutical dosage form or, when it is
multiparticulate, the particles according to the invention which
contain the pharmacologically active ingredient further comprise a
plasticizer. The plasticizer improves the processability of the
prolonged release matrix material and additional prolonged release
matrix material, respectively. A preferred plasticizer is
polyalkylene glycol, like polyethylene glycol, triacetin, fatty
acids, fatty acid esters, waxes and/or microcrystalline waxes.
Particularly preferred plasticizers are polyethylene glycols, such
as PEG 6000.
[0307] Preferably, the content of the plasticizer is within the
range of from 0.5 to 30 wt.-%, more preferably 1.0 to 25 wt.-%,
still more preferably 2.5 wt.-% to 22.5 wt.-%, yet more preferably
5.0 wt.-% to 20 wt.-%, most preferably 6 to 20 wt.-% and in
particular 7 wt.-% to 17.5 wt.-%, based on the total weight of the
pharmaceutical dosage form and the particles, respectively.
[0308] Plasticizers can sometimes act as a lubricant, and
lubricants can sometimes act as a plasticizer.
[0309] In a preferred embodiment, the pharmaceutical dosage form
according to the invention contains no substances which irritate
the nasal passages and/or pharynx, i.e. substances which, when
administered via the nasal passages and/or pharynx, bring about a
physical reaction which is either so unpleasant for the patient
that he/she does not wish to or cannot continue administration, for
example burning, or physiologically counteracts taking of the
corresponding active compound, for example due to increased nasal
secretion or sneezing. Further examples of substances which
irritate the nasal passages and/or pharynx are those which cause
burning, itching, urge to sneeze, increased formation of secretions
or a combination of at least two of these stimuli. Corresponding
substances and the quantities thereof which are conventionally to
be used are known to the person skilled in the art. Some of the
substances which irritate the nasal passages and/or pharynx are
accordingly based on one or more constituents or one or more plant
parts of a hot substance drug. Corresponding hot substance drugs
are known per se to the person skilled in the art and are
described, for example, in "Pharmazeutische Biologie--Drogen and
ihre Inhaltsstoffe" by Prof. Dr. Hildebert Wagner, 2nd., revised
edition, Gustav Fischer Verlag, Stuttgart-New York, 1982, pages 82
et seq. The corresponding description is hereby introduced as a
reference and is deemed to be part of the disclosure.
[0310] The pharmaceutical dosage form according to the invention
furthermore preferably contains no antagonists for the
pharmacologically active ingredient, preferably no antagonists
against psychotropic substances, in particular no antagonists
against opioids. Antagonists suitable for a given pharmacologically
active ingredient are known to the person skilled in the art and
may be present as such or in the form of corresponding derivatives,
in particular esters or ethers, or in each case in the form of
corresponding physiologically acceptable compounds, in particular
in the form of the salts or solvates thereof. The pharmaceutical
dosage form according to the invention preferably contains no
antagonists selected from among the group comprising naloxone,
naltrexone, nalmefene, nalide, nalmexone, nalorphine or naluphine,
in each case optionally in the form of a corresponding
physiologically acceptable compound, in particular in the form of a
base, a salt or solvate; and no neuroleptics, for example a
compound selected from among the group comprising haloperidol,
promethacine, fluphenazine, perphenazine, levomepromazine,
thioridazine, perazine, chlorpromazine, chlorprothixine,
zuclopenthixol, flupentixol, prothipendyl, zotepine, benperidol,
pipamperone, melperone and bromperidol.
[0311] The pharmaceutical dosage form according to the invention
furthermore preferably contains no emetic. Emetics are known to the
person skilled in the art and may be present as such or in the form
of corresponding derivatives, in particular esters or ethers, or in
each case in the form of corresponding physiologically acceptable
compounds, in particular in the form of the salts or solvates
thereof. The pharmaceutical dosage form according to the invention
preferably contains no emetic based on one or more constituents of
ipecacuanha (ipecac) root, for example based on the constituent
emetine, as are, for example, described in "Pharmazeutische
Biologie--Drogen and ihre Inhaltsstoffe" by Prof. Dr. Hildebert
Wagner, 2nd, revised edition, Gustav Fischer Verlag, Stuttgart, New
York, 1982. The corresponding literature description is hereby
introduced as a reference and is deemed to be part of the
disclosure. The pharmaceutical dosage form according to the
invention preferably also contains no apomorphine as an emetic.
[0312] Finally, the pharmaceutical dosage form according to the
invention preferably also contains no bitter substance. Bitter
substances and the quantities effective for use may be found in
US-2003/0064099 A1, the corresponding disclosure of which should be
deemed to be the disclosure of the present application and is
hereby introduced as a reference. Examples of bitter substances are
aromatic oils, such as peppermint oil, eucalyptus oil, bitter
almond oil, menthol, fruit aroma substances, aroma substances from
lemons, oranges, limes, grapefruit or mixtures thereof, and/or
denatonium benzoate.
[0313] The pharmaceutical dosage form according to the invention
accordingly preferably contains neither substances which irritate
the nasal passages and/or pharynx, nor antagonists for the
pharmacologically active ingredient, nor emetics, nor bitter
substances.
[0314] In a preferred embodiment, the pharmaceutical dosage form
provides prolonged release of the pharmacologically active
ingredient.
[0315] Particularly preferably, the pharmacologically active
ingredient is embedded in a prolonged release matrix comprising the
EVA polymer, wherein the prolonged release matrix provides
prolonged release of the pharmacologically active ingredient.
[0316] For the purpose of specification "prolonged release"
preferably means a product in which the rate of release of active
compound from the formulation after administration has been reduced
over time, in order to maintain therapeutic activity, to reduce
toxic effects, or for some other therapeutic purpose such as
reducing the dosing frequency.
[0317] Preferably, under physiological conditions the
pharmaceutical dosage form according to the invention has released
after 30 minutes 0.1 to 75%, after 240 minutes 0.5 to 95%, after
480 minutes 1.0 to 100% and after 720 minutes 2.5 to 100% of the
pharmacologically active ingredient (A). Further preferred release
profiles R.sub.1 to R.sub.8 are summarized in the table here below
[all data in wt.-% of released pharmacologically active
ingredient]:
TABLE-US-00001 time R.sub.1 R.sub.2 R.sub.3 R.sub.4 R.sub.5 R.sub.6
R.sub.7 R.sub.8 60 min 0-30 0-50 0-50 15-25 20-30 20-50 40-70 40-80
120 min 0-40 0-75 0-75 25-40 35-50 40-75 60-95 80-100 240 min 3-55
3-95 10-95 40-70 55-75 60-95 80-100 480 min 10-65 10-100 35-100
60-90 80-95 80-100 90-100 720 min 20-75 20-100 55-100 70-100 90-100
90-100 960 min 30-88 30-100 70-100 >80 95-100 1440 min 50-100
50-100 >90 2160 min >80 >80
[0318] Further preferred release profiles R.sub.9 to R.sub.16 are
summarized in the table here below [all data in wt.-% of released
pharmacologically active ingredient]:
TABLE-US-00002 time R.sub.9 R.sub.10 R.sub.11 R.sub.12 R.sub.13
R.sub.14 R.sub.15 R.sub.16 30 min 17.5 .+-. 7.5 25 .+-. 15 30 .+-.
15 30 .+-. 15 12 .+-. 10 5 .+-. 4 .sup. 2 .+-. 1.5 50 .+-. 15 60
min 27.0 .+-. 8.0 35 .+-. 15 38 .+-. 10 38 .+-. 10 18 .+-. 15 6
.+-. 4 3 .+-. 2 70 .+-. 10 120 min 41.5 .+-. 9.5 43 .+-. 15 48 .+-.
10 48 .+-. 10 20 .+-. 10 8 .+-. 4 4 .+-. 2 88 .+-. 10 240 min 64.5
.+-. 12.5 60 .+-. 15 55 .+-. 10 60 .+-. 10 32 .+-. 10 9 .+-. 5 5
.+-. 3 90 .+-. 8 480 min 88.0 .+-. 12.0 83 .+-. 10 63 .+-. 10 68
.+-. 10 50 .+-. 10 10 .+-. 5 6 .+-. 4 >95 720 min 96.0 .+-. 9.0
98 .+-. 2 67 .+-. 10 70 .+-. 10 60 .+-. 10 12 .+-. 5 6.5 .+-.
5.sup. 840 min 97.5 .+-. 7.5 >98 70 .+-. 15 73 .+-. 15 65 .+-.
20 17 .+-. 10 7 .+-. 6
[0319] Suitable in vitro conditions are known to the skilled
artisan. In this regard it can be referred to, e.g., the Eur. Ph.
Preferably, the release profile is measured under the following
conditions: Paddle apparatus equipped without sinker, 50 rpm,
37.+-.5.degree. C., 900 mL simulated intestinal fluid pH 6.8
(phosphate buffer) or pH 4.5. In a preferred embodiment, the
rotational speed of the paddle is increased to 75 rpm.
[0320] Preferably, the release profile, the pharmacologically
active ingredient, the EVA polymer, the optionally present
additional prolonged release matrix material and the optionally
present pharmaceutical excipients of the pharmaceutical dosage form
according to the invention are stable upon storage, preferably upon
storage at elevated temperature, e.g. 40.degree. C., for 3 months
in sealed containers.
[0321] In connection with the release profile, the term "stable"
preferably means that when comparing the initial release profile
with the release profile after storage, at any given time point the
release profiles deviate from one another by not more than 20%,
more preferably not more than 15%, still more preferably not more
than 10%, yet more preferably not more than 7.5%, most preferably
not more than 5.0% and in particular not more than 2.5%.
[0322] In connection with the pharmacologically active ingredient,
the EVA polymer, the optionally present additional prolonged
release matrix material and the optional pharmaceutical excipients,
the term "stable" preferably means that the pharmaceutical dosage
forms satisfy the requirements of EMEA concerning shelf-life of
pharmaceutical products.
[0323] In a preferred embodiment, the additional prolonged release
matrix material exerts an influence on the release profile of the
pharmacologically active ingredient. According to this embodiment,
a pharmaceutical dosage form according to the invention comprising
a pharmacologically active ingredient, an EVA polymer and an
additional prolonged release matrix material preferably exhibits an
increased release rate of the pharmacologically active ingredient
than a pharmaceutical dosage form comprising the same types and
amounts of the pharmacologically active ingredient and the EVA
polymer but not containing any additional prolonged release matrix
material.
[0324] In a preferred embodiment, the pharmaceutical dosage form
according to the invention is adapted for administration once
daily. In another preferred embodiment, the pharmaceutical dosage
form according to the invention is adapted for administration twice
daily. In still another preferred embodiment, the pharmaceutical
dosage form according to the invention is adapted for
administration thrice daily. In yet another preferred embodiment,
the pharmaceutical dosage form according to the invention is
adapted for administration more frequently than thrice daily, for
example 4 times daily, 5 times daily, 6 times daily, 7 times daily
or 8 times daily.
[0325] For the purpose of the specification, "twice daily" means
equal or nearly equal time intervals, i.e., about every 12 hours,
or different time intervals, e.g., 8 and 16 hours or 10 and 14
hours, between the individual administrations.
[0326] For the purpose of the specification, "thrice daily" means
equal or nearly equal time intervals, i.e., about every 8 hours, or
different time intervals, e.g., 6, 6 and 12 hours; or 7, 7 and 10
hours, between the individual administrations.
[0327] The pharmaceutical dosage form according to the invention
provides tamper resistance in terms of resistance against solvent
extraction, resistance against grinding, and resistance against
dose-dumping in aqueous ethanol.
[0328] Preferably, the prolonged release matrix of the
pharmaceutical dosage form according to the invention not only
provides prolonged release of the pharmacologically active
ingredient, but additionally provides tamper resistance, i.e.
resistance against solvent extraction, resistance against grinding,
and resistance against dose-dumping in aqueous ethanol.
[0329] As used herein, the term "tamper resistant" refers to
pharmaceutical dosage forms that are resistant to conversion into a
form suitable for misuse or abuse by conventional means, particular
for nasal and/or intravenous administration.
[0330] In this regard, when the pharmaceutical dosage form is
multiparticulate, as such it may be crushable by conventional means
such as grinding in a mortar or crushing by means of a hammer.
However, when the pharmaceutical dosage form is multiparticulate,
the particles which contain the pharmacologically active ingredient
exhibit mechanical properties such that they cannot be pulverized
by conventional means any further. As the particles are of
macroscopic size and contain the pharmacologically active
ingredient, they cannot be administered nasally thereby rendering
the pharmaceutical dosage form tamper resistant.
[0331] Further, when trying to disrupt the pharmaceutical dosage
forms by means of a hammer or mortar, the particles tend to adhere
to one another thereby forming aggregates and agglomerates,
respectively, which are larger in size than the untreated
particles.
[0332] The pharmaceutical dosage form according to the invention
exhibits resistance against solvent extraction. Preferably, the
prolonged release matrix provides the pharmaceutical dosage form
according to the invention with resistance against solvent
extraction.
[0333] Preferably, when trying to tamper the pharmaceutical dosage
form in order to prepare a formulation suitable for abuse by
intravenous administration, the liquid part of the formulation that
can be separated from the remainder by means of a syringe at room
temperature is as less as possible, preferably it contains not more
than 75 or 45 or 40 wt.-%, more preferably not more than 35 wt.-%,
still more preferably not more than 30 wt.-%, yet more preferably
not more than 25 wt.-%, even more preferably not more than 20
wt.-%, most preferably not more than 15 wt.-% and in particular not
more than 10 wt.-% of the originally contained pharmacologically
active ingredient.
[0334] Preferably, this property is tested by (i) dispensing a
pharmaceutical dosage form that is either intact or has been
manually comminuted by means of two spoons in 5 ml of solvent,
either purified water or aqueous ethanol (40 vol. %), (ii) allowing
the dispersion to stand for 10 min at room temperature, (iii)
drawing up the hot liquid into a syringe (needle 21G equipped with
a cigarette filter), and (iv) determining the amount of the
pharmacologically active ingredient contained in the liquid within
the syringe.
[0335] The pharmaceutical dosage form according to the invention
exhibits resistance against grinding. Preferably, the prolonged
release matrix provides the pharmaceutical dosage form according to
the invention with resistance against grinding.
[0336] Preferably, when a pharmaceutical dosage form according to
the invention is treated with a commercial coffee mill, preferably
type Bosch MKM6000, 180W, Typ KM13 for 2 minutes, 42.+-.17.5 wt.-%,
more preferably 42.+-.15 wt.-%, still more preferably 42.+-.12.5
wt.-%, yet more preferably 42.+-.10 wt.-%, even more preferably
42.+-.7.5 wt.-%, most preferably 42.+-.5 wt.-%, and in particular
42.+-.2.5 wt.-%, of the total weight of the thus obtained material
does not pass a sieve having a mesh size of 1.000 mm.
[0337] Preferably, when a pharmaceutical dosage form according to
the invention is treated with a commercial coffee mill, preferably
type Bosch MKM6000, 180W, Typ KM13, for 2 minutes, 57.+-.17.5
wt.-%, more preferably 57.+-.15 wt.-%, still more preferably
57.+-.12.5 wt.-%, yet more preferably 57.+-.10 wt.-%, even more
preferably 57.+-.7.5 wt.-%, most preferably 57.+-.5 wt.-%, and in
particular 57.+-.2.5 wt.-%, of the total weight of the thus
obtained material does not pass a sieve having a mesh size of 1.000
mm.
[0338] Preferably, when a pharmaceutical dosage form according to
the invention is treated with a commercial coffee mill, preferably
type Bosch MKM6000, 180W, Typ KM13, for 2 minutes, at least 50
wt.-%, more preferably at least 55 wt.-%, still more preferably at
least 60 wt.-%, yet more preferably at least 65 wt.-%, even more
preferably at least 70 wt.-%, most preferably at least 75 wt.-%,
and in particular at least 80 wt.-%, of the total weight of the
thus obtained material does not pass a sieve having a mesh size of
1.000 mm.
[0339] Particle size distributions of the ground pharmaceutical
dosage form are preferably determined by sieve analysis.
[0340] In a preferred embodiment, more than 55%, more preferably
more than 60%, still more preferably more than 65%, yet more
preferably more than 70%, most preferably 75% and in particular
more than 80% of the particles of the ground pharmaceutical dosage
form have a size in the range of from 0.2 to 3.3 nm, more
preferably of from 0.4 to 3.1 nm, most preferably of from 0.6 to
2.9 and in particular of from 0.7 to 2.8 nm.
[0341] Preferred particle distributions P.sub.1 to P.sub.4 are
summarized in the table below:
TABLE-US-00003 particle size amount in % [nm] P.sub.1 P.sub.2
P.sub.3 P.sub.4 <0.045 0.5 .+-. 0.4 0.1 .+-. 0.09 0.3 .+-. 0.29
0.3 .+-. 0.29 0.045-0.063 0.5 .+-. 0.4 0.3 .+-. 0.29 0.3 .+-. 0.29
0.3 .+-. 0.29 0.063-0.090 0.5 .+-. 0.4 0.3 .+-. 0.29 0.3 .+-. 0.29
1.0 .+-. 0.9 0.090-0.125 0.5 .+-. 0.4 0.3 .+-. 0.29 0.3 .+-. 0.29
1.0 .+-. 0.9 0.125-0.180 0.5 .+-. 0.4 3.0 .+-. 2.9 2.0 .+-. 1.5 2.0
.+-. 1.5 0.180-0.250 1.5 .+-. 1.4 1.0 .+-. 0.8 2.0 .+-. 1.5 1.0
.+-. 0.9 0.250-0.355 4.0 .+-. 3.5 5.0 .+-. 4.0 4.0 .+-. 3.5 3.5
.+-. 2.5 0.355-0.500 7.0 .+-. 6.0 5.0 .+-. 4.0 6.0 .+-. 4.5 7.0
.+-. 6.0 0.500-0.710 11.0 .+-. 8.0 9.0 .+-. 7.0 11.0 .+-. 8.0 10.0
.+-. 7.0 0.710-1.000 15.0 .+-. 12.0 10.0 .+-. 7.0 17.0 .+-. 14.0
18.0 .+-. 15.0 1.000-1.400 20.0 .+-. 17.0 18.0 .+-. 15.0 23.0 .+-.
20.0 28.0 .+-. 25.0 1.400-2.000 23.0 .+-. 20.0 19.0 .+-. 16.0 12.0
.+-. 9.0 18.0 .+-. 15.0 2.000-2.800 13.0 .+-. 10.0 16.0 .+-. 13.0
13.0 .+-. 10.0 11.0 .+-. 8.0 2.800-4.000 1.0 .+-. 0.8 14.0 .+-.
11.0 12.0 .+-. 9.0 0.3 .+-. 0.29 >4.00 0.5 .+-. 0.45 0.3 .+-.
0.29 0.3 .+-. 0.29 0.5 .+-. 0.45
[0342] Further preferred particle distributions P.sub.5 to P.sub.8
are summarized in the table below:
TABLE-US-00004 particle size amount in % [nm] P.sub.5 P.sub.6
P.sub.7 P.sub.8 <0.045 0.3 .+-. 0.29 0.3 .+-. 0.29 0.3 .+-. 0.29
0.3 .+-. 0.29 0.045-0.063 0.3 .+-. 0.29 0.3 .+-. 0.29 1.0 .+-. 0.9
0.3 .+-. 0.29 0.063-0.090 0.3 .+-. 0.29 0.3 .+-. 0.29 1.5 .+-. 1.0
0.3 .+-. 0.29 0.090-0.125 0.3 .+-. 0.29 1.0 .+-. 0.9 3.5 .+-. 3.0
0.3 .+-. 0.29 0.125-0.180 1.0 .+-. 0.9 1.0 .+-. 0.9 1.0 .+-. 0.9
3.0 .+-. 2.9 0.180-0.250 2.0 .+-. 1.5 1.0 .+-. 0.9 0.3 .+-. 0.29
1.5 .+-. 1.0 0.250-0.355 5.0 .+-. 4.0 3.0 .+-. 2.9 0.3 .+-. 0.29
2.0 .+-. 1.9 0.355-0.500 7.0 .+-. 6.0 7.0 .+-. 6.0 5.0 .+-. 4.0 1.0
.+-. 0.9 0.500-0.710 13.0 .+-. 10.0 9.0 .+-. 7.0 8.0 .+-. 6.0 3.5
.+-. 2.5 0.710-1.000 18.0 .+-. 15.0 13.0 .+-. 10.0 55.0 .+-. 30.0
19.5 .+-. 15.0 1.000-1.400 25.0 .+-. 22.0 20.0 .+-. 17.0 6.5 .+-.
5.0 70.1 .+-. 50.0 1.400-2.000 10.0 .+-. 7.0 22.0 .+-. 19.0 13.0
.+-. 10.0 2.0 .+-. 1.9 2.000-2.800 14.0 .+-. 11.0 12.0 .+-. 9.0 3.0
.+-. 2.9 0.3 .+-. 0.29 2.800-4.000 4.0 .+-. 3.5 9.0 .+-. 7.0 2.0
.+-. 1.9 0.3 .+-. 0.29 >4.00 0.3 .+-. 0.29 0.5 .+-. 0.45 13.0
.+-. 10.0 1.5 .+-. 1.0
[0343] In a preferred embodiment, the pharmaceutical dosage form
according to the invention is monolithic and has a breaking
strength of at least 300 N or, when the pharmaceutical dosage form
according to the invention is multiparticulate, at least a fraction
of the individual particles have a breaking strength of at least
300 N.
[0344] Preferably, the mechanical properties, particularly the
breaking strength, substantially relies on the presence and spatial
distribution of the EVA polymer (the prolonged release matrix
material), although its mere presence does typically not suffice in
order to achieve said properties. The advantageous mechanical
properties may not automatically be achieved by simply processing
pharmacologically active ingredient, EVA polymer (the prolonged
release matrix material), optionally additional prolonged release
matrix material, and optionally further excipients by means of
conventional methods for the preparation of pharmaceutical dosage
forms. In fact, usually suitable apparatuses must be selected for
the preparation and critical processing parameters must be
adjusted, particularly pressure/force, temperature and time. Thus,
even if conventional apparatuses are used, the process protocols
usually must be adapted in order to meet the required criteria.
[0345] In general, the desired properties may be obtained only if,
during preparation of the pharmaceutical dosage form, [0346]
suitable components [0347] in suitable amounts are exposed to
[0348] a sufficient pressure [0349] at a sufficient temperature
[0350] for a sufficient period of time.
[0351] Thus, regardless of the apparatus used, the process
protocols must be adapted in order to meet the required criteria.
Therefore, the breaking strength is separable from the
composition.
[0352] The pharmaceutical dosage form or, when it is
multiparticulate, the particles according to the invention which
contain the pharmacologically active ingredient preferably have a
breaking strength of at least 300 N, at least 400 N, or at least
500 N, preferably at least 600 N, more preferably at least 700 N,
still more preferably at least 800 N, yet more preferably at least
1000 N, most preferably at least 1250 N and in particular at least
1500 N.
[0353] When the pharmaceutical dosage form is an oblong tablet,
preferably the breaking strengths of the pharmaceutical dosage form
across and lengthwise are each at least 200 N, at least 300 N, at
least 400 N, at least 500 N, at least 600 N, at least 700 N, at
least 800 N, at least 1000 N or at least 1500 N.
[0354] The "breaking strength" (resistance to crushing) of a
pharmaceutical dosage form and of a particle is known to the
skilled person. In this regard it can be referred to, e.g., W. A.
Ritschel, Die Tablette, 2. Auflage, Editio Cantor Verlag Aulendorf,
2002; H Liebermann et al., Pharmaceutical dosage forms:
Pharmaceutical dosage forms, Vol. 2, Informa Healthcare; 2 edition,
1990; and Encyclopedia of Pharmaceutical Technology, Informa
Healthcare; 1 edition.
[0355] For the purpose of specification, the breaking strength is
preferably defined as the amount of force that is necessary in
order to fracture a pharmaceutical dosage form and a particle,
respectively (=breaking force). Therefore, for the purpose of
specification, a pharmaceutical dosage form and a particle,
respectively, does preferably not exhibit the desired breaking
strength when it breaks, i.e., is fractured into at least two
independent parts that are separated from one another. In another
preferred embodiment, however, the pharmaceutical dosage form and
particle, respectively, is regarded as being broken if the force
decreases by 25% (threshold value) of the highest force measured
during the measurement (see below).
[0356] The pharmaceutical dosage forms and particles, respectively,
according to the invention are distinguished from conventional
pharmaceutical dosage forms and particles, respectively, in that
due to their breaking strength, they cannot be pulverized by the
application of force with conventional means, such as for example a
pestle and mortar, a hammer, a mallet or other usual means for
pulverization, in particular devices developed for this purpose
(pharmaceutical dosage form crushers). In this regard
"pulverization" means crumbling into small particles. Avoidance of
pulverization virtually rules out oral or parenteral, in particular
intravenous or nasal abuse.
[0357] Conventional pharmaceutical dosage forms and particles,
respectively, typically have a breaking strength well below 200
N.
[0358] The breaking strength of conventional round pharmaceutical
dosage forms/particles may be estimated according to the following
empirical formula:
Breaking Strength [in N]=10.times.Diameter of pharmaceutical dosage
form/particle [in mm].
[0359] Thus, according to said empirical formula, a round
pharmaceutical dosage form/particle having a breaking strength of
at least 300 N would require a diameter of at least 30 mm. Such a
particle, however, could not be swallowed, let alone a
pharmaceutical dosage form containing a plurality of such
particles. The above empirical formula preferably does not apply to
the pharmaceutical dosage form and particles, respectively,
according to the invention, which are not conventional but rather
special.
[0360] Further, the actual mean chewing force is about 220 N (cf.,
e.g., P. A. Proeschel et al., J Dent Res, 2002, 81(7), 464-468).
This means that conventional pharmaceutical dosage forms and
particle, respectively, having a breaking strength well below 200 N
may be crushed upon spontaneous chewing, whereas the pharmaceutical
dosage forms and particles, respectively, according to the
invention may preferably not.
[0361] Still further, when applying a gravitational acceleration of
about 9.81 m/s.sup.2, 300 N correspond to a gravitational force of
more than 30 kg, i.e. the pharmaceutical dosage form and particle,
respectively, according to the invention can preferably withstand a
weight of more than 30 kg without being pulverized.
[0362] Methods for measuring the breaking strength are known to the
skilled artisan. Suitable devices are commercially available.
[0363] For example, the breaking strength (resistance to crushing)
can be measured in accordance with the Eur. Ph. 5.0, 2.9.8 or 6.0,
2.09.08 "Resistance to Crushing of Pharmaceutical dosage forms".
The particles may be subjected to the same or similar breaking
strength test as the pharmaceutical dosage form. The test is
intended to determine, under defined conditions, the resistance to
crushing of pharmaceutical dosage forms and individual particles,
respectively, measured by the force needed to disrupt them by
crushing. The apparatus consists of 2 jaws facing each other, one
of which moves towards the other. The flat surfaces of the jaws are
perpendicular to the direction of movement. The crushing surfaces
of the jaws are flat and larger than the zone of contact with the
pharmaceutical dosage form and individual particle, respectively.
The apparatus is calibrated using a system with a precision of 1
Newton. The pharmaceutical dosage form and particle, respectively,
is placed between the jaws, taking into account, where applicable,
the shape, the break-mark and the inscription; for each measurement
the pharmaceutical dosage form and particle, respectively, is
oriented in the same way with respect to the direction of
application of the force (and the direction of extension in which
the breaking strength is to be measured). The measurement is
carried out on 10 pharmaceutical dosage forms and particles,
respectively, taking care that all fragments have been removed
before each determination. The result is expressed as the mean,
minimum and maximum values of the forces measured, all expressed in
Newton.
[0364] A similar description of the breaking strength (breaking
force) can be found in the USP. The breaking strength can
alternatively be measured in accordance with the method described
therein where it is stated that the breaking strength is the force
required to cause a pharmaceutical dosage form and particle,
respectively, to fail (i.e., break) in a specific plane. The
pharmaceutical dosage forms and particles, respectively, are
generally placed between two platens, one of which moves to apply
sufficient force to the pharmaceutical dosage form and particle,
respectively, to cause fracture. For conventional, round (circular
cross-section) pharmaceutical dosage forms and particles,
respectively, loading occurs across their diameter (sometimes
referred to as diametral loading), and fracture occurs in the
plane. The breaking force of pharmaceutical dosage forms and
particles, respectively, is commonly called hardness in the
pharmaceutical literature; however, the use of this term is
misleading. In material science, the term hardness refers to the
resistance of a surface to penetration or indentation by a small
probe. The term crushing strength is also frequently used to
describe the resistance of pharmaceutical dosage forms and
particle, respectively, to the application of a compressive load.
Although this term describes the true nature of the test more
accurately than does hardness, it implies that pharmaceutical
dosage forms and particles, respectively, are actually crushed
during the test, which is often not the case.
[0365] Alternatively, the breaking strength (resistance to
crushing) can be measured in accordance with WO 2008/107149, which
can be regarded as a modification of the method described in the
Eur. Ph. The apparatus used for the measurement is preferably a
"Zwick Z 2.5" materials tester, F.sub.max=2.5 kN with a maximum
draw of 1150 mm, which should be set up with one column and one
spindle, a clearance behind of 100 mm and a test speed adjustable
between 0.1 and 800 mm/min together with testControl software.
Measurement is performed using a pressure piston with screw-in
inserts and a cylinder (diameter 10 mm), a force transducer,
F.sub.max. 1 kN, diameter=8 mm, class 0.5 from 10 N, class 1 from 2
N to ISO 7500-1, with manufacturer's test certificate M according
to DIN 55350-18 (Zwick gross force F.sub.max=1.45 kN) (all
apparatus from Zwick GmbH & Co. KG, Ulm, Germany) with Order No
BTC-FR 2.5 TH. D09 for the tester, Order No BTC-LC 0050N. P01 for
the force transducer, Order No BO 70000 S06 for the centring
device.
[0366] In a preferred embodiment, the pharmaceutical dosage form
and particle, respectively, is regarded as being broken if it is
fractured into at least two separate pieces.
[0367] The pharmaceutical dosage form and particle, respectively,
according to the invention preferably exhibit mechanical strength
over a wide temperature range, in addition to the breaking strength
(resistance to crushing) optionally also sufficient hardness,
impact resistance, impact elasticity, tensile strength and/or
modulus of elasticity, optionally also at low temperatures (e.g.
below -24.degree. C., below -40.degree. C. or possibly even in
liquid nitrogen), for it to be virtually impossible to pulverize by
spontaneous chewing, grinding in a mortar, pounding, etc. Thus,
preferably, the comparatively high breaking strength of the
pharmaceutical dosage form and particle, respectively, according to
the invention is maintained even at low or very low temperatures,
e.g., when the pharmaceutical dosage form is initially chilled to
increase its brittleness, for example to temperatures below
-25.degree. C., below -40.degree. C. or even in liquid
nitrogen.
[0368] The pharmaceutical dosage form and particle, respectively,
according to the invention is characterized by a certain degree of
breaking strength. This does not mean that it must also exhibit a
certain degree of hardness. Hardness and breaking strength are
different physical properties. Therefore, the tamper resistance of
the pharmaceutical dosage form does not necessarily depend on the
hardness of the pharmaceutical dosage form and particle,
respectively. For instance, due to its breaking strength, impact
strength, elasticity modulus and tensile strength, respectively,
the pharmaceutical dosage form and particle, respectively, can
preferably be deformed, e.g. plastically, when exerting an external
force, for example using a hammer, but cannot be pulverized, i.e.,
crumbled into a high number of fragments. In other words, the
pharmaceutical dosage form and particle, respectively, according to
the invention are characterized by a certain degree of breaking
strength, but not necessarily also by a certain degree of form
stability.
[0369] Therefore, in the meaning of the specification, a
pharmaceutical dosage form and particle, respectively, that is
deformed when being exposed to a force in a particular direction of
extension but that does not break (plastic deformation or plastic
flow) is preferably to be regarded as having the desired breaking
strength in said direction of extension.
[0370] Preferred pharmaceutical dosage forms and particles,
respectively, are those having a suitable tensile strength as
determined by a test method currently accepted in the art. Further
preferred pharmaceutical dosage forms and particles, respectively,
are those having a Young's Modulus as determined by a test method
of the art. Still further preferred pharmaceutical dosages form and
particles, respectively, are those having an acceptable elongation
at break.
[0371] The pharmaceutical dosage form according to the invention
exhibits resistance against dose-dumping in aqueous ethanol.
Preferably, the prolonged release matrix provides the
pharmaceutical dosage form according to the invention with
resistance against dose-dumping in aqueous ethanol.
[0372] The pharmaceutical dosage form can be tested in vitro using
ethanol/simulated gastric fluid of 0%, 20% and 40% to evaluate
alcohol extractability. Testing is preferably performed using
standard procedures, e.g. USP Apparatus 1 (basket) or USP Apparatus
2 (paddle) at e.g. 50 rpm or 75 rpm in e.g. 500 ml of media at
37.degree. C., using a Perkin Elmer UV/VIS Spectrometer Lambda 20,
UV at an appropriate wavelength for detection of the
pharmacologically active ingredient present therein. Sample time
points preferably include 0.5 and 1 hour.
[0373] Preferably, when comparing the in vitro release profile at
37.degree. C. in simulated gastric fluid with the in vitro release
profile in ethanol/simulated gastric fluid (40 vol.-%) at
37.degree. C., the in vitro release in ethanol/simulated gastric
fluid (40 vol.-%) is preferably not substantially accelerated
compared to the in vitro release in simulated gastric fluid.
Preferably, in this regard "substantially" means that at any given
time point the in vitro release in ethanol/simulated gastric fluid
(40 vol.-%) relatively deviates from the in vitro release in
simulated gastric fluid by not more than +25%, more preferably not
more than +20%, still more preferably not more than +15%, yet more
preferably not more than +10%, even more preferably not more than
+7.5%, most preferably not more than +5.0% and in particular not
more than +2.5%.
[0374] A substantial relative acceleration of the in vitro release
in ethanol/simulated gastric fluid (40 vol.-%) compared to the in
vitro release in simulated gastric fluid is to be prevented
according to the invention. However, a substantial relative
deceleration of the in vitro release in ethanol/simulated gastric
fluid (40 vol.-%) compared to the in vitro release in simulated
gastric fluid, e.g., a relative deviation by -25% or more, may be
possible and can even be desirable.
[0375] The pharmacologically active ingredient having psychotropic
action is not particularly limited.
[0376] For the purpose of definition, a pharmacologically active
ingredient having psychotropic action is preferably meant to refer
to any pharmacologically active ingredient which crosses the
blood-brain barrier and acts primarily upon the central nervous
system where it affects brain function, resulting in alterations in
perception, mood, consciousness, cognition, and behavior.
[0377] In a preferred embodiment, the pharmaceutical dosage form
contains only a single pharmacologically active ingredient. In
another preferred embodiment, the pharmaceutical dosage form
contains a combination of two or more pharmacologically active
ingredients.
[0378] Preferably, the pharmaceutical dosage form according to the
invention comprises a pharmacologically active ingredient having
potential for abuse and potential for dose dumping in ethanol.
Active ingredients with potential for being abused are known to the
person skilled in the art and comprise e.g. tranquillizers,
stimulants, barbiturates, narcotics, opioids or opioid
derivatives.
[0379] Preferably, the pharmacologically active ingredient is
selected from the group consisting of opiates, opioids, stimulants,
tranquilizers, other narcotics and anesthetics. Preferably, the
pharmacologically active ingredient is selected from the group
consisting of ethers; halogenated hydrocarbons; pain barbiturates;
and barbiturates in combination with other drugs; opioid
anesthetics; or any other general anesthetics.
[0380] In a particularly preferred embodiment, the
pharmacologically active ingredient is an opioid or a
physiologically acceptable salt thereof.
[0381] According to the ATC index, opioids are divided into natural
opium alkaloids, phenylpiperidine derivatives, diphenylpropylamine
derivatives, benzomorphan derivatives, oripavine derivatives,
morphinan derivatives and others.
[0382] The following opiates, opioids, tranquillizers, anesthetics
or other narcotics are substances with a psychotropic action, i.e.
have a potential of abuse, and hence are preferably contained in
the pharmaceutical dosage form and the particles, respectively:
alfentanil, allobarbital, allylprodine, alphaprodine, alprazolam,
amfepramone, amphetamine, amphetaminil, amobarbital, anileridine,
apocodeine, axomadol, barbital, bemidone, benzylmorphine,
bezitramide, bromazepam, brotizolam, buprenorphine, butobarbital,
butorphanol, camazepam, carfentanil, cathine/D-norpseudoephedrine,
chlordiazepoxide, clobazam clofedanol, clonazepam, clonitazene,
clorazepate, clotiazepam, cloxazolam, cocaine, codeine,
cyclobarbital, cyclorphan, cyprenorphine, delorazepam,
desomorphine, dextromoramide, dextropropoxyphene, dezocine,
diampromide, diamorphone, diazepam, dihydrocodeine,
dihydromorphine, dihydromorphone, dimenoxadol, dimephetamol,
dimethylthiambutene, dioxaphetylbutyrate, dipipanone, dronabinol,
eptazocine, estazolam, ethoheptazine, ethylmethylthiambutene, ethyl
loflazepate, ethylmorphine, etonitazene, etorphine, faxeladol,
fencamfamine, fenethylline, fenpipramide, fenproporex, fentanyl,
fludiazepam, flunitrazepam, flurazepam, halazepam, haloxazolam,
heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone,
hydroxymethylmorphinan, ketamine, (S)-ketamine, ketazolam,
ketobemidone, levacetylmethadol (LAAM), levomethadone, levorphanol,
levophenacylmorphane, levoxemacin, lisdexamfetamine dimesylate,
lofentanil, loprazolam, lorazepam, lormetazepam, mazindol,
medazepam, mefenorex, meperidine, meprobamate, metapon, meptazinol,
metazocine, methylmorphine, metamphetamine, methadone,
methaqualone, 3-methylfentanyl, 4-methylfentanyl, methylphenidate,
methylphenobarbital, methyprylon, metopon, midazolam, modafinil,
morphine, myrophine, nabilone, nalbuphene, nalorphine, narceine,
nicomorphine, nimetazepam, nitrazepam, nordazepam, norlevorphanol,
normethadone, normorphine, norpipanone, opium, oxazepam, oxazolam,
oxycodone, oxymorphone, Papaver somniferum, papaveretum, pemoline,
pentazocine, pentobarbital, pethidine, phenadoxone, phenomorphane,
phenazocine, phenoperidine, piminodine, pholcodeine, phenmetrazine,
phenobarbital, phentermine, pinazepam, pipradrol, piritramide,
prazepam, profadol, proheptazine, promedol, properidine,
propoxyphene, remifentanil, secbutabarbital, secobarbital,
sufentanil, tapentadol, temazepam, tetrazepam, tilidine (cis and
trans), tramadol, triazolam, vinylbital,
N-(1-methyl-2-piperidinoethyl)-N-(2-pyridyl)-propionamide,
(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, (1R,2R,4
S)-2-(dimethylamino)methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphenyl)cyclo-
hexanol, (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)phenol,
(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol,
(2R,3R)-1-dimethylamino-3(3-methoxyphenyl)-2-methyl-pentan-3-ol,
(1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-d-
iol, preferably as racemate,
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl
2-(4-isobutyl-phenyl)propionate,
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl
2-(6-methoxy-naphthalen-2-yl)propionate,
3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl
2-(4-isobutyl-phenyl)propionate,
3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl
2-(6-methoxy-naphthalen-2-yl)propionate,
(RR-SS)-2-acetoxy-4-trifluoromethyl-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-4-trifluoromethyl-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-4-chloro-2-hydroxy-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-4-methyl-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-4-methoxy-benzoicacid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2-hydroxy-5-nitro-benzoic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester,
(RR-SS)-2',4'-difluoro-3-hydroxy-biphenyl-4-carboxylic acid
3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, and
corresponding stereoisomeric compounds, in each case the
corresponding derivatives thereof, physiologically acceptable
enantiomers, stereoisomers, diastereomers and racemates and the
physiologically acceptable derivatives thereof, e.g. ethers, esters
or amides, and in each case the physiologically acceptable
compounds thereof, in particular the acid or base addition salts
thereof and solvates, e.g. hydrochlorides.
[0383] In a preferred embodiment, the pharmacologically active
ingredient is selected from the group consisting of tramadol,
tapentadol, faxeladol and axomadol.
[0384] In another preferred embodiment, the pharmacologically
active ingredient is selected from the group consisting of DPI-125,
M6G (CE-04-410), ADL-5859, CR-665, NRP290 and sebacoyl dinalbuphine
ester.
[0385] In still another preferred embodiment, the pharmacologically
active ingredient is selected from the group consisting of
oxycodone, oxymorphone, hydrocodone, hydromorphone, taramdol,
tapentadol, morphine, buprenorphine and the physiologically
acceptable salts thereof.
[0386] In yet another preferred embodiment, the pharmacologically
active ingredient is selected from the group consisting of
1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydrop-
yrano[3,4-b]indole, particularly its hemicitrate; 1,1-[3-dimethyl
amino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydropyrano[3,4-b]indole,
particularly its citrate; and
1,1-[3-dimethylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydropyran-
o[3,4-b]-6-fluoroindole, particularly its hemicitrate. These
compounds are known from, e.g., WO 2004/043967, WO 2005/066183.
[0387] The pharmacologically active ingredient may be present in
form of a physiologically acceptable salt, e.g. physiologically
acceptable acid addition salt.
[0388] Physiologically acceptable acid addition salts comprise the
acid addition salt forms which can conveniently be obtained by
treating the base form of the active ingredient with appropriate
organic and inorganic acids. Active ingredients containing an
acidic proton may be converted into their non-toxic metal or amine
addition salt forms by treatment with appropriate organic and
inorganic bases. The term addition salt also comprises the hydrates
and solvent addition forms which the active ingredients are able to
form. Examples of such forms are e.g. hydrates, alcoholates and the
like.
[0389] It has been surprisingly found that the content of the
pharmacologically active ingredient in the pharmaceutical dosage
form and in the particles, respectively, can be optimized in order
to provide the best compromise between tamper-resistance,
disintegration time and drug release, drug load, processability
(especially pharmaceutical dosage formability) and patient
compliance.
[0390] The pharmacologically active ingredient is present in the
pharmaceutical dosage form in a therapeutically effective amount.
The amount that constitutes a therapeutically effective amount
varies according to the active ingredients being used, the
condition being treated, the severity of said condition, the
patient being treated, and the frequency of administration.
[0391] The content of the pharmacologically active ingredient in
the pharmaceutical dosage form is not limited. The dose of the
pharmacologically active ingredient which is adapted for
administration preferably is in the range of 0.1 mg to 500 mg, more
preferably in the range of 1.0 mg to 400 mg, even more preferably
in the range of 5.0 mg to 300 mg, and most preferably in the range
of 10 mg to 250 mg. In a preferred embodiment, the total amount of
the pharmacologically active ingredient that is contained in the
pharmaceutical dosage form is within the range of from 0.01 to 200
mg, more preferably 0.1 to 190 mg, still more preferably 1.0 to 180
mg, yet more preferably 1.5 to 160 mg, most preferably 2.0 to 100
mg and in particular 2.5 to 80 mg.
[0392] Preferably, the content of the pharmacologically active
ingredient is within the range of from 0.01 to 80 wt.-%, more
preferably 0.1 to 50 wt.-%, still more preferably 1 to 35 wt.-%,
based on the total weight of the pharmaceutical dosage form.
[0393] In a preferred embodiment, the content of pharmacologically
active ingredient is within the range of from 5.0.+-.4.5 wt.-%, or
7.5.+-.7.0 wt.-%, or 10.+-.9.0 wt.-%, or 12.5.+-.12.0 wt.-%, or
15.+-.14 wt.-%, or 17.5.+-.17.0 wt.-%, or 20.+-.19 wt.-%, or
22.5.+-.22.0 wt.-%, or 25.+-.24 wt.-%; more preferably 5.0.+-.4.0
wt.-%, or 7.5.+-.6.0 wt.-%, or 10.+-.8.0 wt.-%, or 12.5.+-.12.0
wt.-%, or 15.+-.12 wt.-%, or 17.5.+-.15.0 wt.-%, or 20.+-.19 wt.-%,
or 22.5.+-.22.0 wt.-%, or 25.+-.24 wt.-%; still more preferably
5.0.+-.3.5 wt.-%, or 7.5.+-.5.0 wt.-%, or 10.+-.7.0 wt.-%, or
12.5.+-.10.0 wt.-%, or 15.+-.10 wt.-%, or 17.5.+-.13.0 wt.-%, or
20.+-.17 wt.-%, or 22.5.+-.19.0 wt.-%, or 25.+-.21 wt.-%; yet more
preferably 5.0.+-.3.0 wt.-%, or 7.5.+-.4.0 wt.-%, or 10.+-.6.0
wt.-%, or 12.5.+-.8.0 wt.-%, or 15.+-.8.0 wt.-%, or 17.5.+-.11.0
wt.-%, or 20.+-.15 wt.-%, or 22.5.+-.16.0 wt.-%, or 25.+-.18 wt.-%;
even more preferably 5.0.+-.2.5 wt.-%, or 7.5.+-.3.0 wt.-%, or
10.+-.5.0 wt.-%, or 12.5.+-.6.0 wt.-%, or 15.+-.6.0 wt.-%, or
17.5.+-.9.0 wt.-%, or 20.+-.13 wt.-%, or 22.5.+-.13.0 wt.-%, or
25.+-.15 wt.-%; most preferably 5.0.+-.2.0 wt.-%, or 7.5.+-.2.0
wt.-%, or 10.+-.4.0 wt.-%, or 12.5.+-.4.0 wt.-%, or 15.+-.4.0
wt.-%, or 17.5.+-.7.0 wt.-%, or 20.+-.11 wt.-%, or 22.5.+-.10.0
wt.-%, or 25.+-.12 wt.-%; and in particular 5.0.+-.1.5 wt.-%, or
7.5.+-.1.0 wt.-%, or 10.+-.3.0 wt.-%, or 12.5.+-.2.0 wt.-%, or
15.+-.2.0 wt.-%, or 17.5.+-.5.0 wt.-%, or 20.+-.9 wt.-%, or
22.5.+-.7.0 wt.-%, or 25.+-.9 wt.-%; in each case either based on
the total weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient.
[0394] In another preferred embodiment, the content of
pharmacologically active ingredient is within the range of from
20.+-.6 wt.-%, more preferably 20.+-.5 wt.-%, still more preferably
20.+-.4 wt.-%, most preferably 20.+-.3 wt.-%, and in particular
20.+-.2 wt.-%, either based on the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, based on the total weight of the particles
that contain the pharmacologically active ingredient. In still
another preferred embodiment, the content of pharmacologically
active ingredient is within the range of from 25.+-.6 wt.-%, more
preferably 25.+-.5 wt.-%, still more preferably 25.+-.4 wt.-%, most
preferably 25.+-.3 wt.-%, and in particular 25.+-.2 wt.-%, either
based on the total weight of the pharmaceutical dosage form or,
when the pharmaceutical dosage form is multiparticulate, based on
the total weight of the particles that contain the
pharmacologically active ingredient. In yet another preferred
embodiment, the content of pharmacologically active ingredient is
within the range of from 30.+-.6 wt.-%, more preferably 30.+-.5
wt.-%, still more preferably 30.+-.4 wt.-%, most preferably 30.+-.3
wt.-%, and in particular 30.+-.2 wt.-%, either based on the total
weight of the pharmaceutical dosage form or, when the
pharmaceutical dosage form is multiparticulate, based on the total
weight of the particles that contain the pharmacologically active
ingredient. In even another preferred embodiment, the content of
pharmacologically active ingredient is within the range of from
34.+-.6 wt.-%, more preferably 34.+-.5 wt.-%, still more preferably
34.+-.4 wt.-%, most preferably 34.+-.3 wt.-%, and in particular
34.+-.2 wt.-%, either based on the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, based on the total weight of the particles
that contain the pharmacologically active ingredient. In a further
preferred embodiment, the content of pharmacologically active
ingredient is within the range of from 40.+-.6 wt.-%, more
preferably 40.+-.5 wt.-%, still more preferably 40.+-.4 wt.-%, most
preferably 40.+-.3 wt.-%, and in particular 40.+-.2 wt.-%, either
based on the total weight of the pharmaceutical dosage form or,
when the pharmaceutical dosage form is multiparticulate, based on
the total weight of the particles that contain the
pharmacologically active ingredient.
[0395] The skilled person may readily determine an appropriate
amount of pharmacologically active ingredient to include in a
pharmaceutical dosage form. For instance, in the case of
analgesics, the total amount of pharmacologically active ingredient
present in the pharmaceutical dosage form is that sufficient to
provide analgesia. The total amount of pharmacologically active
ingredient administered to a patient in a dose will vary depending
on numerous factors including the nature of the pharmacologically
active ingredient, the weight of the patient, the severity of the
pain, the nature of other therapeutic agents being administered
etc.
[0396] In a preferred embodiment, the pharmacologically active
ingredient is contained in the pharmaceutical dosage form in an
amount of 7.5.+-.5 mg, 10.+-.5 mg, 20.+-.5 mg, 30.+-.5 mg, 40.+-.5
mg, 50.+-.5 mg, 60.+-.5 mg, 70.+-.5 mg, 80.+-.5 mg, 90.+-.5 mg,
100.+-.5 mg, 110.+-.5 mg, 120.+-.5 mg, 130.+-.5, 140.+-.5 mg,
150.+-.5 mg, 160.+-.5 mg, 170.+-.5 mg, 180.+-.5 mg, 190.+-.5 mg,
200.+-.5 mg, 210.+-.5 mg, 220.+-.5 mg, 230.+-.5 mg, 240.+-.5 mg,
250.+-.5 mg, 260.+-.5 mg, 270.+-.5 mg, 280.+-.5 mg, 290.+-.5 mg, or
300.+-.5 mg. In another preferred embodiment, the pharmacologically
active ingredient is contained in the pharmaceutical dosage form in
an amount of 5.+-.2.5 mg, 7.5.+-.2.5 mg, 10.+-.2.5 mg, 15.+-.2.5
mg, 20.+-.2.5 mg, 25.+-.2.5 mg, 30.+-.2.5 mg, 35.+-.2.5 mg,
40.+-.2.5 mg, 45.+-.2.5 mg, 50.+-.2.5 mg, 55.+-.2.5 mg, 60.+-.2.5
mg, 65.+-.2.5 mg, 70.+-.2.5 mg, 75.+-.2.5 mg, 80.+-.2.5 mg,
85.+-.2.5 mg, 90.+-.2.5 mg, 95.+-.2.5 mg, 100.+-.2.5 mg, 105.+-.2.5
mg, 110.+-.2.5 mg, 115.+-.2.5 mg, 120.+-.2.5 mg, 125.+-.2.5 mg,
130.+-.2.5 mg, 135.+-.2.5 mg, 140.+-.2.5 mg, 145.+-.2.5 mg,
150.+-.2.5 mg, 155.+-.2.5 mg, 160.+-.2.5 mg, 165.+-.2.5 mg,
170.+-.2.5 mg, 175.+-.2.5 mg, 180.+-.2.5 mg, 185.+-.2.5 mg,
190.+-.2.5 mg, 195.+-.2.5 mg, 200.+-.2.5 mg, 205.+-.2.5 mg,
210.+-.2.5 mg, 215.+-.2.5 mg, 220.+-.2.5 mg, 225.+-.2.5 mg,
230.+-.2.5 mg, 235.+-.2.5 mg, 240.+-.2.5 mg, 245.+-.2.5 mg,
250.+-.2.5 mg, 255.+-.2.5 mg, 260.+-.2.5 mg, or 265.+-.2.5 mg.
[0397] In a particularly preferred embodiment, the
pharmacologically active ingredient is oxycodone, preferably its
HCl salt, and the pharmaceutical dosage form is adapted for
administration twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 1 to 80 mg. In
another particularly preferred embodiment, the pharmacologically
active ingredient is oxycodone, preferably its HCl salt, and the
pharmaceutical dosage form is adapted for administration once
daily. In this embodiment, the pharmacologically active ingredient
is preferably contained in the pharmaceutical dosage form in a
total amount of from 2 to 320 mg.
[0398] In another particularly preferred embodiment, the
pharmacologically active ingredient is oxymorphone, preferably its
HCl salt, and the pharmaceutical dosage form is adapted for
administration twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 5 to 40
mg.
[0399] In another particularly preferred embodiment, the
pharmacologically active ingredient is oxymorphone, preferably its
HCl salt, and the pharmaceutical dosage form is adapted for
administration once daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 10 to 80
mg.
[0400] In another particularly preferred embodiment, the
pharmacologically active ingredient is tapentadol, preferably its
HCl salt, and the pharmaceutical dosage form is adapted for
administration once daily or twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 25 to 250
mg.
[0401] In still another particularly preferred embodiment, the
pharmacologically active ingredient is hydromorphone, preferably
its HCl salt, and the pharmaceutical dosage form is adapted for
administration twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 2 to 52 mg. In
another particularly preferred embodiment, the pharmacologically
active ingredient is hydromorphone, preferably its HCl salt, and
the pharmaceutical dosage form is adapted for administration once
daily. In this embodiment, the pharmacologically active ingredient
is preferably contained in the pharmaceutical dosage form in a
total amount of from 4 to 104 mg.
[0402] In yet another particularly preferred embodiment, the
pharmacologically active ingredient is tramadol, preferably its HCl
salt, and the pharmaceutical dosage form is adapted for
administration twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 5 to 300 mg.
In another particularly preferred embodiment, the pharmacologically
active ingredient is tramadol, preferably its HCl salt, and the
pharmaceutical dosage form is adapted for administration once
daily. In this embodiment, the pharmacologically active ingredient
is preferably contained in the pharmaceutical dosage form in a
total amount of from 10 to 500 mg.
[0403] In another particularly preferred embodiment, the
pharmacologically active ingredient is hydrocodone, preferably its
HCl salt, and the pharmaceutical dosage form is adapted for
administration twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 5 to 250 mg.
In another particularly preferred embodiment, the pharmacologically
active ingredient is hydrocodone, preferably its HCl salt, and the
pharmaceutical dosage form is adapted for administration once
daily. In this embodiment, the pharmacologically active ingredient
is preferably contained in the pharmaceutical dosage form in a
total amount of from 5 to 250 mg.
[0404] In still another particularly preferred embodiment, the
pharmacologically active ingredient is morphine, preferably its HCl
or H.sub.2SO.sub.4 salt, and the pharmaceutical dosage form is
adapted for administration twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 5 to 250 mg.
In another particularly preferred embodiment, the pharmacologically
active ingredient is morphine, preferably its HCl or
H.sub.2SO.sub.4 salt, and the pharmaceutical dosage form is adapted
for administration once daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 5 to 250
mg.
[0405] In another particularly preferred embodiment, the
pharmacologically active ingredient is buprenorphine, preferably
its HCl salt, and the pharmaceutical dosage form is adapted for
administration twice daily. In this embodiment, the
pharmacologically active ingredient is preferably contained in the
pharmaceutical dosage form in a total amount of from 1 to 12 mg. In
another particularly preferred embodiment, the pharmacologically
active ingredient is buprenorphine, preferably its HCl salt, and
the pharmaceutical dosage form is adapted for administration once
daily. In this embodiment, the pharmacologically active ingredient
is preferably contained in the pharmaceutical dosage form in a
total amount of from 2 to 12 mg.
[0406] When the pharmaceutical dosage form is multiparticulate, the
particles present in the pharmaceutical dosage forms according to
the invention preferably comprise 3 to 75 wt.-% of
pharmacologically active ingredient, more preferably 5 to 70 wt.-%
of pharmacologically active ingredient, still more preferably 7.5
to 65 wt.-% of pharmacologically active ingredient, based on the
total weight of a particle.
[0407] When the pharmaceutical dosage form is multiparticulate, the
content of the pharmacologically active ingredient is preferably at
least 5 wt.-%, more preferably at least 10 wt.-%, still more
preferably at least 15 wt.-%, yet more preferably at least 20
wt.-%, most preferably at least 25 wt.-% and in particular at least
30 wt.-%, based on the total weight of a particle.
[0408] When the pharmaceutical dosage form is multiparticulate, the
content of the pharmacologically active ingredient is preferably at
most 70 wt.-%, more preferably at most 65 wt.-%, still more
preferably at most 60 wt.-%, yet more preferably at most 55 wt.-%,
most preferably at most 50 wt.-%, based on the total weight of a
particle.
[0409] In a preferred embodiment, when the pharmaceutical dosage
form is multiparticulate, the content of the pharmacologically
active ingredient is within the range of 35.+-.30 wt.-%, more
preferably 35.+-.25 wt.-%, still more preferably 35.+-.20 wt.-%,
yet more preferably 35.+-.15 wt.-%, most preferably 35.+-.10 wt.-%,
and in particular 35.+-.5 wt.-%, based on the total weight of a
particle. In another preferred embodiment, when the pharmaceutical
dosage form is multiparticulate, the content of the
pharmacologically active ingredient is within the range of 45.+-.30
wt.-%, more preferably 45.+-.25 wt.-%, still more preferably
45.+-.20 wt.-%, yet more preferably 45.+-.15 wt.-%, most preferably
45.+-.10 wt.-%, and in particular 45.+-.5 wt.-%, based on the total
weight of a particle. In still another preferred embodiment, when
the pharmaceutical dosage form is multiparticulate, the content of
the pharmacologically active ingredient is within the range of
55.+-.30 wt.-%, more preferably 55.+-.25 wt.-%, still more
preferably 55.+-.20 wt.-%, yet more preferably 55.+-.15 wt.-%, most
preferably 55.+-.10 wt.-%, and in particular 55.+-.5 wt.-%, based
on the total weight of a particle.
[0410] The pharmacologically active ingredient that is included in
the preparation of the pharmaceutical dosage forms according to the
invention preferably has an average particle size of less than 500
microns, still more preferably less than 300 microns, yet more
preferably less than 200 or 100 microns. There is no lower limit on
the average particle size and it may be, for example, 50 microns.
The particle size of pharmacologically active ingredients may be
determined by any technique conventional in the art, e.g. laser
light scattering, sieve analysis, light microscopy or image
analysis. Generally speaking it is preferable that the largest
dimension of the pharmacologically active ingredient particle be
less than the size of the particles (e.g. less than the smallest
dimension of the particles).
[0411] In a preferred embodiment, the pharmaceutical dosage form
according to the invention, preferably the particles, comprise an
opioid (agonist) as well as an opioid antagonist.
[0412] Any conventional opioid antagonist may be present, e.g.
naltrexone or naloxone or their pharmaceutically acceptable salts.
Naloxone, including its salts, is particularly preferred. The
opioid antagonist may be present within the particles or within the
matrix. Alternatively, opioid antagonist may be provided in
separate particles to the pharmacologically active ingredients. The
preferred composition of such particles is the same as that
described for pharmacologically active ingredient-containing
particles.
[0413] The ratio of opioid agonist to opioid antagonist in the
pharmaceutical dosage forms according to the invention is
preferably 1:1 to 3:1 by weight, for example, about 2:1 by
weight.
[0414] In another preferred embodiment, neither the particles nor
the pharmaceutical dosage form comprise any opioid antagonist.
[0415] Preferably, the pharmaceutical dosage form according to the
invention contains more than 20 wt.-%, more preferably more than 30
wt.-%, still more preferably more than 40 wt.-%, yet more
preferably more than 50 wt.-%, most preferably more than 60 wt.-%,
and in particular more than 70 wt.-% of compounds which are not or
hardly soluble in ethanol with respect to the total weight of the
pharmaceutical dosage form.
[0416] For the purpose of specification, compounds which are not or
hardly soluble in ethanol have a maximum solubility in aqueous
ethanol (96%) at room temperature of preferably less than 1000
mg/L, more preferably less than 800 mg/L, even more preferably less
than 500 mg/L, most preferably less than 100 mg/L and in particular
less than 10 mg/L or less than 1 mg/L.
[0417] Preferably, the pharmaceutical dosage form according to the
invention contains more than 50 wt.-%, more preferably more than 60
wt.-%, still more preferably more than 70 wt.-%, yet more
preferably more than 80 wt.-%, most preferably more than 90 wt.-%,
and in particular more than 95 wt.-% of polymers which are not or
hardly soluble in ethanol with respect to the overall amount of
polymers contained in the pharmaceutical dosage form.
[0418] Preferred polymers which are not or hardly soluble in
ethanol according to the invention are xanthan, guar gum and some
types of HPMC. The skilled person knows what types of HPMC are not
or hardly soluble in ethanol within the sense of the invention.
[0419] In a particularly preferred embodiment, the entire
pharmaceutical dosage form according to the invention contains
polymers which are not or hardly soluble in ethanol and polymers
which are soluble in ethanol, wherein the amount of polymers which
are not or hardly soluble in ethanol relative to the total amount
of polymers contained in the dosage form is 30 to 100 wt.-%, more
preferably 50 to 100 wt.-%, still more preferably 60 to 95 wt.-% or
100 wt.-%, yet more preferably 70 to 90 wt.-% or 100 wt.-%, most
preferably 80 to 90 wt.-% or 90 to 100 wt.-%, and in particular
more than 95 wt.-% or more than 99 wt.-%.
[0420] Preferred compositions of the pharmaceutical dosage form or,
when the pharmaceutical dosage form is multiparticulate, of the
particles are summarized as embodiments B.sup.1 to B.sup.6 in the
table here below:
TABLE-US-00005 wt.-% .sup.a) B.sup.1 B.sup.2 B.sup.3 B.sup.4
B.sup.5 B.sup.6 pharmacologically active ingredient 40 .+-. 10 40
.+-. 5 35 .+-. 10 33 .+-. 10 33 .+-. 10 33 .+-. 10 EVA polymer 40
.+-. 10 40 .+-. 5 50 .+-. 15 57 .+-. 20 60 .+-. 20 67 .+-. 15
additional prolonged release matrix 10 .+-. 10 10 .+-. 10 15 .+-.
10 10 .+-. 7 7.5 .+-. 5.sup. 10 .+-. 10 material excipients 10 .+-.
10 10 .+-. 10 5 .+-. 5 5 .+-. 5 5 .+-. 5 5 .+-. 5 .sup.a) relative
to the total weight of the dosage form and particles,
respectively.
[0421] The subjects to which the pharmaceutical dosage forms
according to the invention can be administered are not particularly
limited. Preferably, the subjects are animals, more preferably
human beings.
[0422] The pharmaceutical dosage form according to the invention
or, when it is multiparticulate, the particles that contain the
pharmacologically active ingredient are preferably thermoformed,
preferably by melt-extrusion, although also other methods of
thermoforming may be useful, such as press-molding at elevated
temperature or heating of compacts that were manufactured by
conventional compression in a first step and then heated above the
softening temperature of the EVA polymer and the prolonged release
matrix material, respectively, in a second step to form break
resistant, hardened compacts, i.e. monolithic dosage forms or
particles, respectively. In this regard, thermoforming preferably
means the forming or molding of a mass after, before or during the
application of heat. Preferably, thermoforming is performed by
hot-melt extrusion.
[0423] In a preferred embodiment, the pharmaceutical dosage form
according to the invention is hot-melt extruded.
[0424] In a preferred embodiment, hot-melt extrusion is performed
by means of a twin-screw-extruder. Melt extrusion preferably
provides a melt-extruded strand that is preferably cut into
monoliths, which are then optionally compressed and formed.
Preferably, compression is achieved by means of a die and a punch,
preferably from a monolithic mass obtained by melt extrusion. If
obtained via melt extrusion, the compressing step is preferably
carried out with a monolithic mass exhibiting ambient temperature,
that is, a temperature in the range from 20 to 25.degree. C.
[0425] The strands obtained by way of extrusion can either be
subjected to the compression step as such or can be cut prior to
the compression step. This cutting can be performed by usual
techniques, for example using rotating knives or compressed air, at
elevated temperature, e.g. when the extruded stand is still warm
due to hot-melt extrusion, or at ambient temperature, i.e. after
the extruded strand has been allowed to cool down. When the
extruded strand is still warm, singulation of the extruded strand
into extruded monolithic pharmaceutical dosage forms and particles,
respectively, is preferably performed by cutting the extruded
strand immediately after it has exited the extrusion die.
[0426] However, when the extruded strand is cut in the cooled
state, subsequent singulation of the extruded strand is preferably
performed by optionally transporting the still hot extruded strand
by means of conveyor belts, allowing it to cool down and to
congeal, and subsequently cutting it. Alternatively, the shaping
can take place as described in EP-A 240 906 by the extrudate being
passed between two counter-rotating calender rolls and being shaped
directly to pharmaceutical dosage forms and particles,
respectively. It is of course also possible to subject the extruded
strands to the compression step or to the cutting step when still
warm, that is more or less immediately after the extrusion step.
The extrusion is preferably carried out by means of a twin-screw
extruder.
[0427] The pharmaceutical dosage forms and particles, respectively,
according to the invention may be produced by different processes,
the particularly preferred of which are explained in greater detail
below. Several suitable processes have already been described in
the prior art. In this regard it can be referred to, e.g., WO
2005/016313, WO 2005/016314, WO 2005/063214, WO 2005/102286, WO
2006/002883, WO 2006/002884, WO 2006/002886, WO 2006/082097, and WO
2006/082099.
[0428] In general, the process for the production of the particles
according to the invention preferably comprises the following
steps: [0429] (a) mixing all ingredients; [0430] (b) optionally
pre-forming the mixture obtained from step (a), preferably by
applying heat and/or force to the mixture obtained from step (a),
the quantity of heat supplied preferably not being sufficient to
heat the EVA polymer and the prolonged release matrix material,
respectively, up to its softening point; [0431] (c) hardening the
mixture by applying heat and force, it being possible to supply the
heat during and/or before the application of force and the quantity
of heat supplied being sufficient to heat the EVA polymer and the
prolonged release matrix material, respectively, at least up to its
softening point; and thereafter allowing the material to cool and
removing the force [0432] (d) optionally singulating the hardened
mixture; [0433] (e) optionally shaping the particles; and [0434]
(f) optionally providing a film coating.
[0435] Heat may be supplied directly, e.g. by contact or by means
of hot gas such as hot air, or with the assistance of ultrasound;
or is indirectly supplied by friction and/or shear. Force may be
applied and/or the particles may be shaped for example by direct
pharmaceutical dosage forming or with the assistance of a suitable
extruder, particularly by means of a screw extruder equipped with
one or two screws (single-screw-extruder and twin-screw-extruder,
respectively) or by means of a planetary gear extruder.
[0436] The final shape of the pharmaceutical dosage forms and
particles, respectively, may either be provided during the
hardening of the mixture by applying heat and force (step (c)) or
in a subsequent step (step (e)). In both cases, the mixture of all
components is preferably in the plastified state, i.e. preferably,
shaping is performed at a temperature at least above the softening
point of the EVA polymer and the prolonged release matrix material,
respectively. However, extrusion at lower temperatures, e.g.
ambient temperature, is also possible and may be preferred.
[0437] Shaping can be performed, e.g., by means of a pharmaceutical
dosage forming press comprising die and punches of appropriate
shape.
[0438] Another aspect of the invention relates to a process for the
production of a tamper-resistant, oral pharmaceutical dosage form
comprising the steps of [0439] (i) mixing a pharmacologically
active ingredient, an ethylene-vinyl acetate (EVA) polymer and
optionally further excipients; and [0440] (ii) thermoforming the
mixture obtained in step (i), wherein said mixture is
simultaneously or before or after the application of heat subjected
to pressure.
[0441] In a preferred embodiment, the tamper-resistant, oral
pharmaceutical dosage form which is produced by said process is
according to the tamper-resistant, oral pharmaceutical dosage forms
described above.
[0442] A particularly preferred process for the manufacture of the
particles according to the invention involves hot-melt extrusion.
In this process, the pharmaceutical dosage forms and particles,
respectively, according to the invention are produced by
thermoforming with the assistance of an extruder, preferably
without there being any observable consequent discoloration of the
extrudate.
[0443] This process is characterized in that [0444] a) all
components are mixed, [0445] b) the resultant mixture is heated in
the extruder at least up to the softening point of the EVA polymer
and the prolonged release matrix material, respectively, and
extruded through the outlet orifice of the extruder by application
of force, [0446] c) the still plastic extrudate is singulated and
formed into the pharmaceutical dosage forms and particles,
respectively, or [0447] d) the cooled and optionally reheated
singulated extrudate is formed into the pharmaceutical dosage forms
and particles, respectively.
[0448] Mixing of the components according to process step a) may
also proceed in the extruder.
[0449] The components may also be mixed in a mixer known to the
person skilled in the art. The mixer may, for example, be a roll
mixer, shaking mixer, shear mixer or compulsory mixer.
[0450] The, preferably molten, mixture which has been heated in the
extruder at least up to the softening point of the EVA polymer and
the prolonged release matrix material, respectively, is extruded
from the extruder through a die with at least one bore.
[0451] The process according to the invention requires the use of
suitable extruders, preferably screw extruders. Screw extruders
which are equipped with two screws (twin-screw-extruders) are
particularly preferred.
[0452] In a preferred embodiment, extrusion is performed in the
absence of water, i.e., no water is added. However, traces of water
(e.g., caused by atmospheric humidity) may be present.
[0453] The extruded strand is preferably water-free, which
preferably means that the water content of the extruded strand is
preferably at most 10 wt.-%, or at most 7.5 wt.-%, or at most 5.0
wt.-%, or at most 4.0 wt.-%, or at most 3.0 wt.-%, or at most 2.0
wt.-%, more preferably at most 1.7 wt.-%, still more preferably at
most 1.5 wt.-%, yet more preferably at most 1.3 wt.-%, even more
preferably at most 1.0 wt.-%, most preferably at most 0.7 wt.-%,
and in particular at most 0.5 wt.-%.
[0454] The extruder preferably comprises at least two temperature
zones, with heating of the mixture at least up to the softening
point of the EVA polymer and the prolonged release matrix material,
respectively, proceeding in the first zone, which is downstream
from a feed zone and optionally mixing zone. The throughput of the
mixture is preferably from 1.0 kg to 15 kg/hour. In a preferred
embodiment, the throughput is from 0.2 kg/hour to 3.5 kg/hour. In
another preferred embodiment, the throughput is from 4 to 15
kg/hour.
[0455] In a preferred embodiment, the die head pressure is within
the range of from 0.5 to 200 bar. The die head pressure can be
adjusted inter alia by die geometry, temperature profile, extrusion
speed, number of bores in the dies, screw configuration, first
feeding steps in the extruder, and the like.
[0456] In a preferred embodiment, the die head pressure is within
the range of from 20.+-.19 bar, more preferably 20.+-.15 bar, and
in particular 20.+-.10 bar; or the die head pressure is within the
range of from 30.+-.20 bar, more preferably 30.+-.15 bar, and in
particular 30.+-.10 bar; or the die head pressure is within the
range of from 40.+-.20 bar, more preferably 40.+-.15 bar, and in
particular 40.+-.10 bar; or the die head pressure is within the
range of from 50.+-.20 bar, more preferably 50.+-.15 bar, and in
particular 50.+-.10 bar; or the die head pressure is within the
range of from 60.+-.20 bar, more preferably 60.+-.15 bar, and in
particular 60.+-.10 bar; or the die head pressure is within the
range of from 70.+-.20 bar, more preferably 70.+-.15 bar, and in
particular 70.+-.10 bar; or the die head pressure is within the
range of from 80.+-.20 bar, more preferably 80.+-.15 bar, and in
particular 80.+-.10 bar; or the die head pressure is within the
range of from 90.+-.20 bar, more preferably 90.+-.15 bar, and in
particular 90.+-.10 bar; or the die head pressure is within the
range of from 100.+-.20 bar, more preferably 100.+-.15 bar, and in
particular 100.+-.10 bar.
[0457] The die geometry or the geometry of the bores is freely
selectable. The die or the bores may accordingly exhibit a flat
(film), round, oblong or oval cross-section, wherein the round
cross-section preferably has a diameter of 0.1 mm to 2 mm for
extruded particles and a larger diameter for extruded monolithic
pharmaceutical dosage forms. Preferably, the die or the bores have
a round cross-section. The casing of the extruder used according to
the invention may be heated or cooled. The corresponding
temperature control, i.e. heating or cooling, is so arranged that
the mixture to be extruded exhibits at least an average temperature
(product temperature) corresponding to the softening temperature of
the prolonged release matrix material and does not rise above a
temperature at which the pharmacologically active ingredient to be
processed may be damaged. Preferably, the temperature of the
mixture to be extruded is adjusted to below 180.degree. C.,
preferably below 150.degree. C., but at least to the softening
temperature of the EVA polymer and the prolonged release matrix
material, respectively. Typical extrusion temperatures are
120.degree. C. and 150.degree. C.
[0458] In a preferred embodiment, the extruder torque is within the
range of from 30 to 95%. Extruder torque can be adjusted inter alia
by die geometry, temperature profile, extrusion speed, number of
bores in the dies, screw configuration, first feeding steps in the
extruder, and the like.
[0459] After extrusion of the molten mixture and optional cooling
of the extruded strand or extruded strands, the extrudates are
preferably singulated. This singulation may preferably be performed
by cutting up the extrudates by means of revolving or rotating
knives, wires, blades or with the assistance of laser cutters.
[0460] Preferably, intermediate or final storage of the optionally
singulated extrudate or the final shape of the pharmaceutical
dosage forms and particles, respectively, according to the
invention is performed under oxygen-free atmosphere which may be
achieved, e.g., by means of oxygen-scavengers.
[0461] The singulated extrudate may be press-formed into
pharmaceutical dosage forms and particles, respectively, in order
to impart the final shape to the pharmaceutical dosage forms and
particles, respectively.
[0462] The application of force in the extruder onto the at least
plasticized mixture is adjusted by controlling the rotational speed
of the conveying device in the extruder and the geometry thereof
and by dimensioning the outlet orifice in such a manner that the
pressure necessary for extruding the plasticized mixture is built
up in the extruder, preferably immediately prior to extrusion. The
extrusion parameters which, for each particular composition, are
necessary to give rise to a pharmaceutical dosage form with desired
mechanical properties, may be established by simple preliminary
testing.
[0463] For example but not limiting, extrusion may be performed by
means of a twin-screw-extruder type ZSE 18 or ZSE 27 (Leistritz,
Nurnberg, Germany) or Thermo Scientific* Pharma 16 HME, screw
diameters of 16, 18 or 27 mm. Screws having eccentric or blunt ends
may be used. A heatable die with a round bore or with a multitude
of bores each having a diameter of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7,
0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0 or 6.0 mm may be used. The
extrusion parameters may be adjusted e.g. to the following values:
rotational speed of the screws: 120 Upm; delivery rate 0.5 kg/h for
Pharma 16, 2 kg/h for a ZSE 18 or 8 kg/h for a ZSE 27; product
temperature: in front of die 100 to 125.degree. C. and behind die
125 to 135.degree. C.; and jacket temperature: 110.degree. C.
[0464] Preferably, extrusion is performed by means of
twin-screw-extruders or planetary-gear-extruders, twin-screw
extruders (co-rotating or contra-rotating) being particularly
preferred.
[0465] The pharmaceutical dosage forms and particles, respectively,
according to the invention are preferably produced by thermoforming
with the assistance of an extruder without any observable
consequent discoloration of the extrudates.
[0466] The process for the preparation of the pharmaceutical dosage
forms and particles, respectively, according to the invention is
preferably performed continuously. Preferably, the process involves
the extrusion of a homogeneous mixture of all components. It is
particularly advantageous if the thus obtained intermediate, e.g.
the strand obtained by extrusion, exhibits uniform properties.
Particularly desirable are uniform density, uniform distribution of
the active compound, uniform mechanical properties, uniform
porosity, uniform appearance of the surface, etc. Only under these
circumstances the uniformity of the pharmacological properties,
such as the stability of the release profile, may be ensured and
the amount of rejects can be kept low.
[0467] Preferably, the pharmaceutical dosage form is
multiparticulate and the particles according to the invention can
be regarded as "extruded pellets". The term "extruded pellets" has
structural implications which are understood by persons skilled in
the art. A person skilled in the art knows that pelletized
pharmaceutical dosage forms can be prepared by a number of
techniques, including: [0468] drug layering on nonpareil sugar or
microcrystalline cellulose beads, [0469] spray drying, [0470] spray
congealing, [0471] rotogranulation, [0472] hot-melt extrusion,
[0473] spheronization of low melting materials, or [0474]
extrusion-spheronization of a wet mass.
[0475] Accordingly, "extruded pellets" can be obtained either by
hot-melt extrusion or by extrusion-spheronization.
[0476] "Extruded pellets" can be distinguished from other types of
pellets because they are structurally different. For example, drug
layering on nonpareils yields multilayered pellets having a core,
whereas extrusion typically yields a monolithic mass comprising a
homogeneous mixture of all ingredients. Similarly, spray drying and
spray congealing typically yield spheres, whereas extrusion
typically yields cylindrical extrudates which can be subsequently
spheronized.
[0477] The structural differences between "extruded pellets" and
"agglomerated pellets" are significant because they may affect the
release of active substances from the pellets and consequently
result in different pharmacological profiles. Therefore, a person
skilled in the pharmaceutical formulation art would not consider
"extruded pellets" to be equivalent to "agglomerated pellets".
[0478] The pharmaceutical dosage forms according to the invention
may be prepared by any conventional method. Preferably, however,
the pharmaceutical dosage forms are prepared by compression. Thus,
particles as hereinbefore defined are preferably mixed, e.g.
blended and/or granulated (e.g. wet granulated), with outer matrix
material and the resulting mix (e.g. blend or granulate) is then
compressed, preferably in molds, to form pharmaceutical dosage
forms. It is also envisaged that the particles herein described may
be incorporated into a matrix using other processes, such as by
melt granulation (e.g. using fatty alcohols and/or water-soluble
waxes and/or water-insoluble waxes) or high shear granulation,
followed by compression.
[0479] When the pharmaceutical dosage forms according to the
invention are manufactured by means of an eccentric press, the
compression force is preferably within the range of from 5 to 15
kN. When the pharmaceutical dosage forms according to the invention
are manufactured by means of a rotating press, the compression
force is preferably within the range of from 5 to 40 kN, in certain
embodiments >25 kN, in other embodiments about 13 kN.
[0480] Another aspect of the invention relates to a
tamper-resistant, oral pharmaceutical dosage form which is
obtainable by any of the processes described above.
[0481] The pharmaceutical dosage form according to the invention is
characterized by excellent storage stability. Preferably, after
storage for 4 weeks at 40.degree. C. and 75% rel. humidity, the
content of pharmacologically active ingredient amounts to at least
98.0%, more preferably at least 98.5%, still more preferably at
least 99.0%, yet more preferably at least 99.2%, most preferably at
least 99.4% and in particular at least 99.6%, of its original
content before storage. Suitable methods for measuring the content
of the pharmacologically active ingredient in the pharmaceutical
dosage form are known to the skilled artisan. In this regard it is
referred to the Eur. Ph. or the USP, especially to reversed phase
HPLC analysis. Preferably, the pharmaceutical dosage form is stored
in closed, preferably sealed containers.
[0482] The pharmaceutical dosage forms according to the invention
may be used in medicine, e.g. as an analgesic. The pharmaceutical
dosage forms are therefore particularly suitable for the treatment
or management of pain. In such pharmaceutical dosage forms, the
pharmacologically active ingredient preferably is analgesically
effective.
[0483] A further aspect of the invention relates to the
pharmaceutical dosage form as described above for use in the
treatment of pain.
[0484] A further aspect of the invention relates to the use of the
pharmacologically active ingredient for the manufacture of a
pharmaceutical dosage form as described above for treating
pain.
[0485] A further aspect of the invention relates to a method of
treating pain comprising the administration of the pharmaceutical
dosage form as described above to a subject in need thereof.
[0486] A further aspect according to the invention relates to the
use of a pharmaceutical dosage form as described above for
providing prolonged release of the pharmacologically active
ingredient contained therein.
[0487] A further aspect according to the invention relates to the
use of a pharmaceutical dosage form as described above for avoiding
or hindering the abuse of the pharmacologically active ingredient
contained therein.
[0488] A further aspect according to the invention relates to the
use of a pharmaceutical dosage form as described above for avoiding
or hindering the unintentional overdose of the pharmacologically
active ingredient contained therein.
[0489] In this regard, the invention also relates to the use of a
pharmaceutical dosage form as described above for the prophylaxis
and/or the treatment of a disorder, thereby preventing an overdose
of the pharmacologically active ingredient, particularly due to
comminution of the pharmaceutical dosage form by mechanical
action.
[0490] In a particularly preferred embodiment, [0491] the
pharmaceutical dosage form according to the invention is monolithic
or multiparticulate or a MUPS formulation; and/or [0492] the
pharmaceutical dosage form according to the invention is hot-melt
extruded; and/or [0493] the pharmaceutical dosage form according to
the invention provides prolonged release of the pharmacologically
active ingredient having psychotropic action; and/or [0494] the
pharmacologically active ingredient having psychotropic action is
an opioid or a physiologically acceptable salt thereof; and/or
[0495] the content of the pharmacologically active ingredient is
within the range of from 1 to 35 wt.-%, based on the total weight
of the pharmaceutical dosage form; and/or [0496] the EVA polymer
comprises repetition units derived from ethylene and vinyl acetate
and/or vinyl alcohol; and/or [0497] the EVA polymer contains
60.+-.30 wt.-%, more preferably 60.+-.5 wt.-% of ethylene
repetition units, relative to the total weight of the EVA polymer;
and/or [0498] the EVA polymer has a melt flow rate at 190.degree.
C. and 2.16 kg of 52.+-.2 g/10 min measured according to ASTM
D1238; and/or [0499] the content of the EVA polymer is within the
range of from 45 to 70 wt.-%, relative to the total weight of the
pharmaceutical dosage form or, when the pharmaceutical dosage form
is multiparticulate, relative to the total weight of the particles
that contain the pharmacologically active ingredient; and/or [0500]
the pharmacologically active ingredient is embedded in a prolonged
release matrix containing the EVA polymer as prolonged release
matrix material and additional prolonged release matrix material;
wherein [0501] the content of the additional prolonged release
matrix material is in the range of 5 to 30 wt.-%, relative to the
total weight of the prolonged release matrix; and/or [0502] the
additional prolonged release matrix material is a polyalkylene
oxide, preferably a polyethylene oxide having a weight average
molecular weight of at least 5,000,000 g/mol; or [0503] the
additional prolonged release matrix material is a mixture of
polyvinyl pyrrolidone and polyvinyl acetate, wherein said mixture
has a K-value in the range of from 60 to 65, measured in a 1%
solution in tetrahydrofurane according to the method described in
the USP and Ph. Eur. monographs "Povidone", wherein the weight
ratio between polyvinyl acetate and polyvinyl pyrrolidone is in the
range of 4.5:1 to 3.5:1; or [0504] the additional prolonged release
matrix material is an anionic acrylic polymer, preferably a
polyacrylic acid polymer which is crosslinked with ally
pentaerythritol having a viscosity of 4,000 to 11,000 mPas,
measured with a Brookfield RVT, 20 rpm, spindle no. 5 at 25.degree.
C. and 0.5 wt.-% neutralized to pH 7.3-7.8.
EXAMPLES
[0505] For manufacturing the pellets, mixtures of the
pharmacologically active ingredient, EVA and excipients were
produced by weighing the ingredients (batch size 500.0 g), sieving
(Mesh size 1.0 mm), blending in a Bohle LM 40 MC 20, followed by
extrusion using a Leistritz ZSE 18 melt extruder type MICRO 18
GL-40D Pharma (melt temperature 124.degree. C., screw rotation
speed 100 rpm, die diameter 1.0 mm, melt pressure 1-4 bar). The
extruded strands were cooled in ambient air and were manually cut
yielding pellets.
[0506] General procedure 1 (GP1) for manufacturing the cut rods:
mixtures of the pharmacologically active ingredient, EVA and
excipients were produced by weighing the ingredients (batch size
500.0 g), sieving (Mesh size 1.0 mm), blending in a Bohle LM 40 MC
20, followed by extrusion using a Leistritz Micro 18 HME (melt
temperature ca. 124.degree. C., screw rotation speed 50-100 rpm,
die diameter 5.0 mm, melt pressure 16-47 bar). The extruded strands
were cooled in ambient air and were manually cut with a hot knife
into cut rods.
[0507] General procedure 2 (GP2) for manufacturing the cut rods:
mixtures of the pharmacologically active ingredient, EVA and
excipients were produced by weighing the ingredients (batch size
500.0 g), sieving (Mesh size 1.0 mm), blending in a Bohle LM 40 MC
20, followed by extrusion using a Leistritz Micro 27 lab extruder
(melt temperature ca. 124.degree. C., screw rotation speed 50-100
rpm, die diameter 5.0 mm, melt pressure 16-47 bar). The extruded
strands were cooled in ambient air and were manually cut with a hot
knife into cut rods.
[0508] The pellets and cut rods, respectively, were subjected to
different tests in order to assess the tamper-resistance with
respect to the pharmacologically active ingredient contained in the
pellets and cut rods, respectively.
[0509] Materials
TABLE-US-00006 Elvax .RTM. 40W ethylene-vinyl acetate copolymer (40
wt.-% vinyl acetate comonomer) Elvax .RTM. 40L-03 ethylene-vinyl
acetate copolymer (40 wt.-% vinyl acetate comonomer) Elvax .RTM.
220W ethylene-vinyl acetate copolymer (28 wt.-% vinyl acetate
comonomer) Elvax .RTM. 265 ethylene-vinyl acetate copolymer (28
wt.-% vinyl acetate comonomer) Elvax .RTM. 660 ethylene-vinyl
acetate copolymer (12 wt.-% vinyl acetate comonomer) PEO 7 Mio.
polyethylene oxide (7 mio) Kollidon SR mixture of polyvinyl acetate
and polyvinyl pyrrolidone Carbopol 71G polymer of acrylic acid
crosslinked with allyl ethers of pentaerythritol Xanthan a
polysaccharide comprising pentasaccharide repeat units comprising
glucose, mannose and glucuronic acid HPMC
hydroxypropylmethylcellulose Kollicoat IR polyvinyl
alcohol-polyethylene glycol graft copolymer
Example 1
[0510] Pellets were prepared having the following composition:
TABLE-US-00007 substance per tablet [mg] amount [%] Tramadol HCl
122.33 34.95 Elvax .RTM. 40W 175.00 50.00 PEO 7 Mio. 52.67 15.05
total 350.00 100.00
[0511] Pellets were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min. Afterwards, the ground
pellets were subjected to a sieving analysis. The result of which
is summarized in FIG. 1.
[0512] The release profile of tramadol HCl from the pellets was
determined under in vitro conditions using the basket method
according to Ph. Eur. at 75 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
3.
Example 2
[0513] Pellets were prepared having the following composition:
TABLE-US-00008 substance per tablet [mg] amount [%] Tramadol HCl
116.48 33.28 Elvax .RTM. 40W 233.52 66.72 total 350.00 100.00
[0514] Pellets were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min. Afterwards, the ground
pellets were subjected to a sieving analysis. The result of which
is summarized in FIG. 2.
[0515] To simulate an addict's attempt at preparing an i.v.
injection, pellets were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min followed by extraction in
boiled water for 5 min. The results are summarized in the below
table.
TABLE-US-00009 TABLE 1 simulated preparation of i.v. injection.
intact ground content [%] 1 13.56 39.62 (n = 3) 2 13.34 29.49 3
12.48 25.98 mean [%] 13.13 31.70
[0516] The release profiles of tramadol HCl from the pellets were
determined under in vitro conditions using the basket method
according to Ph. Eur. at 75 rpm in 900 mL of buffered SIF sp (pH
6.8) and in 900 mL of 40% ethanol in 0.1 N HCl, respectively,
(without sinker, n=3). The results are summarized in FIGS. 3 and
4.
Example 3
[0517] Pellets were prepared having the following composition:
TABLE-US-00010 substance per tablet [mg] amount [%] Tramadol HCl
116.48 33.28 Elvax .RTM. 40W 198.52 56.72 Kollidon SR 35.00 10.00
total 350.00 100.00
[0518] To simulate an addict's attempt at preparing an i.v.
injection, pellets were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min followed by extraction in
boiled water for 5 min. The results are summarized in the below
table.
TABLE-US-00011 TABLE 2 simulated preparation of i.v. injection.
intact ground content [%] 1 16.41 23.98 (n = 3) 2 19.58 30.52 3
15.99 26.25 mean [%] 17.33 26.92
[0519] The release profile of tramadol HCl from the pellets was
determined under in vitro conditions using the basket method
according to Ph. Eur. at 75 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
3.
Example 3A
[0520] Cut rods were prepared according to GP1 having the same
composition as the pellets of Example 3.
[0521] The release profile of tramadol HCl from the cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
5.
Example 4
[0522] Pellets were prepared having the following composition:
TABLE-US-00012 substance per tablet [mg] amount [%] Tramadol HCl
116.48 33.28 Elvax .RTM. 40W 207.27 59.22 Carbopol 71G 26.25 7.50
total 350.00 100.00
[0523] To simulate an addict's attempt at preparing an i.v.
injection, pellets were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min followed by extraction in
boiled water for 5 min. The results are summarized in the below
table.
TABLE-US-00013 TABLE 3 simulated preparation of i.v. injection.
intact ground content [%] 1 11.20 42.90 (n = 3) 2 21.31 44.86 3
32.67 33.42 mean [%] 21.73 40.39
[0524] The release profiles of tramadol HCl from the pellets were
determined under in vitro conditions using the basket method
according to Ph. Eur. at 75 rpm in 900 mL of buffered SIF sp (pH
6.8) and in 900 mL of 40% ethanol in 0.1 N HCl, respectively,
(without sinker, n=3). The results are summarized in FIGS. 3 and
4.
Example 4A
[0525] Cut rods were prepared according to GP1 having the same
composition as the pellets of Example 4.
[0526] To simulate an addict's attempt at preparing an i.v.
injection, cut rods were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min followed by extraction in
boiled water for 5 min. The results are summarized in the below
table.
TABLE-US-00014 TABLE 4 simulated preparation of i.v. injection.
intact ground content [%] 1 29.70 84.71 (n = 3) 2 30.99 79.44 3
38.45 53.18 mean [%] 33.05 72.44
[0527] The cut rods displayed a breaking strength (resistance to
crushing) of 1000 N (average value, n=10) determined with a Zwick Z
2.5 materials tester, F.sub.max=2.5 kN, maximum draw: 1150 mm.
[0528] The release profile of tramadol HCl from the cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
5.
Example 5
[0529] Pellets were prepared having the following composition:
TABLE-US-00015 substance per tablet [mg] amount [%] Tramadol HCl
116.48 33.28 Elvax .RTM. 220W 233.52 66.72 total 350.00 100.00
Example 5A
[0530] Cut rods were according to GP1 prepared having the same
composition as the pellets of Example 5.
[0531] The release profile of tramadol HCl from the cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
5.
Example 6
[0532] Pellets were prepared having the following composition:
TABLE-US-00016 substance per tablet [mg] amount [%] Tramadol HCl
116.48 33.28 Elvax .RTM. 265 233.52 66.72 total 350.00 100.00
[0533] To simulate an addict's attempt at preparing an i.v.
injection, pellets were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min followed by extraction in
boiled water for 5 min. The results are summarized in the below
table.
TABLE-US-00017 TABLE 5 simulated preparation of i.v. injection.
intact ground content [%] 1 3.06 7.45 (n = 3) 2 4.51 8.02 3 4.47
8.38 mean [%] 4.01 7.95
[0534] The release profile of tramadol HCl from the pellets was
determined under in vitro conditions using the basket method
according to Ph. Eur. at 75 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
3.
Example 6A
[0535] Cut rods were prepared according to GP1 having the same
composition as the pellets of Example 6.
[0536] To simulate an addict's attempt at preparing an i.v.
injection, cut rods were ground with a commercial coffee mill, type
Bosch MKM6000, 180W, Typ KM13 for 2 min followed by extraction in
boiled water for 5 min. The results are summarized in the below
table.
TABLE-US-00018 TABLE 6 simulated preparation of i.v. injection.
intact ground content [%] 1 2.38 38.58 (n = 3) 2 2.51 17.47 3 1.51
38.99 mean [%] 2.13 31.68
[0537] The cut rods displayed a breaking strength (resistance to
crushing) of 1000 N (average value, n=10) determined with a Zwick Z
2.5 materials tester, F.sub.max=2.5 kN, maximum draw: 1150 mm.
[0538] The release profile of tramadol HCl from the cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
5.
Example 7
[0539] Pellets were prepared having the following composition:
TABLE-US-00019 substance per tablet [mg] amount [%] Tramadol HCl
116.48 33.28 Elvax .RTM. 40L-03 233.52 66.72 total 350.00
100.00
[0540] The release profile of tramadol HCl from the pellets was
determined under in vitro conditions using the basket method
according to Ph. Eur. at 75 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
3.
Example 7A
[0541] Cut rods were prepared according to GP1 having the same
composition as the pellets of Example 7.
[0542] The release profile of tramadol HCl from the cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
5.
Example 8
[0543] Pellets were prepared having the following composition:
TABLE-US-00020 substance per tablet [mg] amount [%] Tramadol HCl
116.48 33.28 Elvax .RTM. 660 233.52 66.72 total 350.00 100.00
[0544] The release profile of tramadol HCl from the pellets was
determined under in vitro conditions using the basket method
according to Ph. Eur. at 75 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
3.
Example 8A
[0545] Cut rods were prepared according to GP1 having the same
composition as the pellets of Example 8.
[0546] The release profile of tramadol HCl from the cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL of buffered SIF sp (pH
6.8) (without sinker, n=3). The results are summarized in FIG.
5.
[0547] In examples 7 and 7A, and in examples 8 and 8A,
respectively, the pharmacologically active substance was in both
cases tramadol HCl, the releasing polymer was EVA. The composition
of both the cut rods (die diameter 1.0 mm) and the pellets (die
diameter 5.0 mm) was identical. Considering FIGS. 3 and 5, it
becomes evident that the particle size had no influence on the
release behavior of EVA, as in both cases a prolonged-release (PR)
of tramadol HCl could be observed.
Example 9
[0548] Cut rods were prepared according to GP2 having the following
composition:
TABLE-US-00021 Substance per tablet [mg] amount [%] Tramadol HCl
50.00 14.30 Elvax EVA 40W 212.50 60.7 Xanthan 35.00 10.00 HPMC
17.50 5.00 Carbopol 35.00 10.00 total 350.00 100.00
[0549] The release profile of tramadol HCl from cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 75 rpm in 600 mL of buffered SIF sp (pH
6.8) with sinker type 1, n=3. The results are shown in FIG. 6.
[0550] The release profile of tramadol HCl from cut rods was also
determined in aqueous ethanol using the paddle method according to
Ph. Eur. At 75 rpm in 600 mL of 0.1 N HCl 40% EtOH with sinker type
1, n=3. The results are shown in FIG. 7.
[0551] To simulate an addict's attempt at preparing an i.v.
injection, an extraction was carried out according to example 2.
The results are summarized in the below table.
TABLE-US-00022 TABLE 7 simulated preparation of i.v. injection.
intact manipulated content [%] 1 3.50 -- (n = 3) 2 1.49 -- 3 3.31
-- mean [%] 2.77 --
Example 10
[0552] Cut rods were prepared according to GP2 having the following
composition:
TABLE-US-00023 Substance per tablet [mg] amount [%] Tramadol HCl
50.00 14.30 Elvax EVA 40W 107.50 30.70 Elvax 265A 105.00 30.00
Xanthan 35.00 10.00 Kollicoat SR 52.50 15.00 total 350.00
100.00
[0553] The release profile of tramadol HCl from the cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 75 rpm in 600 mL of buffered SIF sp (pH
6.8) with sinker type 1, n=3. The results are summarized in FIG.
6.
[0554] The release profile of tramadol HCl from cut rods was also
determined in aqueous ethanol using the paddle method according to
Ph. Eur. At 75 rpm in 600 mL of 0.1 N HCl 40% EtOH with sinker type
1, n=3. The results are summarized in FIG. 7.
[0555] To simulate an addict's attempt at preparing an i.v.
injection, an extraction was carried out according to example 2.
The results are summarized in the below table.
TABLE-US-00024 TABLE 8 simulated preparation of i.v. injection.
intact manipulated content [%] 1 2.65 -- (n = 3) 2 1.24 -- 3 1.86
-- mean [%] 1.92 --
Example 11
[0556] Cut rods were prepared according to GP2 having the following
composition:
TABLE-US-00025 Substance per tablet [mg] amount [%] Tramadol HCl
50.00 14.30 Elvax 265A 195.00 55.70 Xanthan 35.00 10.00 Kollicoat
IR 70.00 20.00 total 350.00 100.00
[0557] The release profile of tramadol HCl from cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 75 rpm in 600 mL of buffered SIF sp (pH
6.8) with sinker type 1, n=3. The results are summarized in FIG.
6.
[0558] The release profile of tramadol HCl from cut rods was also
determined in aqueous ethanol using the paddle method according to
Ph. Eur. At 75 rpm in 600 mL of 0.1 N HCl 40% EtOH with sinker type
1, n=3. The results are summarized in FIG. 7.
[0559] To simulate an addict's attempt at preparing an i.v.
injection, an extraction was carried out according to example 2.
The results are summarized in the below table.
TABLE-US-00026 TABLE 9 simulated preparation of i.v. injection.
intact manipulated content [%] 1 15.15 -- (n = 3) 2 13.90 -- 3
12.59 -- mean [%] 13.26 --
Example 12
[0560] Cut rods were prepared according to GP2 having the following
composition:
TABLE-US-00027 Substance per tablet [mg] amount [%] Tramadol HCl
50.00 14.30 Elvax 265A 125.00 35.70 Elvax 40W 70.00 20.00 Kollicoat
IR 70.00 20.00 Xanthan 35.00 10.00 total 350.00 100.00
[0561] The release profile of tramadol HCl from cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 75 rpm in 600 mL of buffered SIF sp (pH
6.8) with sinker type 1, n=3. The results are summarized in FIG.
6.
[0562] The release profile of tramadol HCl from cut rods was also
determined in aqueous ethanol using the paddle method according to
Ph. Eur. At 75 rpm in 600 mL of 0.1 N HCl 40% EtOH with sinker type
1, n=3. The results are summarized in FIG. 7.
[0563] To simulate an addict's attempt at preparing an i.v.
injection, an extraction was carried out according to example 2.
The results are summarized in the below table.
TABLE-US-00028 TABLE 10 simulated preparation of i.v. injection.
intact manipulated content [%] 1 15.29 -- (n = 3) 2 15.90 -- 3 8.59
-- mean [%] 13.26 --
[0564] Examples 9-12 demonstrate the resistance of EVA-containing
formulations against dose-dumping in aqueous ethanol. Comparing
FIGS. 6 and 7, it becomes evident that the dissolution behavior of
the corresponding monolithic form (i.e. cut rods with a die
diameter of 5 mm) in aqueous ethanol is equal to the dissolution
behavior under in vitro conditions. Thus, the controlled release
portion of the formulation cannot be defeated by the extraction
with ethanol or by the concomitant intake of ethanol.
[0565] For all examples 9-12, a manipulation of the cud rods did
not allow a winding up of the pharmaceutically active
ingredient.
Comparative Example 13
[0566] Pellets were prepared having the following composition:
TABLE-US-00029 Substance per tablet [mg] amount [%] Tapentadol HCl
116.48 33.28 Hypromellose 100000 mPas 44.0 12.57 PEG 6000 35.00
10.00 alpha Tocopherol 0.04 0.01 PEO 7 Mio 154.48 44.14 total
350.00 100.00
[0567] The release profiles of tapentadol HCl from pellets was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL 0.1N HCl (without sinker,
n=3). The results are summarized in FIG. 8.
Comparative Example 13A
[0568] Cut rods were prepared according to GP1 having the same
composition as the pellets of Example 13.
[0569] The release profile of tapentadol HCl from cut rods was
determined under in vitro conditions using the paddle method
according to Ph. Eur. at 50 rpm in 900 mL 0.1N HCl (without sinker,
n=3). The results are shown in FIG. 8.
[0570] In examples 13 and 13A, the pharmacologically active
substance was in both cases tapentadol HCl, the polymer releasing
the substance was PEO. The composition of both the cut rods and the
pellets was identical. Considering FIG. 8, it becomes evident that
for pellets (die diameter 1.0 mm), an immediate-release (IR) of
tapentadol HCl could be observed, whereas for cut rods (die
diameter 6.0 mm), a prolonged-release (PR) is observed. Thus, for
PEO and in contrast to EVA, the particle size has a pronounced
influence on the dissolution behavior of the pharmacologically
active substance. The smaller the particles, the faster the
release.
[0571] In the above examples 1-12, the pharmacologically active
substance is in all cases tramadol HCl, whereas in examples 13 and
13A, the substance is tapentadol HCl. However, both tapentadol HCl
and tramadol HCl show a comparable dissolution behavior and are
both water-soluble; the dependency of the dissolution behavior on
the particle size is therefore comparable.
* * * * *